Home Blog Page 2

The Best Vitamins for Immunity, Pharmacists Say – Eat This, Not That

0

Every day you are exposed to something that can potentially make you sick. From bacteria to viruses to fungi, the world is full of things that cause disease and infection, but your immune system fights hard every second of the day to protect you from disease. It is therefore essential to take care of your body’s defense mechanism to stay healthy. Lifestyle choices like not smoking, getting 7-9 hours of quality sleep per night, maintaining a healthy weight, and eating a well-balanced diet that includes fruits and vegetables boost the immune system. But vitamins can also help, according to Raja Sannidhi PharmD with Capitol Drugs telling us, “Immune health is very important because it’s your first line of defense against infections. Vitamins are also natural. These are basic elements found in food. the required amounts from our diet.” Please consult your doctor for medical advice before taking any vitamins. Many may interact with other medications and pose health risks, so do your research and speak to your Keep reading – and to ensure your health and the health of others, don’t miss these Sure signs you’ve already had COVID.

Shutterstock

The National Library of Medicine explains: “The immune system has a vital role: it protects your body against harmful substances, germs and cellular changes that could make you sick. It is made up of various organs, cells and proteins. As long as your immune system is working well, you won’t notice it’s there. But if it stops working properly – because it’s weak or can’t fight off particularly aggressive germs – you get sick. Germs your body has never encountered before can also make you sick. germs will only make you sick the first time you come into contact with them. These include childhood illnesses like chickenpox.

Shutterstock

Dr. Sannidhi says, “It is a powerful antioxidant that helps in the production of white blood cells. White blood cells are needed to fight infections.”

The Mayo Clinic states, “When taken in appropriate doses, oral vitamin C supplements are generally considered safe. Taking too much vitamin C can cause side effects, including:

  • Nausea, vomiting and diarrhea
  • Stomach pains
  • stomach cramps or bloating
  • Fatigue and drowsiness, or sometimes insomnia
  • Headache
  • Redness of the skin

In some people, oral vitamin C supplements can cause kidney stones, especially when taken in high doses. Long-term use of oral vitamin C supplements of more than 2,000 milligrams per day increases the risk of significant side effects.”

Vitamin C and Zinc lozenges, food supplement
Shutterstock

“Zinc helps repair wounds, damaged tissues and also helps in the production of white blood cells,” says Dr. Sannidhi.

The Mayo Clinic finds that zinc is relatively safe, but warns of some side effects. Oral zinc can cause:

  • Indigestion
  • Diarrhea
  • Headache
  • Nausea
  • Vomiting

When oral zinc is taken long-term and in high doses, it can cause copper deficiency. People with low copper levels may experience neurological problems, such as numbness and weakness in the arms and legs. The National Institutes of Health consider 40 mg of zinc per day to be the upper limit for adults and 4 mg of zinc per day for infants under 6 months of age.

Do not use intranasal zinc. This form of zinc has been associated with loss of sense of smell.”

Shutterstock

Dr. Sannidhi tells us, “It helps in kidney and kidney detoxification. This is also used for respiratory health. In the body, it gets converted into glutathione, which also helps.”

Mount Sinai recommends, “Due to the potential for side effects and drug interactions, only take dietary supplements under the supervision of a qualified healthcare professional.

Toxic forms of cysteine ​​that should be avoided include:

  • D-cysteine
  • D-cystine
  • 5-methyl cysteine

NAC can increase levels of homocysteine, an amino acid associated with heart disease. Make sure your doctor checks your homocysteine ​​levels if you are taking NAC. Very large doses (more than 7 grams) of cysteine ​​can be toxic to human cells and can even lead to death. Taking NAC by mouth can cause nausea, vomiting, and diarrhea. Intravenous administration of

NAC to treat acetaminophen poisoning can cause serious allergic reactions, including:

  • Angioedema
  • Swelling of the soft tissues just under the skin, including the face, lips, and around the eyes
  • Anaphylaxis, a life-threatening allergic reaction

People with cystinuria, a kidney disease in which too much cysteine ​​is lost in the urine, should not take cysteine ​​supplements. When inhaled into the lungs, NAC can cause chest tightness, numbness in the mouth, runny nose, and drowsiness. This can make asthma symptoms worse. People with asthma who take NAC should be closely monitored by their doctor.”

Shutterstock

Dr. Sannidhi says: “It is an autoimmune modulator that has anti-inflammatory properties and helps against respiratory diseases.”

Heather Newgen

Heather Newgen has two decades of experience reporting and writing about health, fitness, entertainment and travel. Heather is currently a freelancer for several publications. Read more

New lawsuit challenges construction of PADNOS metal crusher at Howell

0

Livingston County Catholic Charities and the nonprofit’s owner have filed a new lawsuit against Dutch company PADNOS Iron and Metal over an auto and scrap metal shredder.

The City of Howell approved a Special Use Permit in September 2019 for the shredder capable of processing approximately 80 cars per hour at 645 Lucy Road.

Livingston County Catholic Charities and its owner, Matem LLC, located next door to the facility in Genoa Township, said noise from the facility will disrupt its operations as one of the county’s only adult child care centers. Livingston for people with dementia. The charity also offers mental health, addictions, foster care and adoption support programs.

Catholic Charities said that due to the nature of their programs, noise abatement already exists in their building. However, the agency argued in its lawsuit that increasing the noise from the shredder would be too harmful and that scrapping the metal often has other harmful effects like pollution, vibration, dust and fires. and spontaneous explosions.

“The impact of noise and vibration from the enormous automobile and scrap metal crusher would significantly disrupt these services and would be incredibly harmful and distinct,” the complaint states.

PADNOS Iron and Metal did not respond to a message left seeking comment. Ben Irwin, chief financial officer of PADNOS, previously told the Livingston Daily that “concerns are overblown” about the chipper.

“We are running a world-class operation,” he said. “We think this is an optimal site for a crusher.”

An initial complaint was dismissed in April because Livingston County Judge Suzanne Geddis said the facility had not been built and she could not rule on a possible future violation, but said that Catholic Charities could return to court if PADNOS begins construction in a manner that does not comply with Howell’s zoning ordinance.

PADNOS has begun construction and Catholic Charities and Matem said in the lawsuit that the crusher will not comply with the zoning ordinance because the structure around the crusher will not be completely enclosed because there is no roof and that air pollution can escape from the installation as a result.

Catholic Charities and Matem want a judge to issue an injunction that stops construction and requires the chipper be enclosed in a building that has a roof, in accordance with the zoning ordinance and all other city building requirements.

Last year, PADNOS agreed to place the crusher inside a structure and pave the exterior storage areas and driving surfaces.

In February 2020, the company applied to the Howell Zoning Appeal Board for three waivers for the project. The requests were to allow the chipper to be outdoors and to allow the company to use gravel throughout the site instead of pavement. The zoning board denied all three discrepancies, so PADNOS sued in hopes of overturning the denials.

A year later, the company denied its Livingston County Circuit Court appeal, and the Howell City Council accepted the revisions.

Catholic Charities has operated from the Matem Building at 2020 E. Grand River Ave., at the corner of Grand River and Lucy Road, for over 20 years.

The agency’s executive director, Mark Robinson, said if the crusher is built, his agency will have to move.

The Michigan Department of Environment, Great Lakes and Energy has approved an aerial permit for the PADNOS site at Howell – with two conditions.

The company needs to test more frequently for particulates and volatile organic compounds, as well as other pollutants. Also, instead of a one-time test, PADNOS will have to test pollutants once every five years until certain conditions are met.

Sophia Lada is a journalist at the Livingston Daily. Contact her at [email protected] or 517.377.1065. Follow her on Twitter @sophia_lada.

Money belt | Tribal member Dr. Sylvestor A. Moses joins the San Carlos Apache Healthcare Corporation

0

In another major step forward in the rapid expansion of high quality health care on the San Carlos Apache Reservation, the Tribe is honored to announce that Tribal Member Dr. Sylvestor A. Moses, MD, Ph. D., joined the medical staff of his hospital hospital in Peridot.

“I am thrilled to return to my tribal community to heal and serve my people,” said Dr Moses. “That was my main motivation for going to medical school; it never wavered and today I can live that dream.

Dr. Moses’ addition to the San Carlos Apache Healthcare Corporation (SCAHC) comes at a time when less than 0.4% of medical providers in the United States are American Indian or Alaska Native. Dr. Moses joins a team of 150 doctors and 90 nurses as the only Native American doctor on staff at the tribe’s healthcare company.

“It is truly a celebratory time to welcome one of our own tribal members to care for, serve and empower our Apache people,” said Steve Titla, Chairman of the Board of SCAHC.

The healthcare company has adopted the Apache practice of Gozhǫǫ, which embraces the principles of kindness, balance, harmony and beauty. As part of this practice, the SCAHC is working to create a health facility dedicated to “Apaches Healing Apaches”.

“To see our goal of having Apaches healing Apaches come to fruition with the addition of Dr. Moses is a beautiful reminder that this is just the beginning,” said Victoria Began, CEO of SCAHC.

Dr. Moses grew up in Morenci, in southeastern Arizona, and remembers making regular trips to Bylas, where his father had many family members living on the reservation. The family later moved to Tucson, where Dr. Moses attended university high school. During the summer after his freshman year, he participated in the medical student research program offered by the University of Arizona.

“This program inspired me to pursue a career in science and research,” said Dr Moses.

He graduated from the University of Arizona with a Bachelor of Science in Molecular and Cellular Biology. He continued his graduate studies at the U of A, earning a master’s degree and a joint doctorate. in biochemistry and molecular/cellular biology. Dr. Moses then worked on the reservation within the Department of Education with the goal of inspiring young Apaches to pursue higher education, particularly in STEM and medical fields.

“Working on the reservation, it was clear that we needed more San Carlos Apache members in the health fields,” Dr. Moses said. “I thought the best way to inspire our employees was to lead by example.”

Dr. Moses was accepted into the U of A College of Medicine and graduated in 2019. He completed his internal medicine residency at the U of A Banner University Medical Center in Tucson earlier this year.

Dr. Moses is an avid outdoorsman and enjoys hiking, camping, canoeinging, fishing and hunting. He also plays racquetball at least four times a week. Dr. Moses plays five instruments; clarinet, guitar, bass guitar, saxophone and classical piano, in which he trained and played for over 35 years.

Dr. Moses credits his mother and father with being his most notable mentors, as well as Dr. Marlys Witte, head of the medical student research program he attended as a high school student. Dr. Moses has no intention of leaving the reservation.

“My overall goal is to be here for a very long time, to inspire and usher in the next generation of Apache healthcare professionals,” he said.

Marin Software Named a Strong Performer in B2B Advertising Solutions by Independent Research Company –

0

SAN FRANCISCO–(BUSINESS WIRE)–Marin Software Incorporated (NASDAQ: MRIN), a leading provider of performance-driven digital marketing software for advertisers and agencies, today announced that it has been recognized as a Strong Performer by Forrester Research, Inc. August 2022 Report, The Forrester Wave™ B2B Advertising Solutions, Q3 2022.

The report evaluated 14 B2B advertising solution providers based on 28 criteria among their current offerings, strategies and market presence. Marin Software received the highest rating for the B2B performance reporting criterion and also received the highest possible rating for the execution roadmap and go-to-market criteria.

According to the report, “Marin Software’s execution roadmap and go-to-market approach is superior and includes the innovative use of audience data to enable a variety of use cases from B2B advertising, commerce electronics to ABM… Ad-level, performance-level and ROI-level ratios are also superior.

“We are proud to be named a Strong Performer in the Forrester Wave™ B2B Advertising Solutions report,” said Chris Lien, CEO of Marin Software. “We are committed to providing B2B advertisers with the best solutions to analyze, automate and optimize their marketing campaigns and we are delighted to be recognized in the report.”

The MarinOne self-service platform unifies industry-leading optimization tools with flexible reporting to help advertisers maximize the impact and reach of their digital marketing investment across paid search, social and search channels. of e-commerce.

Marin has been helping advertisers advance their digital ad campaigns for over 15 years and has managed over $40 billion in ad spend for some of the world’s largest brands.

Access The Forrester Wave™: B2B Advertising Solutions, Q3 2022 here.

About Marin Software

Marin Software Incorporated’s (NASDAQ: MRIN) mission is to empower advertisers to improve the effectiveness and transparency of their paid marketing programs run by the world’s leading publishers. Marin Software offers a unified SaaS advertising management platform for search, social and e-commerce advertising. The company helps digital marketers convert specific audiences, improve financial performance, and make better decisions. Based in San Francisco with offices around the world, Marin Software’s technology powers marketing campaigns around the world. For more information about Marin Software, please visit www.marinsoftware.com.

contacts

Wesley McLaggan

Marketing, Marine Software

(415) 399-2580

[email protected]

AMD Stock: Market Immunity (NASDAQ: AMD)

0

hababapa

With the publication of Q2’22 results, Advanced Micro Devices, Inc. (NASDAQ: AMD) finally provided a breakdown of product lines to specifically detail data center revenues. Research companies had long detailed estimated earnings for different sectors, but now the market has a clear vision of data center growth and the possibility of taking more market share. My investment thesis remains highly optimistic due to AMD’s ability to make significant gains in both the data center space and the new embedded category acquired from Xilinx.

More sharing wins to come

As the media focuses on the potential monetary benefits for Intel (INTC) of the CHIPS Act, AMD is still poised to steal major market share while the chip giant is busy building new fabs for the next few years. BoA analyst Vivek Arya sees Intel getting $10-15 billion in aid from the US bill alone, with Italy and other European countries lining up with grants for other fabs.

As the U.S. chip giant builds new factories and tries to catch up on chip manufacturing leadership from Taiwan Semiconductor Manufacturing Company Limited (TSM), AMD will sell data center chips. According to the Q2’22 report, Intel still held a major market share in the data center space, selling $4.6 billion worth of chips. The number was down from $5.5 billion in the prior Q2.

Data Center Slide

Intel Q2’22 Presentation

The next platform documented the new AMD breakdown provided in this handy business segment chart. The company recorded 83% growth in the data center segment to $1.5 billion in quarterly revenue. The embedded category is almost entirely made up of former Xilinx revenue and reached $1.3 billion.

AMD segment slide

The next platform

Based on revenue alone, AMD has a roughly 25% market share of the data center market, with Intel still controlling 75% of the market. Given the trajectory of the 2 companies, AMD controlling the market over the next two years seems likely. In such a scenario, the company would actually be the one bringing in over $4 billion in quarterly data center revenue, with Intel lucky to maintain $1.5 billion per quarter. This equates to a change of more than $10 billion per year in revenue for this category alone.

Even though the Client segment is weak due to lower PC demand and the Gaming segment may be stagnating with a 1% growth forecast, AMD looks set to expand the Embedded division. The old Xilinx-focused business appears to have been underinvested and was very supply constrained prior to the merger, giving the business now under AMD’s best operations a big boost.

During the Q2’22 earnings call, CEO Lisa Su again confirmed that AMD was limited in supply in parts of the business, oddly led by Xilinx’s integrated wallet:

We are still a bit constrained in some parts of the Xilinx portfolio, although we continue to make good progress. And I expect the additional supply to come, especially towards the end of the year and into 2023. Our view of the company, again, is that I think the quality of the design wins, the quality of the overall diversified market is very strong, and so I think if we’re able to continue to ease some of those supply constraints in the second half of the year, I think we’ll see a good growth trajectory for the company.

Many investors feared Xilinx activity could slow the overall AMD growth rate, but details now suggest that Xilinx was reporting disappointing growth due to supply constraints. The bigger company helped get more capacity and orders, but AMD still can’t keep up with the demand.

Cheap at $100

Somehow, the stock traded as high as $71 on fears of a slowdown in chip demand. Analysts only have earnings approaching $5 for 2023, putting AMD at a forward P/E multiple of around 20x.

Chart
AMD EPS Estimates for Current Year Data by YCharts

Our previous research has shown that AMD is on track for EPS of $6+ next year. The main difference is that forecasts call for 20% revenue growth next year to $32 billion, while analyst consensus estimates only see 14% growth to nearly $30 billion. dollars in revenue in 2023.

Note that pro forma revenue for the year is targeted at approximately $26.7 billion by adding Xilinx’s $450 million in revenue to the figures for the period prior to the February 14 deal close. Using this number, the analyst’s revenue target amounts to just 11% real growth for the company.

Between the huge opportunity to simply take market share from Intel in the data center space and the growth of the Embedded segment, AMD is expected to grow its revenue by far beyond just $3 billion next year. A 20% growth rate as the economy rebounds next year seems a much better base case for the company.

In such a scenario, AMD is only trading at 16 times the EPS targets of $6+ for 2023 with the stock at $100. The stock could easily trade at double the forward P/E multiple with this growth rate. Furthermore, even analysts have 2024 EPS targets heading towards the $6 level providing support for AMD, should our more aggressive growth targets not be met in 2023.

Carry

The main investor takeaway is that AMD is still way too cheap here at $100. The company doesn’t even need macro growth to boost revenue by 20% next year, supporting a much higher EPS target, bringing the stock back to earlier highs. AMD appears to be immune to a market downturn due to market share gains.

The automotive interior ambient lighting market is expected to

0

New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) — According to a comprehensive research report by Market Research Future (MRFR), “Automotive Interior Ambient Lighting Market Analysis by product type, by technology, by vehicle type and by region – Forecast to 2030″ the assessment is about to reach USD 3,800 million by 2030, registering a CAGR of 10.60% throughout the forecast period (2022-2030).

Automotive interior ambient lighting market overview

The automotive interior ambient lighting market is booming. Sustainable and energy-efficient lighting systems have a huge impact on the economy of the automotive industry. Over the past decade, automobile production and sales have exploded worldwide, justifying market demand. Government reforms and regulations and growing demand for improved automotive safety are increasing the size of the market.

Scope of Automotive Interior Ambient Lighting Market Report:

Report Metric Details
Market size by 2030 3800 million dollars
CAGR 10.60%
base year 2021
Forecast period 2022-2030

Get a Free Sample PDF Brochure

https://www.marketresearchfuture.com/sample_request/4965

An efficient lighting system is a crucial aspect of automobiles; hence, they are in high demand. Additionally, durable and energy-efficient interior ambient lighting systems have a huge impact on the economy of the automotive industry. Growing demand for reliable and highest quality lighting solutions is influencing the growth of the market. Moreover, changing consumer demand is accelerating market share.

Automotive interior ambient lighting market segments

This market is segmented into product types, technologies, vehicle types and regions. The product type segment includes dashboard lights, ambient lights, head-up displays, map lights and others. The technology segment includes halogen, LED and xenon. Of these, LED technology represents the largest segment due to the increased energy efficiency it offers. The vehicle type segment includes passenger vehicles and commercial vehicles. The regional segment includes Americas, Asia Pacific, Middle East & Africa, Europe and Rest of the World.

Automotive Interior Ambient Lighting Market Regional Analysis

North America dominates the global automotive interior ambient lighting market. The emergence of high-quality lighting systems that can improve automotive safety is increasing the market size of the region. Furthermore, the presence of major automobile manufacturers and growing demand for luxury cars in the region is driving the growth of the market.

The benefits of indoor ambient lighting such as energy efficiency and reduced greenhouse gas emissions are driving the growth of the regional market. The North American automotive interior ambient lighting market is expected to maintain its dominance throughout the estimated time frame.

Browse In-Depth Market Research Report (100 Pages) on Automotive Interior Ambient Lighting Market:

https://www.marketresearchfuture.com/reports/automotive-interior-ambient-lighting-market-4965

Europe ranks second in the global automotive interior ambient lighting market. The presence of well-established market players and the automobile industry which is witnessing strong growth in the production and sales of vehicles influences the market value. Additionally, increasing adoption of energy efficient lighting sources such as LED lamps in the region is driving the automotive lighting industry market revenue.

Strict government regulations aimed at reducing vehicle CO2 emissions are driving the interior ambient lighting market in the region. With the presence of leading automakers and smart technologies, Germany accounts for a large share of the regional market, followed by the UK and France. The European automotive interior ambient lighting market is expected to witness significant growth over the assessment period.

The Asia-Pacific region is a rapidly growing market for automotive interior ambient lighting systems. Factors such as booming automobile industry and demand for luxury cars are influencing the growth of the regional market. South Korea, India and China are the major automotive interior ambient lighting markets in the region. The APAC automotive interior ambient lighting market is expected to register a substantial CAGR over the next few years.

Industry trends

The automotive industry is going through major transformations. Automakers are increasingly focusing on ensuring minimal inconvenience to drivers by facilitating optimized operational techniques. Over the past decade, automobile production and sales have surged, justifying market demand. The increase in the disposable income of the middle income groups increases the sales in the market, driving the automobile industry.

Growing urban population and expansion of global automakers into new emerging markets are positively influencing the market revenue. Additionally, increasing R&D investment in the development of efficient indoor ambient lighting systems increases the market value. The growing demand for reliable and quality lighting solutions is influencing the growth of the market.

Ask the expert:

https://www.marketresearchfuture.com/ask_for_schedule_call/4965

Automotive Interior Ambient Lighting Market Competitive Analysis

The automotive interior ambient lighting market appears to be highly competitive due to the presence of several small and large players. These players are incorporating strategic initiatives such as innovations in products and manufacturing techniques, mergers and acquisitions, and brand building to boost market competition and maintain their market positions.

For example, on August 04, 2022, Ford unveiled its 2023 Explorer model in China with a revised exterior and interior. The new range comes with a complete facelift from the sixth-generation Explorer, with a redesigned exterior and a massive new screen inside the cabin. The new SUV will likely make its official debut at the Chengdu Auto Show in late August 2022. Ford designed the slimmer air vents to elevate the center console and create a more upscale atmosphere with ambient lighting and leather upholstery.

In another case, on February 22, 2022, Motherson, one of the world’s leading manufacturers of interior and exterior automotive components, announced a partnership with the Valeo group to develop an automotive interior lighting system. This partnership would allow Motherson to integrate Valeo’s innovative lighting systems into its new cabin interior modules and surfaces.

The MOU aims to create a futuristic motor vehicle interior by integrating lighting systems with advanced surface finishes. Thanks to these new technologies, the dashboards, door panels, center consoles and other interior trim will be completely redesigned.

Check the discount:

https://www.marketresearchfuture.com/check-discount/4965

The Dominant Key Players covered in the Automotive Interior Ambient Lighting Market are:

  • Koito Manufacturing Co.Ltd. (Japan)
  • Hella KGaA Hueck & Co (Germany)
  • Federal-Mogul Corporation (USA)
  • OSRAM Licht AG (Germany)
  • GE Lighting (USA)
  • Magneti Marelli SpA (Italy)
  • Valeo (France)
  • Antolin Group (Spain)
  • Zizala Lichtsysteme GmbH (Austria)
  • Stanley Electric Co.Ltd. (Japan)
  • Ichikoh Industries Ltd. (Japan)
  • OSRAM Licht AG (Germany)

Related reports:

Motorsports market share Research Report: Information by Type, by Application, by Model – Forecast to 2030

Automotive Digital Cockpit Market Analysis Research Report: Insights by Equipment, Vehicle Type, Powertrain and Region – Forecast to 2030

Automotive Display Market Trends Research Report, By Applications, By Type, By Display Size – Global Forecast To 2030

About Market Research Future:

Market Research Future (MRFR) is a global market research company that prides itself on its services, offering comprehensive and accurate analysis regarding various markets and consumers around the world. Market Research Future has the distinct objective of providing clients with top quality research and granular research. Our market research by products, services, technologies, applications, end users and market players for global, regional and country market segments enables our clients to see more, know more and do more , which helps answer your most important questions. questions.

Follow us: LinkedIn | Twitter


Superior protection with COVID-19 “mix-and-match” booster strategy

0

The coronavirus disease 2019 (COVID-19) pandemic was caused by the sudden global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since SARS-CoV-2 emerged in late 2019, scientists have worked tirelessly to develop multiple vaccines to reduce SARS-CoV-2 transmission and protect individuals from severe COVID-19.

Recently, a rapid decline in antibody levels induced by vaccination with messenger ribonucleic acid (mRNA) vaccines has been observed. in a new Open Jama Network study, researchers discuss the durability and immunogenicity of homologous and heterologous booster regimens with Johnson & Johnson Ad26.COV2.S and Pfizer-BioNTech BNT162b2 vaccines.

Study: Durability of heterologous and homologous COVID-19 vaccine boosters. Image Credit: PhotobyTawat / Shutterstock.com

Background

Exceptional short-term immunogenicity and protective efficacy have been associated with COVID-19 mRNA vaccines. However, between three and six months after the primary vaccination, neutralizing antibody (nAb) responses decline. A similar drop in nAb levels was observed after the third and fourth mRNA booster doses which were proposed to provide protection against the highly mutated variant of Omicron.

Compared to mRNA vaccines, lower initial nAb titers are induced by the Johnson & Johnson adenovirus vector-based Ad26.COV2.S vaccine against COVID-19. However, these responses were maintained for at least eight months.

Previous research has shown that CD8+ T cell responses may contribute to protection against serious disease and are more durable than serum nAb titers. T-cell responses show significant cross-reactivity against the Omicron variant, despite the ability of this variant to evade vaccination-induced antibody traps.

Optimal recovery strategies are the subject of active research, the results of which will be decisive for the long-term control of the pandemic.

About the study

The main objective of this study was to analyze the durability and immunogenicity of homologous and heterologous vaccine booster strategies.

This study was conducted at a clinical site in Boston, Massachusetts. Taken together, 68 study participants who received two doses of the BNT162b2 vaccine and who received a booster with the BNT162b2 or Ad26.COV2.S vaccines at least six months after completing their primary vaccination course were included in the current study.

People with a history of SARS-CoV-2 infection, as well as receipt of other COVID-19 vaccines or immunosuppressive drugs, were excluded from the study. Additionally, individuals were not permitted to participate if they had confirmed SARS-CoV-2 infection or positive nucleocapsid serology detected by electrochemiluminescence (ECLA) testing.

Study participants were recruited between August 12, 2021 and October 25, 2021, with an additional four months of follow-up after the end of the study period. Data analysis to assess humoral and cellular immune responses was performed between November 2021 and February 2022.

Study results

The homologous boost generated a rapid increase in Omicron nAbs, which peaked in week 2 and then declined nearly seven-fold by 16e the week. Comparatively, boosted heterologous nAbs peaked in week 4 and declined approximately two-fold by 16e the week. These results are consistent with other findings describing the durability of immune responses after initial mRNA vaccination with a booster dose of the Ad26.COV2.S vaccine.

The heterologous booster dose was also associated with higher Omicron-specific CD8+ T cell responses. This response remains highly reactive against the Omicron variant, despite the ability of this variant to escape vaccination-induced traps.

In South Africa, the BNT162b2 and Ad26.COV2.S vaccines provided 70% and 85% efficacy, respectively, against hospitalization with the Omicron variant in the absence of nAbs. This observation suggests the crucial role of other immune responses in protecting against severe COVID-19.

Limits

A key limitation of the current study is its small size at a single site in Boston. In addition, there was a lack of randomization and women were overrepresented.

Thus, future research using larger and more representative samples is needed. Additionally, follow-up times beyond 16 weeks are required to assess long-term durability.

conclusion

Taken together, heterologous and homologous booster vaccination elicited Omicron-specific antibody and T cell responses in mRNA vaccinated individuals. Notably, heterologous vaccination elicited higher nAb and CD8+ T cell responses. These observations suggest the advantages of heterologous vaccine regimens.

Alien-Like Creature Found Deep Sea, Scientists Call It ‘Darth Vader’

0

A new study has found giant isopods deep below the ocean surface in the Gulf of Mexico and it’s been called ‘Darth Vader of the Seas’ because of its resemblance to the ‘Star Wars’ villain. The study showed that the new species called “genus Bathynomus” is about 2,500% larger than common varieties. According to the official statement, the discovery was made in the benthic zone – the deepest part of the ocean – and is a significant addition to existing knowledge.

Read also | 41 dead, 55 injured in Cairo church fire during mass: security sources

“The ecological diversity of the Gulf of Mexico is perhaps more complex than [previously] thought. I was skeptical. Since the Enoshima Aquarium in Japan only bought B. giganteus, I always thought it was B. giganteus,” said Huang Ming-Chih, lead author of the study. , at LiveScience.

The discovery was made when Huang obtained the specimen from Enoshima Aquarium in Japan assuming it was B. giganteus. However, analysis by the team showed that it was different at the cellular level and exhibited qualities not found before.

Read also | Country ‘most at risk of natural disasters’ to switch to renewables by 2030

The specimen was originally found by scientists near Mexico’s Yucatán Peninsula in 2017. While the working theory is that they are related to crustaceans that include woodlice, the size of the specimen found between 2 000 and 2,600 feet below sea level is much larger than the common species.

The first recorded discovery of isopods dates back to 1879 when scientists found it in the ocean and over the years around 20 varieties of the group have been discovered by researchers.

25,951 shares of Minerals Technologies Inc. (NYSE: MTX) purchased by Qube Research & Technologies Ltd

0

Qube Research & Technologies Ltd bought a new position in shares of Minerals Technologies Inc. (NYSE: MTXGet a rating) during Q1, according to its most recent SEC filing. The institutional investor bought 25,951 shares of the basic materials company, valued at around $1,717,000. Qube Research & Technologies Ltd held approximately 0.08% of Minerals Technologies at the end of the most recent period.

Several other hedge funds and other institutional investors have also recently increased or reduced their stakes in the company. Mutual of America Capital Management LLC increased its position in Minerals Technologies by 0.5% during the fourth quarter. Mutual of America Capital Management LLC now owns 29,784 shares of the basic materials company worth $2,179,000 after buying 160 additional shares in the last quarter. Verdence Capital Advisors LLC increased its position in Minerals Technologies by 6.2% during the 1st quarter. Verdence Capital Advisors LLC now owns 3,532 shares of the basic materials company worth $234,000 after buying 207 additional shares in the last quarter. Comerica Bank increased its stake in shares of Minerals Technologies by 1.9% in the 1st quarter. Comerica Bank now owns 15,933 shares of the basic materials company valued at $1,039,000 after buying 295 additional shares last quarter. Barrow Hanley Mewhinney & Strauss LLC increased its equity stake in Minerals Technologies by 22.4% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 1,866 shares of the basic materials company valued at $136,000 after buying 342 additional shares last quarter. Finally, Advisor Group Holdings Inc. increased its stake in shares of Minerals Technologies by 24.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 2,075 shares of the basic materials company valued at $151,000 after buying 414 additional shares last quarter. 94.87% of the shares are currently held by institutional investors.

A Wall Street analyst gives his opinion

Separately, StockNews.com downgraded shares of Minerals Technologies from a “buy” rating to a “hold” rating in a Tuesday, June 28 report.

Mineral Technology Price Performance

NYSE: MTX opened at $65.37 on Friday. The company has a debt ratio of 0.60, a current ratio of 2.29 and a quick ratio of 1.56. The company has a market capitalization of $2.13 billion, a price-earnings ratio of 12.72 and a beta of 1.27. The company has a 50-day moving average price of $62.68 and a 200-day moving average price of $65.01. Minerals Technologies Inc. has a 1-year low of $57.52 and a 1-year high of $80.92.

Mineral Technologies (NYSE: MTXGet a rating) last released its quarterly results on Thursday, July 28. The basic materials company reported EPS of $1.50 for the quarter, beating the consensus estimate of $1.46 by $0.04. The company posted revenue of $577.00 million in the quarter, versus analyst estimates of $533.65 million. Minerals Technologies posted a net margin of 8.46% and a return on equity of 11.44%. The company’s revenue increased by 26.5% compared to the same quarter last year. In the same quarter of the previous year, the company achieved EPS of $1.29. Equity research analysts expect Minerals Technologies Inc. to post EPS of 5.6 for the current year.

Minerals Technologies dividend announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 9. Investors of record on Friday, August 19 will receive a dividend of $0.05. This represents an annualized dividend of $0.20 and a yield of 0.31%. The ex-dividend date is Thursday, August 18. Minerals Technologies’ payout ratio is currently 3.89%.

About Minerals Technologies

(Get a rating)

Minerals Technologies Inc develops, produces and markets a variety of specialty mineral, mineral-based and synthetic mineral products, as well as support systems and services. The Company operates through three segments: Performance Materials, Specialty Minerals and Refractories. The Performance Materials segment provides bentonite and bentonite related products, as well as leonardite.

Further reading

Want to see which other hedge funds hold MTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerals Technologies Inc. (NYSE: MTXGet a rating).

Institutional ownership by quarter for Minerals Technologies (NYSE:MTX)



Receive daily news and reviews for Minerals Technologies – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Minerals Technologies and related companies with MarketBeat.com’s free daily email newsletter.

Ministers accused of letting down 500,000 people with compromised immune systems for delaying Covid drug

0

Ministers accused of failing 500,000 people with compromised immune systems for delaying green light for ‘overcost’ Covid drug

  • The former health secretary has accused ministers of letting up to 500,000 people down
  • Lord Andrew Lansley said more than 20 countries use the drug
  • The drug, Evusheld, could protect those who don’t benefit from Covid shots

Ancient Health Secretary Andrew Lansley has accused ministers of failing up to 500,000 people who don’t get Covid vaccinations by delaying the opportunity to greenlight a drug that could protect them .

Lord Lansley, who served under David Cameron, feared cost was the reason ministers had not approved Evusheld for people with weakened immune systems.

On Friday, the government confirmed that it would not yet buy Evusheld, made by AstraZeneca, due to questions about its protection against Omicron variants.

Lord Andrew Lansley, former health secretary, has accused ministers of letting up to 500,000 people with weakened immune systems down by delaying the green light for a drug that could protect them

The National Institute of Health and Healthcare Excellence (Nice) will examine the drug by next April.

The Tory peer told Today on BBC Radio 4 yesterday that more than 20 countries were using Evusheld, with evidence of its effectiveness against Omicron construction. He said: “It’s very difficult to see what the return to Nice means, other than the fact that there is a cost issue.”

Guide: How to beat Leshy in Cult of the Lamb

0

Leshy is one of the four powerful bishops you will face in Worship of the Lamb. This means they are tougher than the common enemy. Try not to get distracted by his disgusting mouth and follow our tips to defeat Leshy in the game.

How to defeat Leshy in Cult of the Lamb

Leshy is an amalgamation of bosses from the last four levels but on a monstrous level. We’ll walk you through how to avoid every move at his disposal.

The first is a circle of huge spikes that cover the entire arena. You will want to be patient with this. Wait for the spikes to separate as you run towards the edge of the arena. Now once there is a gap, roll towards Leshy but not too close where you take damage. The green plumes from the ground will look scary, but you can pass them without a problem.

Another one of his attacks is when he unleashes a ton of poisonous projectiles towards your lamb. When this happens, you will see red crosses on the ground. Avoid them by dodging to the other side of the arena.

While all the chaos is happening, try to take out the minor enemies around you. You don’t want to accidentally dodge them and take unnecessary damage.

The best time to attack Leshy is when he is charging for an attack. He will tilt his head forward for a few seconds. Strike during these crucial moments, then dodge to avoid projectiles coming your way.

Towards the end of the fight, Leshy will start banging her head on the ground around her. Make sure to keep your distance and get into your damage range once he’s finished banging his head and jumping out of the burrow he creates. By the way, do not come into contact with Leshy while he is underground, because his thorns will hurt you. Honestly, the best option is to use ranged attacks if you’re storing energy for them.

Leshy is a more powerful version of Valefar and Barbatos, but if you can manage the timing of your dodges and find the most optimal moment to attack, you’ll succeed against the first fool that gets in your way.

Follow our other pattern guides for Worship of the Lamb if you need help:

Cult of the Lamb is currently available on PS4, Xbox One, Switch, and PC.

Research: Rating Action: Moody’s Confirms Aretec (B3 Business Family) Ratings, Changes Outlook from Stable to Positive

0


No related data.

© 2022 Moody’s Corporation, Moody’s Investors Service, Inc., Moody’s Analytics, Inc. and/or their licensors and affiliates (collectively, “MOODY’S”). All rights reserved.

THE CREDIT RATINGS ISSUED BY MOODY’S CREDIT RATINGS AFFILIATES CONSTITUTE THEIR CURRENT OPINIONS ON THE RELATIVE FUTURE CREDIT RISK OF THE ENTITIES, CREDIT COMMITMENTS, INDEBTEDNESS OR SECURITIES ASSOCIATED WITH INDEBTEDNESS, AND THE DOCUMENTS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY’S (COLLECTIVELY, THE “PUBLICATIONS”) MAY INCLUDE SUCH CURRENT OPINIONS. MOODY’S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY FAILURE TO MEET ITS CONTRACTUAL FINANCIAL OBLIGATIONS WHEN DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT OR IMPAIRMENT. SEE THE APPLICABLE PUBLICATION OF MOODY’S RATINGS SYMBOLS AND DEFINITIONS FOR MORE INFORMATION ON THE TYPES OF CONTRACTUAL FINANCIAL OBLIGATIONS COVERED BY MOODY’S CREDIT RATINGS. THE CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK OR PRICE VOLATILITY. CREDIT RATINGS, NON-CREDIT ASSESSMENTS (“RATINGS”) AND OTHER OPINIONS INCLUDED IN MOODY’S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACTS. MOODY’S PUBLICATIONS MAY ALSO INCLUDE MODEL-BASED QUANTITATIVE ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY’S ANALYTICS, INC. AND/OR ITS AFFILIATES. MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS FOR BUYING, SELLING OR HOLDING PARTICULAR SECURITIES. MOODY’S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT COMMENT ON THE SUITABILITY OF ANY INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY’S ISSUES ITS CREDIT RATINGS, ASSESSMENTS AND OTHER OPINIONS AND PUBLISHES ITS PUBLICATIONS WITH THE CARE AND UNDERSTANDING THAT EACH INVESTOR WILL CAREFULLY MAKE HIS OWN RESEARCH AND EVALUATION OF EACH SECURITY THAT IS CONSIDERED FOR PURCHASE, HOLDING OR SALE.

MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE UNINTENDED AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE ANY CREDIT RATINGS, RATINGS, OTHER OPINIONS OR PUBLICATIONS OF MOODY’S WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT, YOU SHOULD CONTACT YOUR FINANCIAL ADVISOR OR OTHER PROFESSIONAL.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY NOT BE COPIED OR OTHERWISE REPRODUCED, RECONDITIONED, TRANSMITTED, TRANSFERRED, DISTRIBUTED , REDISTRIBUTED OR RESOLD, OR STORED FOR FUTURE USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER, OR BY ANY MEANS, BY ANY PERSON WITHOUT THE PRIOR WRITTEN CONSENT OF MOODY’S .

MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY ANYONE AS A REFERENCE AS THIS TERM IS DEFINED FOR REGULATORY PURPOSES AND SHOULD NOT BE USED IN A MANNER THAT COULD CONSIDER THEM AS A REFERENCE.

All information contained herein is obtained by MOODY’S from sources believed to be accurate and reliable. However, due to the possibility of human or mechanical error and other factors, all information contained herein is provided “AS IS” without warranty of any kind. MOODY’S takes all necessary measures to ensure that the information it uses to assign a credit rating is of sufficient quality and comes from sources that MOODY’S considers to be reliable including, where applicable, independent third-party sources. However, MOODY’S is not an auditor and cannot in any case independently verify or validate the information received as part of the rating process or the preparation of its Publications.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim all liability to any person or entity for any indirect, special, consequential or incidental loss or damage whatsoever , arising out of or relating to the information contained herein or the use or inability to use such information, even if MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is informed in advance of the possibility of such loss or damage, including but not limited to: (a) any loss of actual or potential profits or (b) any loss or damage occurring when the financial instrument concerned does not not subject to a particular credit rating assigned by MOODY’S.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim all liability for any direct or compensatory loss or damage to any person or entity, including but not limited to limit, any negligence (but excluding fraud, willful misconduct or any other type of liability which, for the avoidance of doubt, cannot be excluded by law) on the part of, or any contingency within the control or beyond the control of MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising out of or in connection with the information contained herein or the use or inability to use this information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY CREDIT RATING, RATINGS, OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY’S IN ANY FORM OR MANNER.

Moody’s Investors Service, Inc., a credit rating agency wholly owned by Moody’s Corporation (“MCO”), hereby declares that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred shares rated by Moody’s Investors Service, Inc. have, prior to the assignment of any credit rating, agreed to pay Moody’s Investors Service, Inc. for rating opinions credit and the services it renders fees ranging from $1,000 to approximately $5,000,000. MCO and Moody’s Investors Service also maintain policies and procedures to ensure the independence of credit ratings and Moody’s Investors Service credit rating processes. Information regarding certain affiliations that may exist between MCO directors and rated entities, and between entities that hold credit ratings from Moody’s Investors Service and that have also publicly disclosed to the SEC an ownership interest in MCO of more than 5% , are published annually on www .moodys.com under the heading “Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy”.

Additional Terms for Australia Only: Any publication in Australia of this material is in accordance with the Australian Financial Services License of MOODY’S subsidiary, Moody’s Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody’s Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (if applicable). This document is intended for supply only to “wholesale customers” within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from Australia, you represent to MOODY’S that you are, or are accessing to the document as a representative of a “wholesale customer” and that neither you nor the entity you represent will directly or indirectly distribute this document or its contents to “retail customers” within the meaning of section 761G of the Corporations Act 2001. MOODY’S credit rating is an opinion of the creditworthiness of a debt security of the issuer, and not of the equity securities of the issuer or any form of security available to investors in detail.

Additional Terms for Japan Only: Moody’s Japan KK (“MJKK”) is a wholly owned subsidiary credit rating agency of Moody’s Group Japan GK, which is wholly owned by Moody’s Overseas Holdings Inc., a wholly owned subsidiary of MCO. Moody’s SF Japan KK (“MSFJ”) is a wholly owned subsidiary credit rating agency of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization (“NRSRO”). Accordingly, the credit ratings assigned by MSFJ are non-NRSRO credit ratings. Non-NRSRO credit ratings are assigned by an entity that is not an NRSRO and therefore the rated obligation will not qualify for certain types of treatment under US law. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stocks rated by MJKK or MSFJ (as applicable) have, prior to the assignment of any credit rating, agreed to pay MJKK or MSFJ (as applicable) for credit rating opinions and the services it renders a fee ranging from 100 000 JPY to around 550,000,000 JPY.

MJKK and MSFJ also maintain policies and procedures to meet Japanese regulatory requirements.

Covid-19 antibodies found in non-immune blood cancer patients after receiving booster shot

0

Patients with blood cancers have been reported to be less likely to develop immunity to COVID-19 vaccination. However, new data has been found indicating that those who were previously vaccinated with no immunity, then followed up with a booster dose, eventually developed antibodies against the virus.

Patients with blood cancers have been reported to be less likely to develop immunity to COVID-19 vaccination. However, new data has been found indicating that those who were previously vaccinated with no immunity, then followed up with a booster dose, eventually developed antibodies against the virus.

These data are based on a study published in July in the journal of the American Cancer Society, Cancer.

The study authors retrospectively analyzed the serological responses to initial and booster COVID-19 vaccination in 378 patients with hematological malignancies or blood cancers such as leukemia, lymphoma and multiple myeloma, and reported then tracked results related to COVID-19.

Antibodies were found in 181 patients after initial vaccination; patients who had an active malignancy or those who were recently treated with a B-cell depleting monoclonal antibody had the lowest levels of antibodies developed, according to the study.

For initial non-responders to vaccination, immunity after a booster dose occurred in 48 of 85 patients (56%). The rate of seroconversion or immunity after the booster was similar for patients on (53%) and off (58%) active treatment.

The study results also revealed that 33 patients (8.8%) developed COVID-19 infection and three succumbed to COVID-19-related deaths (0.8%).

The researchers found that the post-vaccination antibody response may not be associated with a decrease in any COVID-19 infection. They suggested effective vaccination with booster, supplemented by passive immunization with tixagevimab/cilgavimab in the absence of seroconversion, effective in the otherwise high-risk population.

U of U Health receives $28 million to explore the inner workings of HIV

0

A multi-institutional research center run by the University of Utah Health that studies the inner workings and vulnerabilities of HIV, the human immunodeficiency virus that causes AIDS, recently received a $28 million grant renewal. over five years from the National Institutes of Health.

Since its creation in 2007, the CHEETAH Center for Structural Biology of HIV Infection Restriction and Viral Dynamics has published over 300 research articles that have led to a better understanding of HIV and its potential treatments.

Wesley Sunquist, director of the center, professor and chair of the department of biochemistry at U of U Health, leads 20 research teams from 12 institutions. With the renewal of the grant, researchers will focus on:

Wesley Sundquist, director of CHEETAH. Photo credit: Charlie Ehlert.

  • Determine how HIV infects cells,
  • Understand how host cells defend themselves against the virus,
  • Analyze how the virus becomes dormant and rebounds, and
  • Develop next-generation tools and methodologies to better understand the structure and mechanisms of HIV.

“The exceptional science emerging from this program is changing the understanding of HIV/AIDS, other viral diseases and cell biology, enabling the development of new therapies such as lenacapavir and D-peptide inhibitors,” says Rachel Hesseassociate vice president for research at U of U Health, referring to two experimental drugs with roots in CHEETAH.

From Deep Understanding to Experimental Drugs

Just half a century ago, HIV infection almost inevitably led to serious illness and death. Today’s antiretroviral therapies can suppress the virus and prevent symptoms, but improvements are still needed. If these drugs are not taken daily, the virus can rebound and develop drug resistance. Medications can also cause harsh side effects. The foundations for two new experimental drugs that could help circumvent these problems are based on years of research by CHEETAH scientists.

Debra Eckert, PhD, and Michael Kay, PhD

Research by CHEETAH investigators Debra Eckert (left) and Michael Kay (right), and Wesley Sundquist and Christopher Hill (not pictured) and their teams has led to two experimental HIV drugs that are currently being tested in clinical tests. Photo credit: Charlie Ehlert.

Sundquist Research, Christopher Hill, distinguished professor of biochemistry at U of U Health and other CHEETAH Center labs on the HIV capsid – a structure they found vital to different stages of the HIV life cycle – laid the groundwork that has leads the pharmaceutical company Gilead Sciences to identify the capsid inhibitor, lenacapavir. This investigational drug is currently in phase 3 clinical trials and is already very promising as a powerful, long-acting treatment.

By taking a different approach, Michael KayCHEETAH researcher and professor of biochemistry, and Debra Eckertassistant research professor of biochemistry, used synthetic chemistry to design a D-peptide inhibitor called CPT31 that blocks the HIV infection machinery. The molecule is now in phase 1 clinical trials sponsored by Navigen, Inc.

“People often forget that drug development is based on basic research,” says Sundquist. “These are two more instances where this has happened, and it’s very satisfying.”

Learning the lessons of HIV

CHEETAH continues to bring an understanding of HIV, related viruses, and host biology in new directions through collaborations among its scientists, who come from a variety of disciplines. “The CHEETAH Center does exciting, interdisciplinary science in a collaborative environment that allows us to do projects that otherwise wouldn’t be possible in a single lab,” says Pamela Bjorkman, professor of biology and bioengineering at Caltech.

Nels Elde, a professor of human genetics at U of U Health, looks to evolution for inspiration, noting that many animals are not as susceptible as humans to illnesses caused by HIV. He is collaborating with other CHEETAH scientists to determine whether a gene found in mice and squirrel monkeys that prevents HIV from leaving cells after replication could become the basis of a new type of antiviral.

“Nature has apparently had countless billions of experiments that have brought us to where we are today,” says Elde. “Can we learn from what happened and borrow and deploy them in useful ways?”

A close up image of the HIV virus

At 130 nanometers, HIV is about 60 times smaller than a red blood cell. Advances in cryo-electron microscopy (left) and molecular modeling (right) have made it possible to see the virus in unprecedented detail. Image credit: Owen Pornillos, Barbie Ganser-Pornillos.

In contrast, Owen Pornillos, a CHEETAH researcher at the University of Virginia who earned his Ph.D. from the U, takes advantage of his expertise in biochemistry to take a different approach. In a collaborative project with several members of the CHEETAH Center, he removes the virus from the host cell’s complex environment and brings it to the test tube. By adding a few specific ingredients at a time, the team identifies key virus and host cell components that are essential in the early stages of viral infection and replication. Combining this approach with new microscope technologies allows them to visualize these steps with unprecedented clarity.

“CHEETAH is committed to scientific excellence and is always planning where we envision the field five years from now,” Pornillos said. “It’s exciting to be a part of it.”

These diverse tactics provide valuable insights into virology and biology, and uncover targets for new types of therapeutic interventions.

Research: Rating Action: Moody’s Affirms Parkview Medical Center (CO) Baa1; outlook revised to negative

0


No related data.

© 2022 Moody’s Corporation, Moody’s Investors Service, Inc., Moody’s Analytics, Inc. and/or their licensors and affiliates (collectively, “MOODY’S”). All rights reserved.

THE CREDIT RATINGS ISSUED BY MOODY’S CREDIT RATINGS AFFILIATES CONSTITUTE THEIR CURRENT OPINIONS ON THE RELATIVE FUTURE CREDIT RISK OF THE ENTITIES, CREDIT COMMITMENTS, INDEBTEDNESS OR SECURITIES ASSOCIATED WITH INDEBTEDNESS, AND THE DOCUMENTS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY’S (COLLECTIVELY, THE “PUBLICATIONS”) MAY INCLUDE SUCH CURRENT OPINIONS. MOODY’S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY FAILURE TO MEET ITS CONTRACTUAL FINANCIAL OBLIGATIONS WHEN DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT OR IMPAIRMENT. SEE THE APPLICABLE PUBLICATION OF MOODY’S RATINGS SYMBOLS AND DEFINITIONS FOR MORE INFORMATION ON THE TYPES OF CONTRACTUAL FINANCIAL OBLIGATIONS COVERED BY MOODY’S CREDIT RATINGS. THE CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK OR PRICE VOLATILITY. CREDIT RATINGS, NON-CREDIT ASSESSMENTS (“RATINGS”) AND OTHER OPINIONS INCLUDED IN MOODY’S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACTS. MOODY’S PUBLICATIONS MAY ALSO INCLUDE MODEL-BASED QUANTITATIVE ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY’S ANALYTICS, INC. AND/OR ITS AFFILIATES. MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS FOR BUYING, SELLING OR HOLDING PARTICULAR SECURITIES. MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS DO NOT COMMENT ON THE SUITABILITY OF ANY INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY’S ISSUES ITS CREDIT RATINGS, ASSESSMENTS AND OTHER OPINIONS AND PUBLISHES ITS PUBLICATIONS WITH THE CARE AND UNDERSTANDING THAT EACH INVESTOR WILL CAREFULLY MAKE HIS OWN RESEARCH AND EVALUATION OF EACH SECURITY THAT IS CONSIDERED FOR PURCHASE, HOLDING OR SALE.

MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE UNINTENDED AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE ANY CREDIT RATINGS, RATINGS, OTHER OPINIONS OR PUBLICATIONS OF MOODY’S WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT, YOU SHOULD CONTACT YOUR FINANCIAL ADVISOR OR OTHER PROFESSIONAL.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY NOT BE COPIED OR OTHERWISE REPRODUCED, RECONDITIONED, TRANSMITTED, TRANSFERRED, DISTRIBUTED , REDISTRIBUTED OR RESOLD, OR STORED FOR FUTURE USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER, OR BY ANY MEANS, BY ANY PERSON WITHOUT THE PRIOR WRITTEN CONSENT OF MOODY’S .

MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY ANYONE AS A REFERENCE AS THIS TERM IS DEFINED FOR REGULATORY PURPOSES AND SHOULD NOT BE USED IN A MANNER THAT COULD CONSIDER THEM AS A REFERENCE.

All information contained herein is obtained by MOODY’S from sources believed to be accurate and reliable. However, due to the possibility of human or mechanical error and other factors, all information contained herein is provided “AS IS” without warranty of any kind. MOODY’S takes all necessary measures to ensure that the information it uses to assign a credit rating is of sufficient quality and comes from sources that MOODY’S considers to be reliable including, where applicable, independent third-party sources. However, MOODY’S is not an auditor and cannot in any case independently verify or validate the information received as part of the rating process or the preparation of its Publications.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim all liability to any person or entity for any indirect, special, consequential or incidental loss or damage whatsoever , arising out of or relating to the information contained herein or the use or inability to use such information, even if MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is informed in advance of the possibility of such loss or damage, including but not limited to: (a) any loss of actual or potential profits or (b) any loss or damage occurring when the financial instrument concerned does not not subject to a particular credit rating assigned by MOODY’S.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim all liability for any direct or compensatory loss or damage to any person or entity, including but not limited to limit, any negligence (but excluding fraud, willful misconduct or any other type of liability which, for the avoidance of doubt, cannot be excluded by law) on the part of, or any contingency within the control or beyond the control of MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising out of or in connection with the information contained herein or the use or inability to use this information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY CREDIT RATING, RATINGS, OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY’S IN ANY FORM OR MANNER.

Moody’s Investors Service, Inc., a credit rating agency wholly owned by Moody’s Corporation (“MCO”), hereby declares that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred shares rated by Moody’s Investors Service, Inc. have, prior to the assignment of any credit rating, agreed to pay Moody’s Investors Service, Inc. for rating opinions credit and the services it renders fees ranging from $1,000 to approximately $5,000,000. MCO and Moody’s Investors Service also maintain policies and procedures to ensure the independence of credit ratings and Moody’s Investors Service credit rating processes. Information regarding certain affiliations that may exist between MCO directors and rated entities, and between entities that hold credit ratings from Moody’s Investors Service and that have also publicly disclosed to the SEC an ownership interest in MCO of more than 5% , are published annually on www .moodys.com under the heading “Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy”.

Additional Terms for Australia Only: Any publication in Australia of this material is in accordance with the Australian Financial Services License of MOODY’S subsidiary, Moody’s Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody’s Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (if applicable). This document is intended for supply only to “wholesale customers” within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from Australia, you represent to MOODY’S that you are, or are accessing to the document as a representative of a “wholesale customer” and that neither you nor the entity you represent will directly or indirectly distribute this document or its contents to “retail customers” within the meaning of section 761G of the Corporations Act 2001. MOODY’S credit rating is an opinion of the creditworthiness of a debt security of the issuer, and not of the equity securities of the issuer or any form of security available to investors in detail.

Additional Terms for Japan Only: Moody’s Japan KK (“MJKK”) is a wholly owned subsidiary credit rating agency of Moody’s Group Japan GK, which is wholly owned by Moody’s Overseas Holdings Inc., a wholly owned subsidiary of MCO. Moody’s SF Japan KK (“MSFJ”) is a wholly owned subsidiary credit rating agency of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization (“NRSRO”). Accordingly, the credit ratings assigned by MSFJ are non-NRSRO credit ratings. Non-NRSRO credit ratings are assigned by an entity that is not an NRSRO and therefore the rated obligation will not qualify for certain types of treatment under US law. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stocks rated by MJKK or MSFJ (as applicable) have, prior to the assignment of any credit rating, agreed to pay MJKK or MSFJ (as applicable) for credit rating opinions and the services it renders a fee ranging from 100 000 JPY to around 550,000,000 JPY.

MJKK and MSFJ also maintain policies and procedures to meet Japanese regulatory requirements.

New test can tell how immune you are to COVID-19 – Jammu Kashmir Latest News | Tourism

0

BOSTON, August 10: Researchers in the United States have developed an easy-to-use test that can predict how well people are immune to COVID-19, whether through vaccination, infection or a combination of both.
Easy access to this type of testing could help people determine what kind of precautions to take against COVID-19 infection, such as an extra booster shot, the researchers said.
Described in the journal Cell Reports Methods, the test measures the level of neutralizing antibodies — responsible for defending cells against the virus — that target SARS-CoV-2 in a blood sample.
“Among the general population, a lot of people probably want to know how protected they are,” said Hojun Li from the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), USA.
“But I think where this test could make the biggest difference is for anyone receiving chemotherapy, anyone taking immunosuppressive drugs for rheumatological disorders or autoimmune diseases, and for anyone older. or who doesn’t have good immune responses in general,” Li said.
These people might need to be boosted earlier or given more doses to get adequate protection, the researchers said.
The test is designed so that different viral spike proteins – which help the virus enter and infect cells – can be swapped.
This makes it possible to detect immunity against any existing or future variant of SARS-CoV-2, the researchers said.
The researchers have filed for a patent on the technology and now hope to partner with a diagnostics company that could manufacture the devices and seek approval from the US Food and Drug Administration (FDA).
Currently, the gold standard approach to measuring immunity is to mix a blood sample with live virus and measure the number of cells in the sample that are killed by the virus.
This procedure is too dangerous to perform in most laboratories, so the most commonly used approaches involve non-infectious modified “pseudovirus” particles.
However, these approaches still require trained personnel working in a laboratory with specialized equipment, so they are not practical for obtaining immediate results. Li was inspired by home pregnancy tests, which are based on a type of test called a lateral flow test.
Lateral flow tests generally consist of strips of paper embedded with test lines that bind to a particular target molecule if present in a sample.
This technology is also the basis of most rapid home tests for COVID-19.
Li and his collaborators have developed a device capable of detecting the presence of antibodies that prevent the SARS-CoV-2 receptor binding domain (RBD) from binding to ACE2, the human receptor that the virus uses to infect humans. cells.
The first step in the test involves mixing human blood samples with a viral RBD protein that has been tagged with tiny gold particles that can be visualized when bound to a strip of paper.
After the antibodies in the sample have been allowed time to interact with the viral protein, a few drops of the sample are placed on a test strip integrated with two test lines.
One of these lineages attracts free viral RBD proteins, while the other attracts any RBD that has been captured by neutralizing antibodies, the researchers said.
A strong signal from the second line indicates a high level of neutralizing antibodies in the sample, they said. (PTI)

Previous posthoroscope
Next postSkoda reopens reservations for Kodiaq; deliveries in January-March next year

The main daily newspaper in Jammu and Kashmir, India

Agreement on gene-editing technology for biofuel advancement

0

A new licensing agreement between three parties will allow CRISPR-Cas9 and similar gene-editing tools to be used to produce varieties of camelina for the advancement of biofuels.

Corteva Agriscience, Broad Institute of MIT and Harvard, and Sustainable Oils, a subsidiary of Global Clean Energy Holdings, Inc. are the three parties to the agreement. They said the technology will be used to further develop camelina for energy purposes.

“We are excited to add CRISPR-Cas9 technology to accelerate our camelina breeding practices,” said Jerry Feitelson, Chief Scientific Officer of Sustainable Oils, in a press release. “With this powerful innovation in plant breeding, we plan to further expand our intellectual property portfolio of advanced camelina varieties, which is already the largest in the world. Through state-of-the-art breeding methods, optimal agronomic advancements and large-scale logistics, we hope to bring the carbon intensity of our finished fuels to near or below zero.”

Camelina has been considered a biofuel feedstock that can also function as a cover crop, allowing growers to practice soil health practices while generating a harvestable crop.

Sustainable Oils said the deal allows it to target specific traits for crop improvement. The company said it hopes to increase oil yield, accelerate maturity and improve drought resistance. Overall, its goals include creating a more efficient culture with a lower breeding cost.

For more news, visit www.Agri-Pulse.com.

OIG: VHA’s digital health program saw less than 50% of devices used

0

According to a report from the Office of Inspector General, the Veterans Health Administration’s Digital Divide program distributed about 41,000 telehealth tablets to veterans for virtual visits, but less than half actually had those visits, and good many of these devices were not returned. properly.

The Veterans Health Administration has found that it’s one thing to give veterans digital health tools, but another thing to see them use technology.

The VA’s Office of Inspector General (OIG) released a report on a VHA’s Digital Divide program, developed by the Office of Connected Care and launched in late 2020, which has provided approximately 41,000 veterans with iPads so they can connect with healthcare providers on a virtual platform. Investigators found that more than half of veterans had not used the devices by the end of 2021.

And that was just one of many problems with the program.

“In total, the review team determined that VHA could have made better use of approximately $14.5 million in program funds with better monitoring of devices and controls and better monitoring of recovery” , concluded the OIG report.

The study highlights the challenges of developing and launching a telehealth program, as well as the many checkboxes to ensure it works properly. And all this before clinical data is even collected.

Launched at the height of the pandemic, the program was designed to give veterans access to digital health tools so they can connect with healthcare providers without having to travel to a hospital, doctor’s office or a clinic. Program officials said it would not only reduce the risk of infection for veterans, but it would improve access to care and lead to better clinical outcomes.

According to the report:

  • Only an estimated 20,300 of the 41,000 patients, or 49%, used the device to plan and conduct a virtual visit.
  • An estimated 10,700 patients have never scheduled a virtual visit, in part because there was no obligation to do so and neither the patient nor the care team took the initiative.
  • Another 10,000 patients scheduled a virtual visit but did not follow through.
  • Several devices were delivered to 3,119 patients.
  • Some 11,000 devices were not recovered after the patient’s participation in the program ended, and after a review was launched in November 2021, nearly 8,300 devices were still missing, costing the VHA about $6. $3 million, plus an additional $78,000 in cellular data charges.
  • As of January 2022, some 14,800 devices that had been returned had not yet been refurbished, in part due to technical issues in the refurbishment process, so these devices were not yet ready to be reused. Despite this backlog, the VHA purchased 9,720 new devices at a cost of $8.1 million.

Many of the problems cited in the OIG report are blamed on poor program design and management, without clear protocols for scheduling virtual visits, managing devices, or returning them. In response, the OIG listed 10 recommendations:

  1. Establish clear oversight rules and responsibilities for healthcare providers involved in the program with a “digital divide standard operating procedure”.
  2. Create a mechanism to alert healthcare providers when their patient has received a device and is ready to schedule a virtual visit.
  3. Clarify the value of scheduling virtual visits and establish timelines, combined with a schedule for ordering devices.
  4. Ensure that all healthcare providers involved in the program are properly trained and updated whenever protocols change.
  5. Implement protocols to ensure that each patient receives one device and that no patient receives more than one device.
  6. Set an alert if a patient receives a second device and a protocol to retrieve that device.
  7. Ensure program managers monitor a dashboard for device usage, scheduled and completed virtual visits, and recovered devices.
  8. Establish an automated mechanism to identify devices that need to be recovered and initiate the recovery process.
  9. Track all devices sent to patients and returned to the VHA so that they can be refurbished and ready for use in a timely manner.
  10. Solve the challenges of the refurbishment process, improve the process of tracking devices awaiting recovery and refurbishment, and create a structured purchasing model to ensure that these issues do not reoccur and that new devices are purchased when needed.

In response to the report, VHA officials said they “agree or agree in principle” with all of the OIG’s recommendations.

Eric Wicklund is the innovation and technology editor for HealthLeaders.

AI and computer models of brain cells open the door to experiments not possible in the lab

0

Writing in an August 9 article in the newspaper Cell reportsthe scientists say their computational models are the first to combine data sets from different types of laboratory experiments, providing a comprehensive picture of the electrical, genetic and biological activity of individual neurons.


To create the models, the researchers used two different datasets of the mouse’s primary visual cortex, the area of ​​the brain that processes information from the eyes. The first dataset presented comprehensive genetic images of tens of thousands of individual cells, while the second linked the electrical responses and physical characteristics of 230 cells from the same brain region.


“We introduce a computational optimization workflow to generate 9,200 single neuron models with active conductances. These models are based on 230 in vitro electrophysiological experiments followed by morphological reconstruction from mouse visual cortex. We show that, contrary to current belief, the generated models are robust representations of individual experiences and cortical cell types as defined by cellular electrophysiology or transcriptomics,” the study authors state.


The models can be used to test theories that would require dozens of lab experiments, according to Costas Anastassiou, PhD, the study’s lead author and a researcher in Cedars-Sinai’s Department of Neurosurgery.


“Imagine you wanted to study how 50 different genes affect biological processes in a cell,” Anastassiou said in a statement. “You would need to create a separate experiment to ‘knock out’ each gene and see what happens. Using our computational models, we will be able to modify the recipes for these genetic markers for as many genes as we want and predict what happens. will pass. .”


Related reading



Copyright © 2022 scienceboard.net

Dell’Oro Group Announces Appointment of Research Director, Wireless LAN

0

REDWOOD CITY, CA., August 9, 2022 /PRNewswire/ — Dell’Oro Group, the trusted source of market information for the telecommunications, networking and data center industries, is pleased to announce the appointment of Ms. Siân Morgan as Chief research, wireless LAN, with immediate effect. Ms. Morgan brings more than two decades of experience as an executive director in telecommunications and networking technologies such as 5G, OpenStack, LTE, IMS and Wi-Fi. Ms. Morgan will lead the research program on Wireless LANs , which includes the enterprise wireless LAN market, the adoption of public and private cloud platforms, and artificial intelligence.

“Siân has a proven track record of excellence and I am confident that she will add great value to our customers and to the wireless LAN industry. Over the past few weeks, it has already revealed some interesting trends in the data,” said Tam DellGoldFounder and CEO.

“It is an honor to join such a valued team of analysts. Over my 20-year career, I have often trusted Dell’gold benchmark information, and it’s a real pleasure to expand the analysis of the enterprise wireless LAN market as it evolves with new cloud-based AI services,” Ms. Morgan said.

Prior to Dell’Oro Group, Ms. Morgan held various positions in the telecommunications industry, working at both a service provider and an equipment manufacturer. She spent a decade working in Europe and is fluent in French and English. She has spoken at international conferences on a variety of topics including next-generation networks, Wi-Fi traffic direction, voice over LTE, and online charging systems. She taught a university networking course and worked with start-ups developing 5G and IoT products. Ms. Morgan has professional designations in engineering and accounting, a bachelor’s and master’s degree in electrical engineering from McGill universityand an MBA from the University of Quebec in the Outaouais.

About the Dell’Oro Group

Dell’Oro Group is a market research firm specializing in strategic competitive analysis in the telecommunications, enterprise networking, data center infrastructure and network security markets. Our firm provides in-depth quantitative data and qualitative analysis to facilitate fact-based critical business decisions. For more information, contact Dell’Oro Group at +1.650.622.9400 or visit www.delloro.com.

SOURCE Dell’Oro Group

Researchers identify immune expression signature in surgical specimens linked to disease progression for non-RCP patients

0

Spanish researchers have identified an immune expression signature in surgical specimens associated with disease progression in pathological incomplete responder patients treated with neoadjuvant chemoimmunotherapy, which may help in follow-up and management therapy for these high-risk patients. The research was presented today at the IASLC 2022 World Conference on Lung Cancer in Vienna.

Pathological response is postulated as a surrogate for survival in patients treated with neoadjuvant chemoimmunotherapy. In this sense, patients with a pathological incomplete responder (non-RCP) have a higher risk of disease progression compared to pathological complete responders (RCP).

To identify gene expression patterns that may affect long-term outcomes in this high-risk group, a group of Spanish researchers, led by Marta Casarrubios, Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro -Majadahonda, Spain, analyzed surgical specimens from non-RCP patients and characterized the differences between progressors and non-progressors.

Dr. Casarrubios and colleagues analyzed surgical tissue samples from 36 patients with resectable stage IIIA NSCLC from the NADIM trial (NCT03081689). The tumor RNA was sequenced using the Oncomine® Immune Response panel which targets 395 genes linked to immunological processes. Differentially expressed genes (DEG) between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis (GSEA). CIBERSORTx was used to estimate the proportions of immune cell subtypes. Patients were classified as CPR pathological complete responders (n = 22) and pathological incomplete responders (n = 14). Patients without PCR were classified as progressors (P, n = 5) or non-progressors (NP, n = 9) based on whether or not they had disease progression at 34.2 months after diagnosis. The values ​​with the highest likelihood ratio from the ROC curve analysis were used as cutoffs to classify DEGs or immune cell subsets for each patient into high or low groups.

Researchers report that 22 genes were upregulated in non-CPR patients compared to CPR, most of them related to proliferation (CDKN3, CCNB2, KIAA0101, MKI67, BUB1, CDK1, TOP2A, FOXM1, MELK, MAD2L1), tumor markers (CDKN2A, KRT5, BRCA1, TWIST1), among others (MAGEA3, CEACAM1, CXCL8, TNFRSF18, G6PD, HMBS, DGAT2, ISG15). Further analysis of GSEA showed upregulation of pathways related to antigen processing, TCR co-expression, and lymphocyte infiltrate in CPR patients. Non-RCP patients showed upregulation of proliferation, tumor marker, interferon signaling, housekeeping, and tumor antigen pathways. Regarding the differences between P and NP, 10 genes have been identified as differentially upregulated in P patients: IFI6 and OAS3, involved in interferon signaling; AKT and KRT7 as tumor markers; BST2, ISG15 and IFI27 involved in type I interferon signaling as well as CD8B, SDHA, HMBS and OAS1. Higher levels of IFI6 (p=0.010), BST2 (p=0.010), CD8B (p=0.019), AKT (p=0.033), OAS3 (p=0.010) and IFI27 (p=0.010) in post samples -treatment of non-RCP patients was associated with lower progression-free survival (PFS). Additionally, higher levels of HMBS (p=0.018) and AKT (p=0.003) were associated with lower overall survival (OS).

Patients with high AKT expression have a higher risk of progression (HR: 10.31; 95% CI 1.2-88.8) and death (HR: 50.6; 95% CI 3 ,77-680.5). The median PFS for patients with high AKT was 12.3 months (95% CI 0-32.6) and was not reached for those with low AKT. No difference was observed between P and NP patients in the estimated cell proportions. However, a higher proportion of activated dendritic cells or neutrophils in patients without CPR was associated with lower PFS (p=0.019, p=0.053) and OS (p=0.033, p=0.003), respectively.

The up-regulated pathways in surgical samples from CPR patients suggest that an effective immune response to PD-1 blockade has been achieved. Additionally, we have identified an immune expression signature in surgical specimens associated with disease progression in non-RCP patients, which may aid in the follow-up and therapeutic management of these high-risk patients.”


Dr Marta Casarrubios, Instituto de Investigacion Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Source:

International Association for the Study of Lung Cancer

Todos Medical Announces First Two Contracts for PCR-Based MonkeyPox Testing at CLIA/CAP Clinical Trials Lab Provista Diagnostics

0

Todos Medical Ltd.

New York, NY, and Tel Aviv, ISRAEL, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified laboratory Provista Diagnostics has entered into two contracts to provide PCR-based MonkeyPox testing services. Under the first agreement, Provista will provide tests related to MonkeyPox to a New Jersey-based medical group that specializes in routine screening of patients with dermatological conditions. Under the second agreement, the company is extending a reference lab agreement with a New Jersey-based CLIA lab that is already sending COVID test samples to add the MonkeyPox test.

Although lesion-based testing is the current standard of care under CDC guidelines, both clinic and laboratory customers have expressed a desire to offer the saliva-based specimen collection method that Provista currently valid alongside lesion-based testing as a way to improve the safety of frontline healthcare workers screening suspected cases of MonkeyPox, given the recent report of a healthcare worker in Israel infected with MonkeyPox after being detected a suspected case. Saliva-based tests are the subject of intense research which the company believes will open up the possibility of testing asymptomatic or very early-stage patients at high risk of serious disease (such as immunocompromised patients) who could lead to a earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate and is currently only available under an Expanded Access Investigational New Drug (EA-IND) protocol. Flow Health in Los Angeles, Calif., has previously reported success in diagnosing asymptomatic MonkeyPox patients and referring patients for TPOXX. Provista MonkeyPox tests are developed as Laboratory Developed Tests (LDTs). A recent peer-reviewed article describing a strong correlation between the sensitivity of lesion- and saliva-based PCR tests was recently published in the journal Eurosurveillance: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.28.2200503

“After announcing last week that we were entering the MonkeyPox testing space, we received many requests to establish business relationships with physician groups, potential referral lab partners and municipalities,” said Gerald. E. Commissiong, President and CEO of Todos Medical. “We are moving quickly to complete lesion and saliva-based MonkeyPox testing so we can begin to meet growing demand and establish Provista as a regional center of excellence for infectious disease and Long COVID testing.”
About Todos Medical Ltd.
Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs life-saving diagnostic solutions for the early detection of various cancers. The company’s state-of-the-art and patented Biochemical Infrared Assays (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that examines the influence of cancer on the immune system, looking for changes biochemicals in blood mononuclear cells and plasma. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos recently acquired US medical diagnostics company Provista Diagnostics, Inc. to obtain the rights to its CLIA/CAP-certified laboratory based in Alpharetta, Georgia, which currently performs COVID PCR testing, Long COVID signand Provista’s exclusive Videssa® breast cancer screening blood test.

Todos also develops blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised cellular machinery that leads to aberrant cell cycle reentry by neurons, which then leads to apoptosis. LymPro is unique in using peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and brain neurons.

Todos formed the Israel-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March 2022 to consolidate all intellectual property pursuing the development of diagnostic tests targeting the 3CL protease, as well as protease inhibitor botanicals and pharmaceuticals 3CL that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through the Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid® in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollvir ®, while also developing the diagnostic 3CL protease inhibitor TolloTest™.
To purchase Tollovid, please visit Amazon Where www.MyTollovid.com. For more information, please visit https://www.todosmedical.com/.
Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based solely on the current expectations of management and are subject to important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties relating to the progress , timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funds necessary to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in the initiation of our clinical trials; changes in legislation; failure to develop and introduce new technologies, products and applications on a timely basis; lack of validation of our technology as we progress and lack of acceptance of our methods by the scientific community; the inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may arise with our process; cost of final product higher than expected; loss of market share and pressure on prices resulting from competition; and laboratory results that do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated by such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please see its reports filed from time to time with the United States Securities and Exchange Commission.

Company contact:
Daniel Hirsch
CFO
All medical
917-983-4229 ext. 104
[email protected]

How Australia’s All G Foods will use $25m in cell milk investment

0

Last week, All G Foods raised $25 million to ramp up production of its cell milk and plant-based alternative protein products.

UK-based Agronomics, a VC that focuses on opportunities in cellular agriculture, contributed $15 million and $10 million through an affiliate investment vehicle called New Agrarian Company.

All G Foods founder Jan Pacas says SmartCompany the lion’s share of that funding will go to the Cellular Milk side of the business.

“It’s a much more complex project,” he says. “It hasn’t been done before in the world, so we’re doubling down on this one.”

All G Foods hopes to be the first in the Asia-Pacific region to launch, and Pacas says the funding will go a long way to addressing the many challenges faced by companies innovating in the fast-growing industry.

“We have to overcome regulatory challenges, we have to overcome scaling challenges. We have the science, we can make it in the lab, but we still have to make it cheaper. »

Agronomics has backed a number of leading companies and has experience in the field, so Pacas says All G Foods feels “privileged” to work with the company.

They really understand the future of protein as well as cellular agriculture,” Pacas said.

As part of the deal, All G Foods will have access to Agronomics’ fermentation tanks and bioreactors to ramp up production, hoping to one day set up facilities in Australia.

The The “bottlenecks” facing alternative protein industries have a lot to do with product novelty and unfamiliarity, Pacas says.

While it is molecularly identical [to cow’s milk]how we make it different, and that’s what the regulator needs to be familiar with. »

He was quick to point out that the technology is already approved in the United States and Singapore, with Singapore set to be an initial test market for All G Foods’ dairy products.

“China is not the first import market [for us] because it’s too important and too big,” Pacas said. Australia, Indonesia, Japan and others will follow Singapore.

Another hurdle is consumer acceptance of an unknown product, even though Pacas was confident they would accept cell milk because of its taste, nutritional value and low environmental impact.

“If I can give you A2 milk, which is free of lactose, allergens and antibiotics, but contains A2 protein, and is produced in a completely sustainable way, where it does not harm animals and does not doesn’t need excessive terrestrial water or the sun to grow, it’s a complete game-changer.

“We take the genetic information of the molecule, we put it in a yeast or in a bacillus, we program it, and then it becomes mini small cellular factories which create on a large scale. It’s basically replicating the same manufacturing process that happens in a cow’s udder – where you have the genetic information from a cow’s udder and you grow the milk into a cow’s udder – but we grow it in a bioreactor.

In February, All G Foods announced a multi-million dollar injection from W23, the Woolworths Group’s venture capital and growth fund, at a investment boom in plant-based alternatives to meat.

Netflix is ​​not in big trouble. It’s becoming a media company

0

Still, its recent struggles may not be the start of a downward spiral or the beginning of the end for the streaming giant. Rather, it’s a sign that Netflix is ​​becoming a more traditional media company.

netflix (NFLX) was originally considered a Big Tech company, part of the Wall Street acronym, “FAANG”, which stood for Facebook (Facebook), Apple (AAPL), Amazon (AMZN)Netflix and Google (GOOG). Wall Street once valued the company at around $300 billion — a figure comparable to many Big Tech companies that Netflix’s business model ultimately couldn’t match.

“I think Netflix was hugely overvalued,” Julia Alexander, chief strategy officer at Parrot Analytics, told CNN Business. “Unlike companies that have different tentacles, Netflix doesn’t have many tentacles.”

But Netflix was never really a technology company.

Yes, it relied on subscriber growth like many companies in the tech world, but its subscriber growth relied on movies and TV shows that people wanted to watch and pay for. It’s more like a studio in Hollywood than a tech company in Silicon Valley.

Netflix was much more like a tech company than, say, Disney’s parent company, Comcast, Paramount, or CNN, Warner Bros. Discovery. But as these traditional media companies start to look a lot more like Netflix, Netflix in turn is starting to pull a page out of its rivals’ playbooks: it’s going to start running ads and it’s been releasing shows over the weeks. and months. rather than all at once.
Netflix said its cheaper ad tier and crackdown on password sharing could come next year. It is in partnership with Microsoft (MSFT) for its advertising activity.

“I think in many ways Netflix’s moves suggest a transition from a technology company to a media company,” Andrew Hare, senior vice president of research at Magid, told CNN Business. “With the introduction of ads, a crackdown on password sharing, flagship shows like ‘Stranger Things’ experimenting with a staggered release, we see Netflix looking more like a traditional media company every day.”

Hare added that Netflix’s old business strategy, which was “once sacrosanct, is now being thrown out the window.”

“Netflix once forced Hollywood out of its comfort zone deep. They brought streaming into the American living room,” he said. “Now it looks like some more conventional practices might be what Netflix needs.”

At Netflix right now, “a lot of these strategic moves are being made as they mature and move into the next phase as a business,” Hare noted. This means focusing on cash flow and revenue rather than just growth.

“In other words, old school stuff,” he said.

— CNN Business’ Moss Cohen contributed to this report.

Children’s COVID Immune Response Index

0

Children’s noses can fight COVID-19 better than adults’ noses.

Dr Kirsty Short from the University of Queensland’s School of Chemistry and Molecular Biosciences says this may be one reason why immune responses in children have been shown to be more effective against the virus.

“Children have a lower COVID-19 infection rate and milder symptoms than adults, but the reasons for this are unknown,” she says.

“We showed that the nasal mucosa of children has a more pro-inflammatory response to ancestral SARS-CoV-2 than the nose of adults.”

Dr. Short and his colleagues exposed cell samples from the nasal mucosa of 23 healthy children and 15 healthy adults to the virus.

The results showed that it replicated less efficiently in children’s nasal cells and there was an increased antiviral response.

“It could be an adaptation to increased threats from ‘foreign invaders’ such as viruses or bacteria seen in childhood,” she said.

“It’s also possible that increased exposure to these threats in childhood ‘triggers’ the nasal mucosa in children to mount a stronger pro-inflammatory response.

“Or alternatively, metabolic differences between children and adults could alter how genes that fight the virus are expressed.”

The researchers found that the Delta COVID-19 variant was significantly less likely to replicate in children’s nasal cells, but the trend was significantly less pronounced in the case of Omicron.

Meanwhile, state and federal authorities fear the number of Australians receiving their third dose of the COVID-19 vaccine is lagging.

Some 71.4% of eligible people, or just over 14.1 million people, have so far received a third dose.

But there are more than 5.6 million who have not yet received their reminder.

Queensland is the worst performing state, with 64.5% of eligible residents receiving a third shot, while the ACT has the best coverage (79.9%).

The recall rate is 55% for Indigenous Australians nationwide.

The concern comes amid nearly 29,000 new cases of the virus recorded across the country on Saturday with 89 deaths.

Although it has been declining daily over the past week, the number of hospitalized virus patients also remains slightly below 4,500, or nearly one in every 12 hospital beds.

Homeward secures $50 million and partners with Priority Health for rural value-based care

0

When Dr. Jennifer Schneider, CEO of rural health care startup Homeward, was 12, she was diagnosed with type 1 diabetes. But living in rural Minnesota, she didn’t see a endocrinologist for a long time.

“It wasn’t until I went to medical school that I realized how scary and dangerous it was,” said Schneider, who previously served as president and chief medical officer of Livongo.

San Francisco-based Homeward works to fill the primary and specialty care void in rural areas. The company announced Wednesday that it has secured $50 million in Series B funding from ARCH Venture Partners and Human Capital. The company launched in March with an initial investment of $20 million from General Catalyst, bringing the total funds raised to $70 million. Schneider’s own experience reflects the lack of specialists and primary care physicians in rural areas across the country. For momente, 61% of primary care health worker shortage areas are rural, according to the Rural Health Information Hub.

The startup also announced its first value-based care partnership with Michigan-based Priority Health, a health insurer under BHSH System. Through this partnership, Homeward will provide primary and specialty care to more than 30,000 Medicare Advantage members in rural Michigan.

With the new funding, Homeward hopes to expand outside of Michigan into other markets and partner with other health plans, though Schneider declined to mention which partnerships the company is currently exploring.

“Through this partnership, we are able to demonstrate how new types of technology-enabled care models that are purpose-built for rural Americans and integrate with local health care providers and systems can expand capacity. clinic within these communities and deliver better clinical outcomes at reduced costs,” said Schneider. “Following the announcement of the partnership, we have experienced great excitement across the industry.”

Working with Priority Health, Homeward’s clinicians — who are local to the communities in which they provide care — will begin with home visits for its patients.

“It’s really essential in a rural market, and it gives us a lot of knowledge about how to provide care for that person,” Schneider said.

Clinicians are also available to patients virtually or in the community with mobile clinics. If necessary, Homeward will refer patients to other local providers or hospital systems for in-person visits.

Members use mobile phone-based remote monitoring technology so that Homeward clinicians can track their patients’ health status between visits. Using this form of technology rather than internet connection is beneficial in rural areas where broadband is lacking, Schneider said.

“For sure, broadband connectivity in rural markets is limited,” Schneider said. “But there are a lot of innovations and technologies that can be exploited without broadband. There are many remote monitoring devices that work with cellular connectivity, so you don’t need the internet.

Homeward makes money through a value-based model of care, which means it takes full financial risk of the cost of care and the outcomes of its patients. It is encouraged to provide preventative home care by leveraging technology. The aim is to keep patients healthy and thus avoid the risk of needing expensive medical procedures.

Homeward isn’t the only startup in the rural value-based care market, Schneider said. Another is Nashville-based Main Street Health, which spear in June 2021 and matches Medicare beneficiaries at participating healthcare facilities with a local healthcare navigator. But Homeward differentiates itself by working with existing providers and adding care with its own clinicians, Schneider said.

Photo: Pongasn68, Getty Images

Research: Mitochondrial DNA Mutations Linked to Heart Disease Risk

0

In a recent study, researchers discovered how the function and dysfunction of mitochondria plays a critical role in many diseases, and even in aging. In a new study published in the online issue of Immunity, scientists from the University of California San Diego School of Medicine and the Salk Institute for Biological Studies report a surprising link between mitochondria, inflammation and DNMT3A and TET2, a pair of genes that normally help regulate blood cell growth, but when mutated they are associated with an increased risk of atherosclerosis.

“We found that the DNMT3A and TET2 genes, in addition to their normal job of modifying chemical tags to regulate DNA, directly activate the expression of a gene involved in mitochondrial inflammatory pathways, which seems to be a new molecular target for atherosclerosis therapeutics,” said Gerald Shadel, PhD, study co-lead author and director of the San Diego Nathan Shock Center of Excellence in the Basic Biology of Aging at the Salk Institute. “They also interact with mitochondrial inflammatory pathways, suggesting a novel molecular target for atherosclerosis therapeutics.” While studying the roles of DNMT3A and TET2 mutations in clonal hematopoiesis, which occurs when stem cells begin making new blood cells with the same genetic mutation, study co-lead author Christopher Glass, MD, PhD, Professor in the Departments of Medicine and Cellular and Molecular Medicine at UC San Diego School of Medicine and colleagues noted that abnormal inflammatory signaling related to DNMT3A and TET2 deficiency in blood cells played a major role in the inflammatory response that promotes the development of atherosclerosis.

But the question remained as to how the DNMT3A and TET2 genes were involved in inflammation and atherosclerosis – the buildup of fatty plaques in the arteries and the main underlying cause of cardiovascular disease. It is estimated that about half of Americans between the ages of 45 and 84 suffer from atherosclerosis, which is the leading cause of death in the United States and Westernized countries. “The problem was that we couldn’t figure out how DNMT3A and TET2 were involved because the proteins they encode apparently do opposite things when it comes to DNA regulation,” Glass said. “Their antagonistic activity led us to believe that there might be other mechanisms at play, which prompted us to take a different approach and contact Shadel, who had discovered the same inflammatory pathway years earlier during examining mitochondrial DNA stress responses.”

What they discovered Inside the mitochondria resides a unique subset of the cell’s DNA that must be organized and condensed correctly to maintain normal function. Shadel’s team had previously studied the effects of mitochondrial DNA stress by deleting TFAM, a gene that helps ensure that mitochondrial DNA is properly conditioned.

Shadel and his colleagues determined that when TFAM levels are reduced, mitochondrial DNA is expelled from the mitochondria into the cell interior, triggering the same molecular alarms that alert cells to a bacterial or viral invader and trigger a defensive molecular pathway that triggers an inflammatory response. The Glass and Shadel labs worked together to better understand why DNMT3A and TET2 mutations led to inflammatory responses similar to those seen during mitochondrial DNA stress. The teams applied genetic engineering and cell imaging tools to examine cells from people with normal cells, those with loss-of-function mutations in DNMT3A or TET2 expression, and those with atherosclerosis.

They found that experimentally reducing the expression of DNMT3A or TET2 in normal blood cells produced similar results to blood cells with loss-of-function mutations and blood cells from patients with atherosclerosis. In all three cases, there was an increased inflammatory response. They also observed that low levels of DNMT3A and TET2 expression in blood cells led to reduced expression of TFAM, which in turn led to abnormal mitochondrial DNA conditioning, causing inflammation due to to released mitochondrial DNA.

“We found that the DNMT3A and TET2 mutations impede their ability to bind and activate the TFAM gene,” said first author Isidoro Cobo, PhD, a postdoctoral researcher in Glass’ lab. “The absence or reduction of this binding activity results in the release of mitochondrial DNA and an overactive mitochondrial inflammatory response. We believe this may exacerbate plaque buildup in atherosclerosis.” Shadel said the findings broaden and deepen the understanding of mitochondrial function and their role in disease.

“It’s very exciting to see our discovery of TFAM depletion causing mitochondrial DNA stress and inflammation now have direct relevance to a disease like atherosclerosis,” Shadel said. “Since we revealed this pathway, there has been an explosion of interest in the mitochondria involved in inflammation and many reports linking mitochondrial DNA release to other clinical contexts.” (ANI)

(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)

Forrester Research, Inc. (NASDAQ:FORR) Fiscal Year 2022 Earnings Estimate Released by William Blair

0

Forrester Research, Inc. (NASDAQ: FORR – Get a rating) – Equity researchers William Blair cut their fiscal year 2022 earnings estimates for Forrester Research in a research report delivered to clients and investors on Monday, August 1. William Blair analyst A. Nicholas now expects the technology company to post earnings of $1.79 per share for the year, down from its previous forecast of $1.81. William Blair currently has a “Market Perform” rating on the stock. Forrester Research’s current annual earnings consensus estimate is $1.79 per share. William Blair also released estimates for Forrester Research Q4 2022 earnings at $0.35 EPS, Q1 2023 earnings at $0.37 EPS, Q2 2023 earnings at $0.79 EPS, Q4 2023 at $0.46 EPS and FY2023 earnings at $1.99 EPS.

Forrester Research Stock Performance

FORR opened at $46.14 on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt ratio of 0.30. The company has a market capitalization of $871.12 million, a price-earnings ratio of 29.20, a PEG ratio of 1.73 and a beta of 0.92. The company’s 50-day moving average is $47.70 and its 200-day moving average is $51.61. Forrester Research has a 12-month low of $42.59 and a 12-month high of $60.90.

Forrester Research (NASDAQ: FORR – Get a rating) last announced its quarterly results on Thursday, May 5. The technology company reported EPS of $0.31 for the quarter, beating consensus analyst estimates of $0.20 by $0.11. The company posted revenue of $124.97 million in the quarter, compared to analyst estimates of $121.62 million. Forrester Research had a net margin of 5.82% and a return on equity of 18.43%.

Insider buying and selling

In related news, insider Alicia Lee sold 1,428 shares of the company in a trade that took place on Friday, May 27. The shares were sold at an average price of $52.00, for a total value of $74,256.00. Following the transaction, the insider now owns 3,819 shares of the company, valued at $198,588. The transaction was disclosed in a legal filing with the SEC, accessible via this link. In related news, insider Alicia Lee sold 1,428 shares of the company in a trade that took place on Friday, May 27. The shares were sold at an average price of $52.00, for a total value of $74,256.00. Following the transaction, the insider now owns 3,819 shares of the company, valued at $198,588. The transaction was disclosed in a legal filing with the SEC, accessible via this link. Also, director David Boyce sold 2,000 shares of the company in a trade that took place on Tuesday, May 10. The stock was sold at an average price of $50.53, for a total transaction of $101,060.00. Following completion of the transaction, the administrator now directly owns 7,183 shares of the company, valued at approximately $362,956.99. Disclosure of this sale can be found here. 40.60% of the shares are currently held by insiders.

Hedge funds weigh on Forrester Research

Several large investors have recently increased or reduced their stake in the company. The New York State Teachers’ Retirement System increased its stake in Forrester Research by 27.5% in the second quarter. The New York State Teachers’ Retirement System now owns 8,382 shares of the technology company valued at $401,000 after buying an additional 1,810 shares last quarter. Russell Investments Group Ltd. increased its stake in Forrester Research by 147.9% during the second quarter. Russell Investments Group Ltd. now owns 12,145 shares of the technology company valued at $579,000 after purchasing an additional 7,245 shares last quarter. Assenagon Asset Management SA increased its stake in Forrester Research by 102.6% during the second quarter. Assenagon Asset Management SA now owns 153,432 shares of the technology company valued at $7,340,000 after buying an additional 77,719 shares last quarter. KBC Group NV acquired a new position in Forrester Research during the second quarter, valued at approximately $45,000. Finally, Exchange Traded Concepts LLC increased its stake in Forrester Research by 2.4% in the second quarter. Exchange Traded Concepts LLC now owns 11,311 shares of the technology company valued at $541,000 after buying an additional 260 shares last quarter. Hedge funds and other institutional investors hold 52.96% of the company’s shares.

Forrester Research Company Profile

(Get a rating)

Forrester Research, Inc operates as an independent research and consulting firm. The Company operates in three segments: Research, Consulting and Events. Core services in the Research segment’s subscription-based research portfolio include Forrester Research, SiriusDecisions Research and Forrester Decisions, which are designed to provide business and technology leaders with a proven path to growth through customer obsession.

Recommended Stories

Earnings history and estimates for Forrester Research (NASDAQ:FORR)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Forrester Research right now?

Before you consider Forrester Research, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Forrester Research wasn’t on the list.

While Forrester Research currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Hybrid immunity retained six months after exposure to SARS-CoV-2

0

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) pandemic. Since the start of the pandemic, several variants of SARS-CoV-2 have emerged with different rates of transmission, virulence, and ability to evade immune responses elicited either by COVID-19 vaccination or natural infection compared to to the ancestral variant.

Study: Hybrid immunity at 6 months after exposure to SARS-CoV-2 in people in the community treatment program. Image Credit: Cinefootage Visuals / Shutterstock.com

Background

The SARS-CoV-2 Delta variant was the dominant strain circulating in Thailand in mid-August 2021. The spread of this variant has dramatically increased the number of COVID-19 cases and deaths.

During this period, the number of daily cases reached around 20,000, with more than 300 deaths reported each day. The subsequent decline in COVID-19 cases occurred following the implementation of pharmaceutical and non-pharmaceutical measures.

Previous studies have indicated that vaccination against COVID-19 plays an important role in reducing daily infections and hospitalizations due to severe infection. According to the United States Centers of Disease Control and Prevention (CDC), vaccination against COVID-19, especially when messenger ribonucleic acid (mRNA) vaccines are used, has significantly reduced the death rate of the COVID-19.

Most of the Thai population was vaccinated with inactivated vaccines, with a small percentage given an mRNA vaccine as a booster dose.

The emergence of the SARS-CoV-2 Omicron variant in Thailand caused an increase in daily infections which reached nearly 50,000 per day. However, the number of deaths due to SARS-CoV-2 infection remained low, at around 120 per day.

Scientists have previously speculated that herd immunity will develop after a majority of the population has been vaccinated or recovered from COVID-19. However, the herd immunity threshold could not be reached due to the emergence of new variants, as well as reluctance to vaccinate.

A study from the UK coined the concept of “hybrid immunity”, which refers to the protection conferred by vaccination against COVID-19 and natural infection. Previous studies have indicated that hybrid immunity can protect individuals against symptomatic infection.

About the study

In a new study being reviewed in the journal Scientific Reports and currently available on the Research Square* preprint server, the scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as reduced severity of Omicron infections.

The current study included 79 participants from 15 families registered in a Bangkok Home Care Service database between August 1, 2021 and August 31, 2021. In this study cohort, 34 people had recovered from COVID -19 at least four weeks before registration. , while the remaining 45 participants were in close contact with COVID-19 patients.

Study results

T-cell responses against neuromyelitis optica (NMO) antigens were detected by the interferon release assay in 11 of 45 close contacts six months after exposure to SARS-CoV-2. The rate of asymptomatic COVID-19 was estimated at 24.4%.

SARS-CoV-2 receptor binding domain (RBD) immunoglobulin G (IgG) antibody levels, as well as T cell responses against the SARS-CoV-2 spike protein, after second dose of COVID-19 vaccine, were associated with comparable rates of immunity between COVID-19 patients and close contacts. Thus, participants who received a COVID-19 booster vaccination without any prior history of COVID-19 also received hybrid immunity.

The antibody response to RBD IgG (Figure 2A) demonstrated the correlation between antibody levels and neutralizing capacity to the alpha variant of the SAR-CoV-2 virus (R = 0.5571, P < 0,0001).  Les niveaux d'IgG RBD chez les patients COVID-19 et les contacts fermés en fonction du nombre de vaccinations sont présentés à la figure 2B.  NT = anticorps neutralisant, RBD IgG = immunoglobuline G du domaine de liaison au récepteur SARS-CoV-2, AU/ml = unités arbitraires par millilitre.

The antibody response to RBD IgG (Figure 2A) demonstrated the correlation between antibody levels and neutralization capacity to the alpha variant of the SAR-CoV-2 virus (R = 0.5571, P

A similar level of immunity was seen in people who were in close contact with asymptomatic and symptomatic infected people.

Previously, long-term observational data were not available regarding the rate of reinfection in people exposed to SARS-CoV-2. In the present study, none of the participants were reinfected with SARS-CoV-2 at enrollment. Picture 3.

Immune response against SARS-CoV-2 viral antigens compared between close contacts with and without asymptomatic infection, antibody response (RBD IgG) P = 0.1922

Immune response against SARS-CoV-2 viral antigens compared between close contacts with and without asymptomatic infection, antibody response (RBD IgG) P=0.1922 t=1.325, df=43 (Figure 3A), T cell response against the spike protein P=0.5325, t=0.6293, df=43 (Figure 3B). RBD IgG = SARS-CoV-2 receptor binding domain immunoglobulin G, AU/ml = arbitrary units per milliliter.

Most of the study participants had received a heterogeneous booster vaccination against COVID-19 that included viral vector vaccines, inactivated vaccines and mRNA vaccines. To this end, reduced T cell responses against the spike protein and higher levels of IgG RBD were observed after the booster vaccination.

After a short period of exhaustion, T cells can recover three months after receiving a booster dose of COVID-19. This observation is consistent with a previous study that reported an effective retained immune response after heterogeneous immunization against the Omicron variant.

Previous studies have revealed that individuals may possess varying levels of cellular and humoral immune responses during similar viral infections. Since the majority of study participants received an mRNA vaccine as a booster dose, this could impair T-cell function after vaccination.

Thus, the authors strongly recommend multiple booster doses of the COVID-19 vaccine only for immunocompromised individuals with poor T cell responses. T cell-based vaccines would also provide increased therapeutic benefit, especially for these patients.

conclusion

The current study found that antibody and cellular responses define immunity to COVID-19 in society. Taken together, these responses may confer long-term hybrid immunity following booster vaccination against symptomatic and asymptomatic COVID-19.

An important limitation of the present study is its small size, which limits the generalizability of its results. In addition, the immune response was disrupted by vaccination.

*Important Notice

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be considered conclusive, guide clinical practice/health-related behaviors, or treated as established information.

Improving RED Algorithm Congestion Control Using Markov Decision Process

0

The AQM algorithm

The default work of the AQM algorithm is represented in the RED algorithm. Congestion RED Inception depends on the average queue size (avg), two thresholds ((min_{th}) and (max_{th})) and the maximum fall probability ((max_p)). Each packet arrives in the router’s queue; the algorithm calculates the average using the exponentially weighted moving average (EWMA) as a low-pass filter, as shown in the equation. (1) as follows:

$$begin{aligned} avg = left( 1-w_qright) avg+w_qq end{aligned}$$

(1)

where (w_q) is the queue weight and q is the current queue size. If the average value is (min_{th}, the algorithm starts marking incoming packets in the router queue using the Explicit Congestion Notification (ECN) available in TCP/IP. Therefore, to reduce the sending rate, the drop probability P can be calculated based on the equation. (2) as follows:

$$begin{aligned} P= max_p(avg-min_{th})/(max_{th}+min_{th}) end{aligned}$$

(2)

RED algorithm starts dropping all incoming packets when avg exceeds (max_th) to manage queue congestion. The disadvantages of RED are slow response to congestion and difficulty in setting the parameter. Thus, these drawbacks cause the algorithm to not work well when different applications and services use different data rates. The GRED has three threshold values ​​((min_th),(max_th) and double (max_th)) to reduce the fall probability slope curve. The proposed algorithm used three thresholds as in GRED and the dynamic value of (w_q) selected using the Markov process.

Markov process

The MDP depends on the combination of ((St), (at), (r_t)t)17 with transition probability to determine what action should be taken for a given state, which can be seen in Eq. (3) as follows:

$$begin{aligned} P(s_{t+1}vert s_t,a)=P(s_{t+1}=jvert s_t=i,a=k) end{aligned}$$

(3)

where (St) and (s_{t+1}) respectively indicate the current state and the next state, while a indicates that an action must be taken. I and I can be 1,2,3, … which represent states, where I is the next state and I is the current state; and k can be 1,2,3, … to indicate which action is taken.

(r_t) is the reward (return) from the environment to the agent after an action is applied to the current state, as shown in the equation. (4), and this reward can be the maximum or the minimum. In this work, the reward represents a minimum number of discarded packets as follows:

$$begin{aligned} R_t=sum _{i=t}^{infty } r_{i}=r_t+r_{t+1}+r_{t+2}+… end{aligned }$$

(4)

MDP includes discount factor (gamma), which has a value between 0 and 1 to give weight to future rewards. In this study, the value of (gamma)=0 includes only the immediate reward without implying future rewards, which is indicated in the equation. (5) as follows:

$$begin{aligned} R_t=r_t+sum _{i=t+1}^{infty } gamma ^i r_i end{aligned}$$

(5)

To map MDP to the RED algorithm, it is necessary to consider the average queue length, avg, as a state and the type of dropped packets as an action. We assume four sets of states S=(s_1, s_2, s_3, s_4). Then we have the (4times 4) transition probability matrix shown in equation. (6). (s_1) means the average TCP state for a slow start below a minimum threshold ((0, (s_2) indicates the average state between (min_{th}) thresholds and halfway between the two thresholds ((min_{th} indicates the state when the avg is between half of the two thresholds and below the (max_{th} ((min_{th} + max_{th})/2and (s_4) indicates the state when the average is greater than (max_{th}) and less than double (max_{th}) ((max_th. We assume that there are three sets of actions A=(a_1,a_2,a_3)where (a_1) represents the no-drop packet, while (a_2) and (a_3) indicate the non-forced fall and the forced fall, respectively, as follows:

$$begin{aligned} P_{ij} = begin{bmatrix} P_{00} &{} P_{01} &{} P_{02} &{} P_{03} P_{10} &{ } P_{11} &{} P_{12} &{} P_{13} P_{20} &{} P_{21} &{} P_{22} &{} P_{23} P_{ 30} &{} P_{31} &{} P_{32} &{} P_{33} end{bmatrix} end{aligned}$$

(6)

Design and methodology

Point-To-Point network topology Dumbbell constructed by NS3 with ON-OFF application was used in this study as shown in Fig. 1. In the current study, the network has five nodes on each left and right side at the start then increasing by 5 nodes in each simulation round up to 200 nodes, the source and the destination, respectively, and the two nodes of the middle that reflect the router in the core network create a bottleneck. Figure 1 shows that the sending nodes did not send any packets, while in Figure 2 the bottleneck link was congested and the packet drop procedure started.

Figure 1

NS3 point-to-point dumbbell topology before starting the simulation.

Figure 2
Figure 2

NS3 point-to-point dumbbell topology after 10 seconds of execution.

TCP slow start

The TCP protocol has default congestion control with four phases: slow start, congestion avoidance, fast retransmit, and fast recovery18. The slow start phase allows the TCP to inform the capacity of the links in the transition path; this happens by duplicating the window size per RTT of each acknowledgment received. If no acknowledgment is received, the TCP indicates that congestion is occurring, and the congestion avoidance phase begins; then the window size increases by one for all successful acknowledgments. Therefore, the slow TCP begins to increase exponentially in each RTT, which means that congestion can occur in a short time.

Tuning Algorithm Parameters

The default values ​​in the RED algorithm settings are (w_q)=0.002, (min_{th})=5, (max_{th})=15, (max_p)=1/502. In the present study, the probability transition matrix (P_{ij}) in eq. (6) is calculated based on the weight of the queue (w_q). Equation (7) shows the relationship between the loading rate and (w_q)as well as their effect on the mean value2 as following:

$$begin{aligned} avg=L+1+frac{(1-w_q)^{(L+1)}-1}{w_q} end{aligned}$$

(seven)

where L represents the load rate of the sending packets. (w_q) works as a time constant in a low-pass filter on the average queue value, which reflects the response time and the queue weight of incoming packets, as shown in Fig. 3. Therefore, if (w_q) is too large, then the algorithm does not filter the congestion that appeared in a short time, especially during slow start of TCP protocol, as mentioned in the previous subsection. Whether (w_q) is too small, then the algorithm’s response to congestion is too slow to reflect the change in queue size, and the small value of the queue weight is suitable for the slow start phase in the TCP. In this study, the initial value of (w_q) set to zero and incremented by 0.002 when the state of avg transitions to another state, these values ​​selected to handle the exponential increase in TCP slow start flow. Table 1 shows the range of (w_q) used in the suggested algorithm.

picture 3
picture 3

The effect of the mean as a function of (w_q) and the charge rate.

Table 1 The value of avg as a function of queue length status.

Using the values ​​from the (w_q), the MDP probability transition matrix is ​​obtained, shown in Equation. (6) as follows:

$$begin{aligned} P_{ij} = begin{bmatrix} 0 &{} 0.002 &{} 0.002 &{} 0.002 0.004 &{} 0 &{} 0.004 &{} 0.004 0.006 &{ } 0.006 &{} 0 &{} 0.006 0.008 &{} 0.008 &{} 0.008 &{} 0 end{bmatrix} end{aligned}$$

(8)

The diagonal matrix assigns a null value, which means there is no change in the weight value of the queue if the state is the same. The network parameters implemented are shown in Table 2:

Table 2 The values ​​of the parameters of the implemented algorithm.
figure a

Todos Medical Launches Validation Plan for PCR-Based MonkeyPox Test at CLIA/CAP Provista Diagnostics Clinical Trials Lab

0

§ Lesion collection (standard of care) and planned saliva collection

§ Peer-reviewed publication demonstrating sensitivity of saliva testing opens door to asymptomatic testing

New York, NY, and Tel Aviv, ISRAEL, Aug. 03, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based MonkeyPox tests. As part of the plan, the company is validating several PCR tests for MonkeyPox and will launch the most sensitive ones for lesion-based and saliva-based sample collection. While lesion-based testing is the current standard of care under CDC guidelines, saliva-based sample collection is currently the subject of intense research that could open up the possibility of testing patients who are asymptomatic or at a very early stage at high risk of severe disease (such as as immunocompromised patients) which could lead to earlier diagnosis and early intervention with therapeutic drugs such as Tecovirimat (TPOXX). TPOXX is an investigational drug candidate and is currently only available under an Expanded Access Investigational New Drug (EA-IND) protocol. MonkeyPox tests are being developed as laboratory developed tests (LDTs). A recent peer-reviewed article describing a strong correlation between the sensitivity of lesion- and saliva-based PCR tests was recently published in the journal Eurosurveillance: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.28.2200503

“The significant investment we made to automate PCR testing at Provista to maximize COVID testing capacity can now be partially redeployed to MonkeyPox as we prepare to help the country scale up MonkeyPox testing capacity to cope. to the emerging public health crisis,” said Gerald E. Commissiong, President and CEO of Todos Medical.

About Todos Medical Ltd.
Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs life-saving diagnostic solutions for the early detection of various cancers. The company’s state-of-the-art and patented Biochemical Infrared Assays (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that examines the influence of cancer on the immune system, looking for changes biochemicals in blood mononuclear cells and plasma. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos recently acquired US medical diagnostics company Provista Diagnostics, Inc. to obtain the rights to its CLIA/CAP-certified laboratory based in Alpharetta, Georgia, which currently performs COVID PCR testing, Long COVID signand Provista’s exclusive Videssa® breast cancer screening blood test.

Todos also develops blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised cellular machinery that leads to aberrant cell cycle reentry by neurons, which then leads to apoptosis. LymPro is unique in using peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and brain neurons.

Todos formed the Israel-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March 2022 to consolidate all intellectual property pursuing the development of diagnostic tests targeting the 3CL protease, as well as protease inhibitor botanicals and pharmaceuticals 3CL that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through the Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid® in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollvir ®, while also developing the diagnostic 3CL protease inhibitor TolloTest™.

To purchase Tollovid, please visit Amazon Where www.MyTollovid.com. For more information, please visit https://www.todosmedical.com/.

Forward-looking statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based solely on the current expectations of management and are subject to important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties relating to the progress , timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funds necessary to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in the initiation of our clinical trials; changes in legislation; failure to develop and introduce new technologies, products and applications on a timely basis; lack of validation of our technology as we progress and lack of acceptance of our methods by the scientific community; the inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; cost of final product higher than expected; loss of market share and pressure on prices resulting from competition; and laboratory results that do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated by such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please see its reports filed from time to time with the United States Securities and Exchange Commission.

Company contact:
Daniel Hirsch
CFO
All medical
917-983-4229 ext. 104
[email protected]


main logo

Optical imaging of dynamic interactions between molecules in a cell — ScienceDaily

0

Super-resolution microscopy makes it possible to acquire fluorescence images of cells, organelles and molecular complexes with unprecedented spatial resolution. However, this resolution is not sufficient to resolve proteins as small as a few nanometers and their interactions with other molecules or the architecture of protein complexes. It prevents, for example, the study of the molecular interaction of neurons in the processes of learning and memory.

Exceed dynamic resolution limits

Developed by the research group of Prof. Markus Sauer (Rudolf Virchow Center and Biocenter) and Dr. Gerti Beliu (Rudolf Virchow Center) of the University of Würzburg, the new photoswitching fingerprint analysis enables optical imaging of interactions dynamics with other molecules in the cell. “So far, there is no method that reliably enables structural optical resolution in cells in the sub-10 nm range. By elucidating this underlying cause of the barrier, we have succeeded for the first time, in combination with new methods of direct labeling, to enable a cellular resolution of a few nanometers. This progress makes it possible to reveal the molecular functions and the architecture of important components of our cells”, reports Sauer.

Single molecule localization microscopy methods such as dSTORM, developed in the group of Prof. Markus Sauer, allow resolutions of the order of 10 to 20 nm. In combination with structured illumination methods, localization accuracies of up to 1 nm could be achieved for dyes. Unfortunately, this high localization precision could not be translated into a spatial resolution of a few nanometers in the cells.

The problem: current labeling methods, for example immunolabeling with an antibody, cause a spacing error of more than 10 nm. As a result, the size of the labeling molecules impedes nanoscale resolution. Other causes of the sub-10 nm resolution barrier were previously unknown. “In our publication, we have now shown for the first time that the photoswitching (blinking) rates of dyes between an on and off state are strongly affected at distances less than 10 nm due to various energy transfer processes between dyes. This results in a cluster of on-states during the first few seconds of an experiment associated with rapid photobleaching of the dyes, which makes their individual localization more difficult,” Sauer explains. “The reduced localization probability of the dyes results in therefore lower structural resolution than would be expected based on individual location accuracy. This is similar to an orchestra when all instruments play their contributions simultaneously at the start of the piece; it is not possible to choose individual soundtracks. »

The fluorescence intensity trace

However, the photoswitching fingerprint and fluorescence decay time also contain information about the number of dyes present and, due to the distance dependence of energy transfer, also information about their powerless distances. optically resolve individual dyes. By incorporating unnatural amino acids into multimeric membrane receptors by expanding the genetic code followed by bioorthogonal click-tagging with small fluorescent dyes, the Würzburg research groups have now been able to show in the next step how a Site-specific labeling of proteins in cells can be achieved without spacing errors with distances less than 10 nm. “By analyzing the photoswitching fingerprints of multimeric receptors in the plasma membrane, we were thus able for the first time to estimate the distances between receptor subunits in the range of 5-7 nm in cells and determine the number of subunits. -marked units,” says Beliu.

Visualize and understand molecular communication

In the next step, the research team intends to optimize photoswitching fingerprint analysis and use it in combination with single-molecule localization microscopy using single-molecule excitation patterns. patterns and DNA-PAINT for reliable super-resolution imaging in cells with sub-10nm resolution. This should provide new insights into the molecular organization of cellular structures, organelles and multiprotein complexes, as well as the structural elucidation of protein structures using optical methods.

The newly developed method not only offers unique insights into molecular mechanisms in infection, lipid and cancer research: photoswitchable fingerprinting also has the potential to more realistically represent the dynamics and complexity of receptors of the nervous system that are important for signal transduction at synapses. of neurons. This interaction of neurons defines our daily processes of learning and memory. “It is therefore fundamentally important to understand how this molecular orchestra assembles and functions,” says Beliu, describing the significance of these research findings.

Source of the story:

Materials provided by University of Würzburg. Note: Content may be edited for style and length.

Cloth Towel Market Detailed in New Research Report 2022 | Kruger Inc., Wepa Leuna GmbH, Cascades Inc, Georgia-Pacific LLC, Metsä Tissuem Procter & Gamble Co., Kimberly-Clark Corporation

0

Coherent Market Insights published a trade research report on Cloth Towel Market: Industry Analysis, Size, Share, Growth, Trends and Forecasts 2022-2028. Tissue Towels Market with 150+ Market Data Tables, Pie Charts, Graphs & Figures spread across pages and easy to understand detailed analysis. The information is collected on the basis of modern floats and requests identified with administrations and posts.

The Cloth Towels market analysis additionally provides market pioneer landscape along with market rise history and key development involved in the industry. The report also presents a comprehensive research study for a professional survey of high growth potential industries with market analysis. The Cloth Towels market report helps companies to understand the market trends and future market prospects, opportunities and articulate the critical business strategies.

Get the Research Report PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1619

Geographic segmentation of the Cloth Towels market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Cloth Towels Market: Competitive Landscape

Key players operating in the Cloth Towels Market include: Kruger Inc., Wepa Leuna GmbH, Cascades Inc, Georgia-Pacific LLC, Metsä Tissuem Procter & Gamble Co., Kimberly-Clark Corporation, Asaleo Care Limited, Hengan Group, SHP Slovak Hygienic Paper Group, AB Grigeo, Essity Aktiebolag (publ) , Industry Celtex SpA, Lucart SpA, Sofidel SpA

Report scope

The key features of the Cloth Towels Market report 2022-2028 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Major part of the report is made up of tables, graphs and figures which give our clients a clear picture of the Cloth Towels market. The structure of Cloth Towels Market by identifying its various segments and sub-segments to aid in understanding the report.

The Cloth Towels Market research report gives current competitive analysis along with valuable insights to clients/industries which will help them to plan a new strategy to expand or enter in a Cloth Towels market.

As the report progresses, it covers the analysis of major market players associated with development plans and policies, production techniques, price structure of the Cloth Towel Market. The report also identifies the other essentials such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit ratio and of consumption.

Important data of Cloth Towels Market available in this report:

  • Strategic recommendations, forecast of growth areas in the Cloth Towels Market.
  • Emerging Opportunities, Competitive Landscape, Major Manufacturers Revenue Share.
  • This report discusses the Cloth Towels market summary; The market scope gives a brief overview of the market.
  • The top performing regions (APAC, EMEA, Americas) along with their major countries are detailed in this report.
  • Company profiles, product analysis, marketing strategies, emerging market segments and comprehensive analysis of the Cloth Towels Market.
  • Challenges for New Entrants, Trends, Market Drivers, Year-over-Year Market Share Growth of Key Players in Promising Regions.

𝗕𝘂𝘆-𝗡𝗼𝘄 𝘁𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗮𝗻𝗱 𝗙𝗹𝗮𝘁 𝗨𝗦𝗗 𝟮𝟬𝟬𝟬 𝗢𝗙𝗙 𝗢𝗙𝗙

Direct purchase of a copy of this business research report: https://www.coherentmarketinsights.com/promo/buynow/1619

An overview of the impact of COVID-19 on this market:

The COVID-19 pandemic continues to expand and affect more than 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has had a global impact. The pandemic could affect three main aspects of the global economy: production, the supply chain, as well as businesses and financial markets. National governments have announced largely uncoordinated and country-specific responses to the virus. As authorities encourage “social distancing” and consumers stay indoors, several businesses are being affected. However, coherent, coordinated and credible policy responses should offer the best chance of limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, some sectors have remained unscathed from the impact of the pandemic and some are the hardest hit.

At Coherent Market Insights, we understand the economic impact on various industries and markets. Using our holistic market research methodology, we are focused on helping your business sustain and grow during the COVID-19 pandemics. With deep expertise in various industries, regardless of size, and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you impact analysis of the coronavirus outbreak across industries to help you prepare you for the future.

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact us

Mr Shah
Consistent market information
1001 4th Avenue, #3200
Seattle, WA 98154
Phone: USA +12067016702 / UK +4402081334027
E-mail: [email protected]

Gotabaya Rajapaksa not granted any privileges or immunities by Singapore government: minister

0

Former Sri Lankan President Gotabaya Rajapaksa’s short-term pass has been extended until August 11, reports say

Former Sri Lankan President Gotabaya Rajapaksa’s short-term pass has been extended until August 11, reports say

Former Sri Lankan President Gotabaya Rajapaksa, who fled his country amid massive protests against his government last month, did not enjoy any privileges, immunities or hospitality, said Singapore’s Foreign Minister Vivian Balakrishnan .

Mr. Rajapaksa fled to the Maldives on July 13 and reached Singapore the following day in the face of popular revolt against his government’s mismanagement of the economy.

The 73-year-old leader sent his resignation letter to the Speaker of Parliament on July 14, shortly after Singapore was allowed to enter the city-state for a “private visit”.

“In general, the Singapore government does not grant privileges, immunity and hospitality to former heads of state or heads of government,” Balakrishnan said in a written response to a question in parliament on Monday.

“Therefore, former President Gotabaya Rajapaksa was not granted any privilege, immunity or hospitality,” he wrote in response to a question from parliamentarian Gerald Giam of the opposition Workers’ Party.

Read also | Brief history of the rise and fall of Sri Lankan President Gotabaya Rajapaksa

Responding to a question from ruling People’s Action Party MP Yip Hon Weng over concerns that Singapore is becoming a “destination for political fugitives”, Home and Law Minister K Shanmugam said: ” Foreigners who possess a valid travel document and meet the entry requirements will be permitted to enter Singapore. Of course, we also reserve the right to refuse entry to a foreigner if we believe it is in our national interest. “If a foreigner entering Singapore is wanted by their government and their government has made a request, the government will provide assistance in accordance with our laws,” Mr Shanmugam said.

Mr Shanmugam added that travelers transiting through Singapore had “technically not entered” the country if they remained in the transit area and did not clear immigration.

“It’s international law. Nevertheless, if we are aware of the presence of undesirable people, we can always control them and take appropriate action,” Channel said. Asia News quoted Mr Shanmugam in parliament.

Read also | Crisis in Sri Lanka: in depth

The government may grant additional security based on the current and previous status of any person, taking into account the safety and security risk that may be posed to the person and the general public, the minister said.

According to reports, Mr Rajapaksa’s short-term pass has been extended until August 11.

Singapore’s Immigration and Checkpoints Authority (ICA) said last week that visitors from Sri Lanka entering Singapore for social visits will generally be issued a short-term pass of one maximum duration of 30 days.

Those who need to extend their stay here can request an extension online and requests will be assessed on a case-by-case basis, he said.

Bridgestone DURAVIS R207A tires with ENLITEN technology selected as original equipment on Hino Motor’s first full-scale lightweight battery-electric truck, Hino Dutro Z EV

0

TokyoBridgestone Corporation (Bridgestone) today announced that its DURAVIS R207A tires have been selected as original equipment on the all-new Hino Dutro Z EV launched in Japan by Hino Motors Ltd. (Hino) on June 28, 2022.

Contributing to the development of electric vehicles through the development of tires optimized to their measure, the Bridgestone Group strives to achieve its commitment to “Energy: Committed to achieving a carbon-neutral mobility society” set out in the “Bridgestone E8 Commitment”.1

The Hino Dutro Z EV is Hino’s first full-scale battery-electric truck. The vehicle offers both user-friendliness and carbon-free at advanced levels for the field of logistics as a solution to serious problems ranging from shortage of drivers to the physical burden of cargo handling and other delivery work. and to an increasingly diverse range of goods than the field of last mile logistics that delivers freight and goods to consumers. These issues are becoming increasingly serious due to factors such as the shrinking workforce and the growth of e-commerce.2

With the long-term co-creation of the two companies, Bridgestone continues to help realize the value that Hino provides through its wide range of vehicles. DURAVIS R207A tires for Hino Dutro Z EV are the first light truck tires with the innovative “ENLITEN” tire technology, which is optimal for mounting electric vehicles and maximizes the environmental and driving performance of the tires. With ENLITEN technology, DURAVIS R207A tires combine reductions in rolling resistance and weight, and high wear resistance using the latest tread compound, pattern and tire carcass. Contributing to extending the driving distance, reducing the environmental impact of the last-mile logistics field through carbon neutralization and resource saving of tire materials, and improving productivity with reduced frequency of tire recharging and replacement, the tires support the realization of both the social value and the customer value of the Hino Dutro Z EV.

The Bridgestone Group has positioned ENLITEN as a new premium for the era of electric vehicles, its values ​​will be extended not only as a tire technology, but also as ENLITEN’s business strategy. Through ENLITEN’s business strategy, the group will maximize social value and customer value by simultaneously creating values ​​that can sometimes be contradictory, such as “business growth and sustainability” and “personalization of customer performance”. tires and improving productivity / optimizing costs throughout the value chain”.

About Bridgestone Corporation

Bridgestone is a global tire and rubber leader that leverages its expertise to provide solutions for safe and sustainable mobility. Based at Tokyo, the company employs approximately 140,000 people worldwide and does business in more than 150 countries and territories around the world. Bridgestone offers a diverse product portfolio of premium tires and advanced solutions backed by innovative technologies, improving the way people around the world move, live, work and play.

Contact:

Tel: 615-937-1000

Fax: 615-937-3621

(C) 2022 electronic news edition, source ENP Newswire

Telit to acquire cellular IoT products from Thales

0

Telit, a global leader in the Internet of Things (IoT), and Thales, a global leader in aerospace, defence, security and digital identity, jointly announced that they have entered into an agreement under which Telit intends to acquire cellular IoT products from Thales.

The contemplated transaction includes Thales’ portfolio of cellular wireless communication modules, gateways and data (modem) cards, ranging from 4G LTE, LPWAN to 5G.

The proposed transaction establishes California-based Telit Cinterion as one of the Western leading providers of IoT solutions, strengthening the company’s presence in growing IoT industry segments and end markets, including payment systems , energy, e-health and security. It also strengthens the company’s ability to respond more expertly to the growing demand for cyber-secure IoT solutions in modules and cellular connectivity, thanks to cutting-edge Thales technologies.

Thales’s cellular IoT modules business, which has around 550 employees in 23 countries, serves many of the world’s leading brands. It generated more than €300 million in revenue in 2021. The transaction is expected to close in the fourth quarter of 2022, subject to the conclusion of a binding share transfer agreement, regulatory and regulatory approvals. Under other customary closing conditions, Thales becomes a shareholder in Telit Cinterion, controlled by DBAY Asset Advisors and led by Telit CEO Paolo Dal Pino.

Thales’s cellular IoT products business and Telit’s customers and partners will continue to benefit from the exceptional provisioning, support and service to which they are accustomed. All parties involved will receive regular updates throughout the transaction, during closing and subsequent integration periods.

To better focus on industrial IoT, Telit Cinterion plans to spin off and separately manage the automotive IoT unit after closure.

Deutsche Bank acted as exclusive financial advisor to Thales, and Rothschild & Co as exclusive financial advisor to Telit, DBAY Advisors.

Paolo Dal Pino, CEO of Telit
Innovation, scale and efficient IoT solutions are the key to success. This transaction with Thales is undoubtedly the most impactful for Telit’s competitiveness. While it will strengthen our ability to respond more precisely to customer needs from a richer portfolio, it will also allow us to offer all new offers resulting from the experience, expertise and DNA of two companies that have made safety and quality an integral part of their brand. promise from the start.

Philippe Vallée, EVP Digital Identity and Security at Thales
The Thales and Telit merger brings together complementary strengths. The activity will provide a unique value proposition in a highly competitive global IoT market and allow Thales to focus its investments on its three core businesses of Aerospace, Defense & Security and Identity & Security. digital. The new merger will be based on a unique set of expertise provided by Thales and Telit employees. It will also benefit from the richness and complementarity of the product portfolio of the two companies and from Thales’s experience in cellular connectivity.

2 out of 5 Indian children lack preventive dose of vitamin A: study

0

NEW DELHI : Two in five children in India lack vitamin A supplements designed to prevent health problems associated with vitamin deficiency, according to an analysis of representative survey data published in the British Medical Journal (BMJ) Global Health.

Vitamin A is important for many cellular processes in the human body that are essential for eyesight, growth and development, wound healing, reproduction, and immunity, among others.

A total of 123,836 (60.5%) of the 204,645 children surveyed aged 9 to 59 months (9 months to 5 years) had received vitamin supplements.

A cross-sectional, population-level study was conducted in 640 districts across all states and union territories (UTs) using data collected during the fourth cycle of the National Family and Health Survey 4 (NFHS -4) between January 2015 and December 2016.

Participants included 699,686 women and 112,122 men, recruited from 601,509 households nationwide to obtain information from parents on whether their children had received a vitamin A supplement (VAS) within 6 months of birth. ‘investigation.

Study author Dr Kaustubh Bora, Division of Haematology, ICMR Regional Center for Medical Research in Assam, noted: “The study showed that the coverage of vitamin A supplements (VAS) the highest was recorded in Goa (89.5%) followed by Sikkim (84.3%). Coverage was lowest in Nagaland (29.5%), followed by Manipur (32.1%), Uttarakhand (36.9%), Uttar Pradesh (40.0%). Coverage was lowest in Rajasthan (20%) compared to the district. »

Since 2006, the central government has recommended high-dose vitamin A supplements for all children aged 9-59 months.

Evidence-based approaches are needed to assess the impact of these differences and ensure that appropriate vitamin A interventions are provided to those who need them most, Dr. Bora noted.

Nationally, nearly two out of five Indian children in the eligible age bracket did not receive a vitamin A supplement during the reporting period.

Worldwide, an estimated 190 million (or one in three) children under the age of 5 have VAD (vitamin A deficiency).

Dr. Sanjeev Bagai, Chairman of the Nephron Clinic and renowned pediatrician, said: “Vitamin A deficiency is common in children and remains largely undiagnosed and undetected, especially in developing countries. About 30-35% of children under the age of 5 have some form of vitamin A deficiency.

“Predisposing factors are maternal malnutrition, early pregnancy, small gap between pregnancies, prematurity and intrauterine growth retardation (IUGR), child malnutrition, chronic diarrhea due to vitamin and micronutrient deficiency, poor eating habits, etc.

“If left untreated, it leads to poor growth, chronic infection, night blindness and xerophthalmia. Vitamin A is an extremely important micronutrient and one that is not talked about more often than vitamin D.”

Catch all the trade news, market news, breaking news and latest updates on Live Mint. Download the Mint News app to get daily market updates.

More less

To subscribe to Mint Bulletins

* Enter a valid email

* Thank you for subscribing to our newsletter.

The space boom raises environmental questions on Earth

0

Comment

With the rapid expansion of the commercial space industry, more states are vying to host satellite launch sites and other cargo, hoping to tap into a growing new revenue stream.

But even as proposals for “spaceports” proliferate from Georgia to Maine to Michigan – far from long-established federal launch sites in California and Florida⁠ – they are being pushed back over fears of harming sensitive habitats, the public safety and even drinking water.

Critics warn that noise and light generated by launch sites could harm wildlife and that failed launches could spread toxic materials and debris or even cause forest fires.

“Spaceports have become a fashionable economic development tool,” said Brian Gist, senior attorney at the Southern Environmental Law Center, which opposes efforts to establish a launch site in Camden County, Georgia. “But not all locations are good candidates for a spaceport site, and you have to balance economic development with risk to the public and risk to natural resources.”

Space experts say the innovation has driven down the cost of rocket launches even as the miniaturization of electronics has enabled much smaller satellites. This means more companies can access space for a wider variety of uses, including mapping, internet access, weather forecasting, agricultural monitoring, environmental sensing, and tracking fleets of vehicles.

SpaceX launches first fully private mission to the International Space Station

“In the old days, [building a local spaceport] was unreasonable because a launch site meant big, expensive, unreliable rockets,” said George Nield, who served as associate administrator for commercial space transportation at the Federal Aviation Administration and now runs a consulting business. “We’re seeing smaller satellites, smaller rockets, a move towards reusable space-launch systems that could potentially be more reliable.”

Elon Musk’s SpaceX has paved the way for the commercialization of space, and many local officials see the company’s Starbase production and launch site in Boca Chica, Texas – with its more than 1,600 employees – as the type of economic driver they would like to attract. But Starbase also represents the fears of some environmental groups.

In May, documents released by the US Fish and Wildlife Service showed that SpaceX activity had caused a decline in endangered piping plovers in the habitat surrounding its facility, while potentially harming sea turtles and other shorebirds. Environmental groups have drawn attention to these findings and criticized the agency’s mitigation requirements as insufficient. The FAA issued a notice in June stating that the company should do over 75 environmental adjustments to continue its Starship heavy rocket program.

Scientists marvel at Webb’s long-awaited photos – and imagine future research

Jared Margolis, senior attorney for the Center for Biological Diversity, a non-profit group focused on endangered species, said rocket blasts damaged habitat in the area and the company conducted more flights trial and caused more environmental damage than it had proposed in its original application. for authorization.

“The lesson from Boca Chica is that impacts can be covered up early on, and then what actually happens is much worse than expected, and you have significant habitat and species damage that goes unaddressed,” did he declare. “I’d be worried if I was these local governments with a company coming in saying everything will be fine.”

SpaceX did not respond to a request for comment.

But many local leaders still see potential in the development of spaceports. Camden County, Georgia, received FAA approval for its proposed spaceport late last year, after years of pushing the project and spending more than $10 million in taxpayer dollars to support the plan. County commissioners believe the site, which could launch small commercial rockets, would diversify the local economy.

Take a cosmic tour inside images captured by NASA’s Webb Telescope

Several groups are suing to challenge the decision, saying the launches threaten the national coastline of Cumberland Island, a haven for sea turtles and migratory birds. Environmentalists believe that small rockets have a higher risk of misfire, which could blast the island with debris and fuel or even start a forest fire.

“If we need a certain capacity for certain rockets, we should launch them from the safest places and not just license them to anyone who thinks they can meet the minimum criteria,” said Gist, the l environmental lawyer.

This year, Camden County residents voted overwhelmingly in a referendum to block county officials from buying land for the spaceport. As a result, the company owning the land says it is unable to sell to the county, the Associated Press reported.

County Administrator Steve Howard responded with a statement from the county’s external legal counsel, the Robbins firm, which says the referendum is not “legally proper”; County commissioners then sent another statement saying they were suing the owner to close the deal.

Howard also touted “active negotiations” with several launch companies that would produce a return on investment within 12 to 25 months. Another Camden County spokesperson emailed a county-funded study that determined the launches were unlikely to cause a fire on the island.

Sarah Gaines Barmeyer, senior executive director of conservation programs for the National Parks Conservation Association, said Florida’s Merritt Island National Wildlife Refuge has also been proposed as a potential spaceport site.

Launches from a site inside the refuge would send rockets over the Canaveral National Coastline, unlike launches at the nearby Kennedy Space Center. She said proposed launch sites, which must avoid populated areas to meet federal safety guidelines, will likely continue to threaten protected coastal parks.

“The same attributes that attract visitors to these national parks are the same that commercial spaceports seek because there is less human development nearby,” she said.

In Michigan, state officials in 2019 awarded a $2 million grant to the Michigan Aerospace Manufacturers Association to study the feasibility of a spaceport in the Upper Peninsula. The proposal includes a vertical launch facility for traditional rockets, a site for horizontal launches – in which planes take off with a rocket, which releases into the air and propels itself into space – as well as a command center and control. Backers say the project could benefit from manufacturing expertise in the state’s auto industry and help the state attract and retain talent.

Cars were killing salamanders. A student had the road closed to save them.

Gavin Brown, chief executive of the aerospace group, said the spaceport would capitalize on the environmentally friendly launch technologies that are still emerging. He said infrastructure development would be costly, but the benefits could be enormous.

“We’re not trying to get into the space business where it is, we’re trying to be a frontrunner in where space is going,” he said. “There are some things in the testing phase that we’re waiting to see if it makes sense to us, and then we can share with people what it is.”

But the plan drew attention to environmental concerns. Dennis Ferraro, chairman of the board of Citizens for a Safe & Clean Lake Superior, a community group that opposes the project, pointed to launch failures at other spaceports that have damaged or polluted nearby ecosystems.

“If we start industrializing the shoreline on the shores of Lake Superior, Katy, bar the door. What’s next after a rocket launch site? ” he said.

A spokesperson for the Michigan Economic Development Corporation, which awarded the grant, did not make the officials available for an interview.

Other states, including Alabama, Florida and Maine, have created agencies or public-private partnerships to develop the space industry. This year, Maine lawmakers voted to establish the Maine Space Port Corp., a public-private partnership that will seek to create a complex that hosts launches, research and development operations, and data analytics businesses. Backers say Maine’s location makes it ideal for launches into polar orbit.

‘Chemicals forever’ upset a Maine farm – and signals a bigger problem

“The state government has had to demonstrate to the investment and business community that it is very serious about increasing state involvement in the new space economy,” said Terry Shehata, director executive of the Maine Space Grant Consortium, a nonprofit group funded by the NASA grant. aerospace research recovery program.

But some in Maine are wary.

The city of Jonesport voted late last year to temporarily ban commercial rocket launches, after a company announced plans to build a launch site.

Locals in the fishing industry led the opposition, fearing that launching operations on a nearby island would interfere with their work and damage their equipment, the Portland Press Herald reported.

Some analysts question the economic viability of spaceports.

“There are 14 licensed spaceports in the United States, and most of them don’t see traffic,” said Phil Smith, program manager and principal analyst at BryceTech, an analytics and analytics firm. engineering. “Taxpayers want to see a return on investment, and they haven’t seen it. Much of the space industry’s growth comes from big batches of small satellites on big rockets.

James Causey, executive director of the Global Spaceport Alliance, a membership organization that supports the planning and operation of such launch sites, countered that skeptics underestimate how quickly the commercial space industry is on its way. to develop oneself.

“In the time it takes to build a spaceport to the point where it will actually have launch operations, the demand will be there,” he said.

Stateline is an initiative of the Pew Charitable Trusts.

Ask the Doctors: Adults Vaccinated Against Smallpox Can Be Immune Against Monkeypox | Various

0

Dear Doctors: How long does the smallpox vaccine remain effective? I ask because I received it as a child in the 1950s. Does anyone know if the vaccine would be effective against monkeypox some 60 years later, or is a booster needed? Does a booster exist?

Dear reader: With cases of monkeypox spreading around the world, concerns about this rare virus are growing. The disease, which is endemic to central and western Africa, began to appear in Europe and the United States in May. Since then, the United States has recorded more than 350 cases. Still, health officials warn that due to lack of knowledge about the disease and limited testing, the true number of cases in this country is likely higher. We’ve discussed this outbreak before, but with cases on the rise, we think a recap is wise.

Monkeypox is related to smallpox, but the disease it causes is not as severe. For the majority of people infected, the symptoms resemble those of the flu. This includes fever, chills, headache, body aches, swollen lymph nodes, and fatigue. In more severe cases, patients develop a rash and distinctive lesions, most commonly on the hands, face, and soles of the feet.

People also read…

Monkeypox is not known to linger in the air and is not transmitted during brief periods of shared airspace. Instead, the disease is most often spread through direct physical contact with an infected person or with their bodily fluids. Since the sores can be inside the body, including the mouth, vagina, or anus, sexual transmission is possible. The virus can also spread through contact with objects that have touched the infectious rash or bodily fluids, such as sheets or clothing.

An infected individual is contagious from the onset of symptoms. Those who develop a rash or lesions may continue to spread the disease until the rash is completely healed and covered with a new layer of skin.

Adults like you who received the smallpox vaccine during the national program in effect from the late 1940s until 1972 are thought to have continued immunity. This includes members of the United States military, who continued to be vaccinated against smallpox until 1991.

The Centers for Disease Control and Prevention says that, based on previous data collected in Africa, the smallpox vaccine is at least 85% effective in preventing monkeypox. However, since this situation is so new, the precise degree of protection is not known. Researchers say that while older adults who have been vaccinated against smallpox may be susceptible to monkeypox infection, they will likely only experience mild symptoms. Data shows that the majority of healthy adults who are infected do not become seriously ill. And to your question about smallpox boosters, no they are not available.

To combat this epidemic, the United States has just purchased 2.5 million doses of vaccine against monkeypox, which adds to the 500,000 doses already stockpiled. Distribution to high-risk individuals is expected to begin soon. You can find detailed information on smallpox and monkeypox on the CDC website. Visit cdc.gov/poxvirus and click on the appropriate link.

Shacktown Residents File Lawsuit Against Pittsfield Over Cell Tower / iBerkshires.com

0

PITTSFIELD, Mass. — Residents of the Shacktown neighborhood have filed a lawsuit against the city after it overturned its cease-and-desist order for the Verizon cell tower at 877 South St..

On Thursday, a civil action was filed in Berkshire Superior Court against Mayor Linda Tyer, city solicitor Stephen Pagnotta, Pittsfield Cellular Telephone Co. (Verizon Wireless) and the Board of Health.

This is an appeal of the June board’s decision to rescind the order after the telecommunications company filed a lawsuit against the city of Pittsfield in federal court and is a request for declaratory relief. .

The document alleges that the decision to rescind the order exceeded or derogated from the authority or jurisdiction of the Commission; that it has been tainted and rendered illegal by the unlawful actions of the mayor, city attorney and/or others under the influence and control of the mayor; and is not supported by substantial evidence.

There are four counts: an appeal of the decision, the mayor’s refusal to enforce the council’s order, and the city’s attorney’s conflict of interest and improper coercion, and declaratory judgment .

Attorney Scott McCollough pointed out that the plaintiffs had to name the board of health in the lawsuit, but added that they weren’t really complaining about anything from the board, but rather “legal complaints about what they were forced to do”.

Courtney Gilardi, head of the lawsuit, said neither side wanted there to be litigation, but wanted to find a solution for their neighborhood. The purpose of the lawsuit is to get back to where the board was urging Verizon to come to the table.

“This health advice has been phenomenal, and especially under [Chair Bobbie Orsi’s] leadership,” she explained.

“They took this seriously, they treated us with dignity and respect, and they exercised due diligence in their investigation, findings and conclusions and the board truly deserves to have all the practical resources and legal support what he needs to find meaningful solutions for Shacktown.”

In early April, the council voted to proceed with the order nearly two months after first approving it. This vote was conditional on the withdrawal of the order without prejudice if the council was unable to retain a lawyer prior to an administrative or legal procedure.

The order stated that the cellphone company had one week to respond or come to the table with a solution the panel would like, which would be to remove or turn off the tower. The board had planned to meet on April 20 to follow through on the order, but never met.

In May, Verizon, doing business as Pittsfield Cellular Telephone, sought declaratory judgment from the U.S. District Court in Springfield against the city. The company claimed the tip violated Section 332 of the Federal Telecommunications Act (TCA) of 1996 which prohibits state and local governments from regulating a personal wireless service facility due to perceived health effects. radio frequency emissions comply with Federal Communications Commission (FCC) regulations.

The city council was expected to agree to a request from the board for $84,000 to hire a lawyer against the telecommunications company, but that was shelved when the council was told of the lawsuit and put to rest in June.

Since the erection of the tower in August 2020, Gilardi, of Alma Street, and her daughter have spoken on an open mic at city council meetings about the negative health effects they say are due to the fields electromagnetic waves (EMF) generated by the antennas on the 115-foot pole. They also said they resided in another location due to the effects.

Five other shacktown residents joined Gilardi in the lawsuit: Charlie and Judy Herzig, Mark and Angelika Markham and Elaine Ireland.

The group representative

Citizens Civil Complaint Ag… by iBerkshires.com

symptoms such as headache, nausea, vomiting, dizziness, insomnia, palpitations, fatigue, skin rashes, tinnitus, memory loss and concentration problems.

Key words: cell tower, lawsuit,

“Murderer” Cells Murder Innocent Cells

0

Scientists have found that a quarter of testicular progenitor cells are “killed” by phagocytes, despite the fact that these cells are not doing anything “wrong”.

Research from the University of Haifa has identified killer cells.

A process that involves the “killing” of newly generated living cells was first discovered in recent research conducted at the University of Haifa. The research, which was described in the prestigious journal Scientists progressfound that throughout the process of cell differentiation in fruit flies, phagocytic cells consume and destroy healthy living cells.

“We discovered that phagocytes can function as ‘murderers’. It is well known that phagocytic cells swallow and dissolve dead cells, but we show for the first time that they also kill newly created normal cells. Essentially, we have characterized a novel cell death mechanism. The more we know about the mechanisms of cell death, the better we understand how to deal with various diseases, including cancer,” explained Professor Hilla Toledano, Head of the Department of Human Biology at the University of Haifa and author of the study. .

The origin of several bodily tissues, including skin, hair, stomach, and testicles, can be traced back to stem cells. By continually supplying new cells to replace old ones, these powerful stem cells enable tissue replenishment. Each stem cell in this process divides into two cells, one of which is saved for future use and the other grows to take the place of the lost cell in the tissue.

In the current investigation, Prof. Toledano, Prof. Estee Kurant and a group of scientists from the University of Haifa examined the sex cells of fruit flies. Since many molecular processes in fruit flies and humans are similar, they can be used as an effective model in this situation.

Fruit fly studies are useful because of the ability to monitor processes in living tissues and the simplicity of genetic alteration, which allows exact identification of cellular processes. Six Nobel Prizes have been awarded over the years to scientists who have discovered biological mechanisms in fruit flies that are conserved in humans.

As mentioned earlier, the division of a stem cell into two cells – a stem cell and a cell called a progenitor – triggers the process of sperm differentiation in male fruit flies. This process continues until the formation of functional sperm. Researchers already knew that a quarter of these progenitor cells perish and do not develop into sperm from previous studies. The goal of the current study was to better understand what happens to these cells.

The body has a well-established and crucial mechanism called cell death. Under normal circumstances, cells have the ability to “commit suicide” when a serious mutation has occurred or after they have achieved their goal. The phagocytes come to “eat” the dying cells, effectively carrying away their contents and dissolving them. We know that phagocytes sometimes “eat” immune system cells that have finished their work of defending the body against intruders.

In the current study, the researchers found that the phagocytes “kill” a quarter of the testicular progenitor cells, although these cells are not doing anything “wrong” and are simply differentiating; they are still new cells and they are not abnormal in any way.

In the first stage, the researchers inhibited the feeding abilities of the phagocytes and found no dead cells in the tissues. In other words, phagocytes are responsible for the death of progenitor cells.

In the second step, the researchers used real-time imaging to monitor living tissue and found that progenitor cells are swallowed alive by the phagocyte, and only then the death process is initiated. “We have discovered for the first time a process leading to the ‘killing’ of completely normal cells. We still don’t know why this is happening. Perhaps this process aims to provide nutrients to maintain a functional population of stem cells throughout the life of the organism,” Professor Toledano suggested.

In addition to understanding a new mechanism, this study may contribute to our ability to develop drugs and means to control cell death, and particularly, of course, to treat cancer. “Tumors are characterized by constant growth and disruption of the natural cell death process. If we manage to introduce into this process phagocytes capable of eliminating living cancer cells, we will be able to control the growth of the tumour. The more we learn about the mechanisms of cell death, the better we can harness these processes to get rid of cancer cells,” Professor Toledano concluded.

Reference: “Phagocytic cyst cells in Drosophila testes eliminate germ cell progenitors via phagoptosis” by Maayan Zohar-Fux, Aya Ben-Hamo-Arad, Tal Arad, Marina Volin, Boris Shklyar, Ketty Hakim-Mishnaevski, Lilach Porat-Kuperstein, Estee Kurant and Hila Toledano, June 17, 2022, Scientific advances.
DOI: 10.1126/sciadv.abm4937

Roku, Amazon, First Solar, Intel, Apple and more

0

People walk past a video sign with the logo of Roku, a Fox-backed video streaming company that staged its IPO at the Nasdaq Marketsite in New York, September 28, 2017.

Brendan McDermid | Reuters

Find out which companies are making headlines Friday at noon.

Amazon – Shares of the e-commerce giant jumped 10.4%, giving the broader market a boost, after the company reported better-than-expected second-quarter revenue and released an outlook optimists. Revenue growth of 7% in the second quarter beat estimates, bucking the trend among its Big Tech peers.

Roku – Shares of Roku fell 23.1% after the streaming company reported disappointing second-quarter results as it faces a slowdown in advertising. The company shared a disappointing guidance for the current quarter, noting that lower advertising spending and recession fears could continue to impact its business going forward.

Apple – Apple shares rose 3.3% after the company beat Wall Street earnings and revenue forecasts, and CEO Tim Cook said he expects growth to continue. is accelerating despite “pockets of sweetness”. Sales of its iPhone saw double-digit growth in new customers.

First Solar – Shares of First Solar jumped 12.1% after the company reported better-than-expected second-quarter earnings. Oppenheimer also upgraded the stock to outperform the neutral on Friday, citing a deal reached between Sen. Joe Manchin, DW.V. and Senate Majority Leader Chuck Schumer, DN.Y., on a bill that includes climate spending.

Chevron, Exxon Mobil – Energy stocks surged on record profits reported in their second-quarter results, boosted by higher oil and gas prices. Chevron jumped 8.9% and Exxon Mobil added 4.6%.

Bloomin’ Brands – Shares jumped 3.1% after Bloomin’ Brands reported second-quarter earnings that beat analysts’ expectations. The restaurant company behind Outback Steakhouse and other brands earned 68 cents a share on revenue of $1.13 billion. Analysts had expected earnings of 61 cents per share on revenue of $1.1 billion, according to Refinitiv.

Stanley Black & Decker – Shares of the tooling company fell 1.3% on Friday, building on a 16% loss on Thursday after a disappointing quarterly report and lower forecast. Wolfe Research downgraded the stock to peer performance from outperform, saying “negative news flow will likely dominate” through the end of this year.

Procter & Gamble – The consumer goods company posted mixed second-quarter results, sending its shares down 6.2%. Procter & Gamble also said it expects rising raw material costs to continue to be a challenge ahead.

Church & Dwight – Shares fell 8.6% after the household products company behind Arm & Hammer reported a revenue loss in its latest quarter, citing stronger inflationary pressures.

Intel – Shares of the chipmaker fell 8.6% after a second-quarter report fell well short of expectations. Intel reported adjusted earnings per share of 29 cents on $15.32 billion in revenue. Analysts polled by Refinitiv had forecast 70 cents of earnings per share on $17.92 billion in revenue. The third quarter forecast also fell short of expectations. Susquehanna downgraded the stock from neutral to negative, warning free cash flow could be “significantly depressed for at least the next few years.”

– CNBC’s Yun Li, Tanaya Macheel, Jesse Pound, Carmen Reinicke and Samantha Subin contributed reporting

Kansas Police Officer Who Killed Innocent Man in Crash Denied Qualified Immunity

0

from only-officer-who-fired-a-shot department

Crushing is really heinous. People angry at the video game somehow believe they are justified in trying to end their opponents’ lives, literally. Toxic subhumans who can’t stand losing turn to second-hand murder for revenge. Absolutely heinous behavior that plays into the warrior mentality of law enforcement who shoot first, handcuff the corpse and later.

In this case, hailing from Wichita, Kansas, the crush performed on behalf of a really shitty Call of Duty player has at least some silver linings. The first is that the author, the “serial swatter” Tyler Rai Barriss, was sentenced to twenty years in prison for his participation in this violent tragedy.

The second silver lining is that the only officer to shoot the victim, Wichita resident Andrew Finch, was denied qualified immunity. He will continue to face a lawsuit filed by Finch’s family, alleging multiple constitutional violations.

The events leading up to Finch’s murder by Wichita PD officer Justin Rapp are almost as gruesome as the deadly result. This is taken from the decision of the Court of Appeals for the Tenth Circuit [PDF] allowing the family lawsuit to continue:

At 6:10 p.m. on December 28, 2017, a City of Wichita duty officer responded to a call. The caller said his mother hit his father with a gun. The duty officer tried several times to connect the caller to 911, but the call was repeatedly dropped. Seven minutes later, the caller gave his number to the officer, who relayed the information to 911 dispatchers in Sedgwick County. At 6:18 p.m., a 911 dispatcher contacted the caller. This time, the caller told the dispatcher that he shot his father in the head and was holding his mother and brother at gunpoint in a closet. He gave the dispatcher an address in a residential area of ​​Wichita. The dispatcher passed alerts to officers that the caller had shot his father and was holding his mother and brother at gunpoint. The dispatcher also reported that the caller was threatening to set the house on fire and kill himself.

The reality of the situation is that the call was made by Tyler Barriss, a resident of Los Angeles. The call was made on behalf of a Call of Duty player who was angry about an in-game online altercation with Andrew Finch.

Officers, understandably, thought they were dealing with an ongoing hostage situation and an armed suspect. As many as 10 officers converged on the address, approaching the house from several sides. Officer Rapp arrived and took up a watch position about 45 feet from the front door of the house. He hadn’t been on the scene long before he decided it was time to pull the trigger.

Rapp had only been in his position for about forty seconds when Finch opened his front door. Finch opened the screen door and stepped onto the porch. An officer on the east side of the residence turned on his rifle light and instructed Finch to raise his hands and step off the porch. Jonker shouted “show your hands!” At the same time, officers east of the house shouted more orders. Jonker then shouted “walk over here!” Officers later testified that they could not understand the commands given by Jonker from the north side. None of the officers identified themselves as police officers.

This lack of identification might have been excusable if it had happened during the day. But by this point in December, the sun had long since set when officers arrived (a little after 6 p.m.). Confused and attempting to respond to multiple, seemingly conflicting orders from several different officers, Finch did something that caused Officer Rapp to shoot him: he moved his hands.

On the north side, an officer saw Finch reach back with his right hand and place it on the front door handle. Jonker saw Finch lower his hand then begin to raise his hands in response to commands. But Jonker was mainly focused on the east side officers, not Finch. Rapp saw Finch grab the right side of his hoodie and lift it up, making a move that looked like a gunshot. Rapp thought Finch was not complying with commands and possibly armed. He testified that he thought he saw a gun in Finch’s hand.

About ten seconds after Finch first opened the door and stepped onto the porch, Rapp fired a single shot from his rifle, hitting Finch in the chest. Finch fell backwards into the residence, where he died within minutes. He was unarmed.

Constable Rapp was the only officer (out of nearly a dozen) to open fire. He was later cleared of any wrongdoing by the Wichita PD internal investigation.

But the exemption by his employer means nothing here. He claimed his shot was fully justified by the nature of the situation and Finch’s movements. The lower court disagreed, saying many facts were still under discussion.

The district court found that a reasonable jury could find that (1) Rapp fired when he could see Finch’s hands were empty, (2) Rapp’s claim that Finch made a threatening move was fake and (3) Rapp couldn’t see Finch’s hands. movements clearly due to darkness and distance, as well as many other facts. Thus, he concluded that a reasonable jury could also conclude that Rapp did not reasonably believe that Finch posed a threat.

The footnote attached to this paragraph also indicates that a jury might conclude that Finch’s movements were not threatening, but rather logical responses to the bizarre situation he found himself in when he walked through his front door.

The district court found that a reasonable jury could conclude: (1) Finch was confused but attempted to comply with officers’ orders and his movements did not indicate hostile or threatening action; (2) the people yelling at Finch were not immediately recognizable as police; (3) Finch simply moved his arms when the officers gave him several orders; (4) Finch’s movements did not suggest he was attempting to draw a gun; (5) Finch was never told to keep his hands up or that he would be shot; (6) an officer could see that Finch was not actively resisting orders; and (7) Rapp was unaware that Finch was trying to get into the house when Finch was shot.

The court agrees that all of this should be considered further. A closer look may show that Rapp’s actions were unreasonable, a violation of Finch’s rights. And the violation here was not moot. It was clearly established.

Certainly, there are no cases with facts identical to these. But “[w]We do not believe that it takes a court ruling on identical facts to make it clear that it is unreasonable to use lethal force when force is completely unnecessary to subdue a suspect or to protect officers, the public or the suspect himself. Taken together, the cases cited by the district court establish that an officer, even when responding to a reported dangerous situation, cannot shoot an unarmed, non-threatening suspect.

And, at this point in the case, that’s enough to keep Officer Rapp from getting out of this trial prematurely. Whether or not a jury will rule in favor of Finch’s survivors remains to be seen, but at least this ruling makes it clear that it takes more than unspecified fears about officer safety to justify lethal force…at least in cases similar to these.

Now for the somewhat disappointing coda:

The Wichita Police Department has promoted the officer who pulled the trigger on the nation’s first deadly ‘swatting’ call, a move the mayor and two city council members say could undermine efforts to restore confidence in Kansas’ largest police department.

Justin Rapp’s June 25 promotion to Detective comes amid ongoing lawsuits and a Netflix docuseries that focused one episode on the set. Rapp shot and killed Andrew Finch, an unarmed 28-year-old father, in December 2017 after a California serial prank reported a fake murder and hostage situation at Finch’s address.

Acting Police Chief Lem Moore told the Wichita Eagle that the shooting did not “disqualify Rapp from the promotion.” It’s probably true, but [gestures at the mayor and council members’ comments] perhaps not the best idea when the officer still faces a federal trial — one in which he was twice stripped of qualified immunity.

Filed Under: 10th circuit, andrew finch, justin rapp, kansas, qualified immunity, swatting, tyler rai barriss

This power station and battery pack is designed to supply your home and electric vehicle with off-grid energy

0

With power cuts becoming the norm around the world due to energy shortages, heat waves and economic fallout, having your own backup power is no longer just a “good idea”, it’s a necessity. . Now in its second generation, Bluetti’s AC500 power station and B300S modular battery allow you to achieve absolute energy independence. Plug them into your home’s power supply or connect them to a solar array and you have backup power supplies that work perfectly during power outages and can even be used outdoors to give you energy without being connected to a traditional network.

Creator: Bluetti

Click here to find out more. Get exclusive offers and special offers.

Built with a 5,000W inverter (which also handles 10,000W surges), the A500 can handle just about anything you throw at it. It’s designed to support 99% of all your power needs, with a UPS system that boots up in just 20 milliseconds, keeping your fridge, microwave, TV, AC, CPAP and other appliances running. Heck, the AC500 can even charge your Tesla if you need to. The beauty of the AC500 system is its modular design, allowing you to plug in as many B300 or B300S batteries as you need (up to 18,432Wh) to meet your energy needs, whether for a whole house, a cabin in the woods, or just the motorhome hanging in the back of your van.

Weighing 66 pounds (30 kilograms), the AC500 is just slightly larger than your average cooler and can be stored in your garage or even in the back of your RV or van. It comes with 16 output ports, including outlet points, USB-A and USB-C ports, and even heavy-duty outlets for your electric vehicle. It sports a screen that details your power usage and even lets you know if there’s a problem with the AC500, although the power station has a comprehensive battery management system, and the LiFePO4 batteries in the B300S provide long term durability and over 3,500 charge cycles at 80% of original capacity.

The AC500 can be charged in 9 different ways, giving you the option of plugging it into your home’s mains supply, a generator, a lead-acid battery or even solar panels, whichever method works best for you. better. You can even connect two AC500s together for a split-phase link, doubling your capacity, voltage and power to 36,864Wh, 240V/6000W (you’ll need Bluetti’s Fusion Box Pro for this). The power station comes with a modular battery system that allows you to connect multiple batteries together depending on your power needs (they recommend at least 2 B300S batteries for optimal use), and Bluetti claims it only takes 40 minutes to charge 2 batteries. at 80%. Plus, to make things even easier, the Bluetti smartphone app lets you see your power stats, monitor usage, and even trigger OTA updates to keep your power station running smoothly. peak performance, so no matter there’s a heat wave or a raging hailstorm outside, you always have power to keep your home and life on track!

Click here to find out more. Get exclusive offers and special offers.

Gene discovery could lead to better treatment for childhood cancers

0

Li’s 2020 discovery was named one of the biggest biomedical discoveries of the year by the editors of health news site STAT. Li’s latest work builds on this research and suggests that AVIL is even more important than previously thought.

Dysfunctions of AVIL, Li and his team discovered, play a critical role in the development of the two main subtypes of rhabdomyosarcoma. In a scientific paper describing the results, he and his colleagues describe rhabdomyosarcoma as “dependent” on excessive gene activity. They ultimately called AVIL the “authentic oncogene” for rhabdomyosarcoma. “Oncogene” means carcinogen.

AVIL could be the confluence of two different cellular processes that cause soft tissue cells to become cancerous, the researchers note. Blocking AVIL activity, they found, prevented the formation of rhabdomyosarcoma in cell samples from laboratory dishes and in mouse models of the disease.

It’s a promising sign of the discovery’s potential to lead to a new, targeted treatment for rhabdomyosarcoma, a relatively rare but potentially deadly cancer. Even with multimodal therapeutic interventions, the survival rate for high-risk children is less than 20%.

The new research also reveals that AVIL is excessively active in other soft tissue cancers, known as sarcomas. Scientists found that the degree of excessive activity correlated with patient outcomes, suggesting that AVIL may also be a vulnerability for these cancers.

“These findings, together with our previous work in brain tumors, suggest that AVIL is an oncogene that, when overactivated, can trigger the development of several types of cancer,” Li said.

Finding better ways to prevent and treat cancer is an urgent mission for the UVA Cancer Center, which was designated a Comprehensive Cancer Center by the National Cancer Institute this year. The designation recognizes elite cancer centers with the nation’s most outstanding cancer programs. UVA is one of 52 comprehensive cancer centers nationwide and the only one in Virginia.

Li and his team published their findings in the scientific journal PNAS. The team consisted of Zhongqiu Xie, Pawel L. Janczyk, Xinrui Shi, Qiong Wang, Sandeep Singh, Robert Cornelison, Jingjing Xu, James W. Mandell, Frederic G. Barr, and Li.

To follow the latest news in UVA medical research, subscribe to the Making of Medicine blog.

Pleiotropy of psychiatric and immune characteristics

0

For one study, researchers sought to investigate the pleiotropy of psychiatric and immune characteristics and risk variables of predicted significance.

Genetic association analysis was performed between July 10, 2020 and January 15, 2022. GWA statistics were used in the analyzes of 14 psychiatric characteristics, 13 immune system-related phenotypes, such as allergies, auto -immune and inflammatory, and 15 risk variables. related to health-related behaviours, social determinants of health and stress response. Mendelian randomization (MR) with sensitivity analysis and multivariate correction for genetic connections of third variables was used to identify genetically associated psychiatric-immune couples. Correction for the false discovery rate (Q value P values. A data-driven method was used, without any pre-planned hypotheses being tested.

There were 44 genetically associated psychiatric-immune pairings found, with 31 positive associations (most commonly including asthma, Crohn’s disease, hypothyroidism, and ulcerative colitis) and 13 negative correlations (most commonly involving allergic rhinitis and type 1 diabetes). For psychiatric traits, correlations with third factors were very high. Additionally, MR identified 7 associations of psychiatric phenotypes with immune-related phenotypes that were robust to multivariate adjustment, including the positive association of the psychiatric disorder phenotype cross-referenced with asthma (odds ratio [OR], 1.04; 95% CI, 1.02-1.06), Crohn’s disease (OR, 1.09; 95% CI, 1.05-1.14) and ulcerative colitis (OR, 1.09; CI at 95%, 1.05-1.14); major depression with asthma (OR, 1.25; 95% CI, 1.13-1.37); schizophrenia with Crohn’s disease (OR, 1.12; 95% CI, 1.05-1.18) and ulcerative colitis (OR, 1.14; 95% CI, 1.07-1.21); and a negative association of risk tolerance with allergic rhinitis (OR, 0.77; 95% CI, 0.67-0.92).

According to the results of the genetic association study, genetic responsibility for psychiatric disorders is associated with responsibility for several immune disorders, implying that vertical pleiotropy related to behavioral traits (or third correlated variables) contributes to clinical associations. observed in population-level data.

Reference: jamanetwork.com/journals/jamapsychiatry/article-abstract/2792053

Researchers have identified a gene that promotes muscle strength when activated by physical activity, unlocking the potential for developing therapeutic treatments to mimic some of the benefits of training. –ScienceDaily

0

Researchers have identified a gene that promotes muscle strength when activated by physical activity, unlocking the potential for developing therapeutic treatments to mimic some of the benefits of training.

Posted in Cellular Metabolism, the study led by the University of Melbourne showed how different types of exercise change molecules in our muscles, leading to the discovery of the new gene C18ORF25 which is activated with all types of exercise and responsible for promoting muscle strength. Animals without C18ORF25 have poor physical performance and weaker muscles.

Project leader Dr Benjamin Parker said that by turning on the C18ORF25 gene, the research team could see muscles get much stronger, without them necessarily getting bigger.

“Identifying this gene may impact how we manage healthy aging, muscle wasting disease, sports science, and even livestock and meat production. of optimal muscle function is one of the strongest predictors of overall health,” said Dr. Parker.

“We know that exercise can prevent and treat chronic diseases, including diabetes, cardiovascular disease and many cancers. Now, we hope that by better understanding how different types of exercise elicit these beneficial health effects in molecular level, the field will be able to work to make new and improved treatment options available.”

In the study, a collaboration between Dr Parker and Professors Erik Richter and Bente Kiens of the University of Copenhagen, Denmark, the team was able to identify molecular similarities and differences between different types of exercise in the biopsies. human muscles by analyzing proteins and how they change inside cells.

“To identify how genes and proteins are activated during and after different exercises, we performed an analysis of human skeletal muscle from a cross-intervention of endurance, sprint and resistance exercise,” said the Dr Parker.

The experimental design allowed researchers to compare signaling responses between exercise modalities in the same individual, relative to their level before exercise. This meant that they could monitor how an individual reacted to different types of exercise directly in their muscles.

Importantly, it also allowed the research team to identify genes and proteins that constantly change across all individuals and exercise types, leading to the discovery of the new gene.

This work was supported by Australian National Health and Medical Research Council Project Grant (APP1122376), Diabetes Australia Grant, University of Melbourne Driving Research Momentum Grant and NHMRC Emerging Grant. Leader Investigator Grant (APP2009642) to Dr. Benjamin Parker.

Source of the story:

Material provided by University of Melbourne. Note: Content may be edited for style and length.

CULT Food Science Signs Letter of Intent to Acquire Food Revolution Media

0

Toronto, OntarioCULT Food Science Corp. (“CULT” or the “Company”) (CSE: CULT) (OTC: CULTF) (FRA: LN0), an innovative investment platform focused exclusively on cellular agriculture that advances the development of new technologies to provide a sustainable environment, an environmental and ethical solution to the global factory farming and aquaculture crises, is pleased to announce that it has signed a Letter of Intent (the “LOI”) pursuant to which the Company and Food Revolution Media Inc. (“FRM”) intend to enter into a share-based transaction (the “Proposed Transaction”) which would see CULT acquire 100% of the issued and outstanding shares of FRM. FRM’s core business is the publication of news, interviews and editorials on its 100% owned and operated online domain and social media accounts, with a particular focus on early stage companies. early growth in the plant-based and cell-based food sectors.

FRM’s main assets include, but are not limited to, the “Plant Finance” brand, the website domain and corresponding social media profiles on Twitter, Instagram, Facebook, as well as the “Cell-Based Finance” brand. and the “CellBased_Fin” profile on Twitter. Created in 2020, the ‘Plant Finance’ website located at https://www.plantfinance.news/ has become a trusted source of information on the plant and cell-based food industry. The brand currently has over 84,000 average monthly impressions and over the past 12 months has generated over 1 million total impressions from a current audience of approximately 3,000. Launched most recently in early 2022, FRM’s “CellBased_Fin” profile already has over 307,000 average monthly impressions and an audience of over 2,000 people. Subject to the closing of the proposed transaction, CULT expects to retain all of FRM’s current employees and contractors who have key skills, knowledge and relationships in FRM’s assets as well as food-related markets. .

The increasing growth rate and level of interest in cellular agriculture and cellular investment is evident in FRM data. Accordingly, the proposed transaction is viewed by CULT’s management as accretive to amplifying the narrative surrounding its investment portfolio as well as its development of intellectual property in the form of patents and other similar assets. As the global food supply chain continues to be challenged due to the COVID-19 pandemic and the invasion of Ukraine, which have led to a significant increase in the costs of fertilizers and energy, among other inputs, the Company considers this to be a critical time to raise awareness of cellular agriculture. Cell-based foods are growing rapidly and should be a viable option to improve the sustainability of the global food system in the short and long term.

The proposed transaction is expected to be completed in accordance with prospectus exemptions available under applicable securities laws. CULT and FRM have agreed to negotiate in good faith the terms of a definitive written agreement regarding the proposed transaction within 60 days of the letter of intent. The proposed transaction is subject to the receipt of all necessary regulatory approvals, including, as applicable, the approval of the Canadian Securities Exchange (the “CSE”), the performance of reasonable due diligence or customary in a transaction of a similar nature, and the conclusion of a definitive agreement, among other conditions. The Proposed Transaction would be an arm’s length transaction for CULT and would not constitute a fundamental change or result in a change of control of the Company, within the meaning of the policies of the CSE.

Management commentary

‘Entering this letter of intent with the intent to acquire FRM marks a strategic move for CULT Food Science as we aim to further harness the power of social media to advance important messages around cellular agriculture in these times of inflationary food prices. The prospect of adding a significant number of people to our audience, who are interested in both food and capital markets, is exciting and we look forward to entering into a definitive agreement for the transaction in the near future.” , said Lejjy Gafour, president of CULT. “Now that CULT is connected to a broad portfolio of companies in the cellular agriculture industry, it’s time to amplify our unique model and provide people with more information to help them understand that various potential solutions global food crises and supply chain issues are on the horizon,” added Mr Gafour.

About CULT Food Science

CULT Food Science Corp. is an innovative investment platform focused exclusively on cellular agriculture that advances the development of new technologies to provide a sustainable, environmental and ethical solution to the global factory farming crisis. The first of its kind in North America, CULT Food Science aims to provide individual investors with unparalleled exposure to the most innovative, private or early-stage cultured meat, cell-based dairy, and other cultured food companies around the world .

Contact:

Tel: +1 (833) HEY-CULT (+1 (833) 439-2858)

Email: [email protected]

Web: www.CULTFoodScience.com

Forward-looking information:

The information contained in this press release may involve forward-looking statements. Forward-looking statements are statements that relate to future and not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend”, statements that an action or event “may”, “might”, “might”, “should” or “will” be undertaken or will occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or other future events, to differ materially from the results, performance or future achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the following risks: those associated with the marketing and sale of securities; the need for additional funding; reliance on key personnel; the potential for conflicts of interest between certain officers or directors with certain other projects; and the volatility of the price and volume of the Common Shares. Forward-looking statements are made based on the beliefs, estimates and opinions of management as of the date the statements are made and, except as required by law, the Company undertakes no obligation to update any forward-looking statements. whether these beliefs, estimates and opinions or other circumstances should prevail. Investors are cautioned against attributing undue certainty to forward-looking statements. For additional information on risk, investors should consult the Company’s MD&A and other disclosure documents filed with regulatory authorities which can be found at www.sedar.com.

Facebook co-founder’s venture firm eyes digital health and fintech

0

It also seeks to invest in logistics and supply chain, helping industries to step up digitalization

Topics
Facebook | Capital risk


Peerzada Abrar |
bangalore



B Capital, the venture capital (VC) firm co-founded by Facebook co-founder Eduardo Luiz Saverin, plans to invest in areas such as enterprise technology, software as a service (SaaS), digital health and fintech.


TO READ THE FULL STORY, SUBSCRIBE NOW FOR JUST RS 249 PER MONTH.

SUBSCRIBE TO PERSPECTIVES


What do you get on Business Standard Premium?


WHERE







Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

First published: Sunday, July 24, 2022. 7:47 PM IST

How to Manage RF Performance and Compliance of Connected Devices

0

Smart sensors can ensure every device in your home is connected, compliant, and performing.

It’s time to think: how many electronic devices do you own? I assume you have at least a cell phone, a home computer, your work laptop, and maybe another tablet or two. Am I right? In 2020, an average US household owned a dozen and growing consumer electronics (CE) devices.

Almost five years ago, annual consumer spending on technology was $1.6 trillion in the United States, and that figure is expected to reach $2.06 trillion by 2023. However, during this period, our lives were interrupted by a global pandemic. The initial uncertainties of COVID-19 forced millions of Americans to stay indoors and rethink how they interacted with tech products inside their homes on a daily basis. Many of us have been working remotely and school has moved online to virtual classrooms. This shift in work, school and play has prompted many of us to purchase new CE devices to perform better and to entertain us and our families.

David Wang

Provide the best customer experience

The way we use our consumer devices (tablets, laptops or smartphones) is essentially the same. We expect these devices to always deliver exactly what is asked of them. You might be streaming a movie on your smartphone and not expecting any network outages, or you might need your laptop running at peak performance while you manage a career entirely remotely. Whatever the situation, when you use these devices, you expect (and deserve) nothing less than an optimal experience.

Consumers don’t have to worry about the performance of their devices. You can be assured that the industry’s leading original equipment manufacturers (OEMs) design the best performing products in the best interests of consumers. OEMs are embedding smart sensors inside their connected devices to deliver always-on connectivity, longer battery life, and high-performance experiences.

The Rise of 5G Devices and Consumer Expectations

Major US carriers have launched 5G networks, with 5G smartphone revenues expected to reach $337 billion by 2025. To ensure these smartphones work with the fastest 5G networks and support bandwidths higher, OEMs need to add more radio frequency (RF) antennas into the design without hampering battery performance or device form factor. The connectivity challenge is also prevalent among laptop and tablet manufacturers. These devices must support many different wireless protocols, from sub-6 5G to Wi-Fi 6, which can add complexity to product designs.

As consumers, we’ve become accustomed to (and demand) the best experiences our devices provide. We rarely think about the design challenges manufacturers face when creating these products. What industry regulations are required when designing? How do OEMs balance performance and connectivity with industry compliance requirements?

For today’s connected devices, OEMs must design and release devices that meet global Specific Absorption Rate (SAR) standards. SAR is a measurement of the amount of RF energy absorbed by the body when a person uses a connected device. Manufacturers are required to ensure that wireless devices such as smartphones, tablets or laptops meet the SAR standards required by the Federal Communications Commission (FCC) before they can be shipped to US markets.

When we talked earlier about all the appliances in your household, consider that each of them is regulated and must be compliant before they can be shipped. In the United States, SAR compliance is 1.6 W/kg (more than 1 gram of tissue) with a separation distance of 25 millimeters. For Europe, the SAR limit is 2 W/kg (more than 10 grams of tissue) with a separation distance of 5 millimeters.

More than 65% of Americans have found a new way to work that doesn’t require a daily office visit, and six in 10 American workers are still able to do their jobs remotely. Instead, with our laptops close at hand, any place can become our office. And because we can work from anywhere, we now take regular video calls. We expect to have the best connectivity possible, regardless of our location. The impact of this requirement is two-fold: will your laptop be able to support these workloads while remaining SAR compliant?

Smart sensors are the answer

Smart sensors intelligently ensure devices deliver the best experience at all times. Consumers can expect their devices to stay connected and extended battery life for any demand placed on the product. When designing 5G-enabled devices, for example, an increase in the number of antennas is required to improve connectivity, but the device must remain SAR compliant.

These sensors can detect human presence and allow RF emissions to be adjusted to maintain optimum performance. Smart sensors are highly accurate and can distinguish an inanimate object from a human, ensuring the device is always operating at peak performance. For example, a pen next to your laptop keyboard will not cause a drop in RF performance. However, if you were to move the laptop from your desk to the couch and work on your lap, you can rest assured that your laptop detects your proximity to the device and self-regulates for compliance.

How many CE devices have you counted in your home? Six, or maybe seven? It’s important that each of your devices provides the functionality and performance you need at all times. Smart sensors can ensure every device in your home is connected, compliant, and performing. Smart sensors can give you that.

David Wong is the Senior Director of Consumer Sensing Products for Semtech’s Wireless and Sensing Products Group. He is responsible for the recently launched PerSe smart sensor platform for improved connectivity and SAR compliance in mobile devices (5G/Wi-Fi) and intuitive control in wearable applications.

Scene from the book: Ready for a deep dive into your immune system? | Explore Yakima

0

There is an immunology joke that appeared in an article I read a few years ago. The article’s author, Ed Yong, attributed it to Jessica Metcalf, a professor and researcher at Princeton. To (very) roughly paraphrase the original joke:

“A cardiologist and an immunologist are kidnapped. Their captors promise to spare the doctor who will prove he has made a greater contribution to society. The cardiologist tells them about his work in creating a life-saving heart drug that has been used by millions of people. The kidnappers, impressed, turn to the immunologist. It begins with “Well, let me start by saying that immunology is a very complex field”, to which the cardiologist adds: “Kill me now!”

The point of the joke being, of course, that our immune system is an incredibly complex conglomeration of intertwined systems, each performing a specific task to protect your body from foreign invaders, and it’s very difficult and often boring to explain how it works on a technical level.

For most of us, our immune system does an admirable job and we don’t need to know or even think about the details of how it protects us until we get sick. But sometimes our immune system is compromised for various reasons. An underlying medical condition or new medication may temporarily or permanently suppress one’s ability to work. Other times, our immune system becomes overzealous in identifying harmless objects such as peanuts or pollen as existential threats. This zeal manifests itself in allergic reactions that can be bothersome and uncomfortable on different levels or, in the worst case, life-threatening.

Given that a person can spend their life trying to understand the immune system and not know everything – new research is being done all the time – how can a layman hope to understand what is going on inside their own body?

“Immune: A Journey Through the Mysterious System That Keeps You Alive” by Philipp Dettmer is not a perfect book, but it is an excellent introduction to gaining a basic understanding of a very complex subject. Dettmer is the creator of Kurzgesagt, a popular science education YouTube channel he has run since 2013.

If you are a true immunologist, you will find that “Immune” is not for you. Dettmer admits it, but for everyone else, it’s a simple and entertaining introduction to the war that rages inside you every day. The language is kept as simple as possible, and color illustrations help to visualize the microscopic processes of the immune system.

Dettmer also includes an extensive bibliography for those who are skeptical of the book’s claims or want to learn more or see the source material for themselves. For better or worse, the bibliography isn’t actually included in the book, but is instead hosted on Dettmer’s website.

We’ve had to think about our immune systems a lot more than normal over the past few years. If you want to learn more, “Immune” is an appropriate introduction for adults and older teens to this vast and complex system, and it might make you want to seek out other sources of information.

• “Immune: A Journey into the Mysterious System That Keeps Alive” by Philipp Dettmer was published by Random House in November 2021. It retails for $35.

• JT Ménard works for the Inklings bookstore. He and other Inklings staff review books in the Sunday Explore section each week.

New technique that helps in the early diagnosis of Parkinson’s disease: study | Health

0

Professor Aviv Mezer’s team at the Hebrew University of Jerusalem (HU) have recognized that by modifying a related procedure known as quantitative MRI (qMRI), cellular alterations in Parkinson’s disease can be uncovered.



Their method allowed them to examine microstructures in the part of the deep brain known as the striatum – an organ known to deteriorate during the progression of Parkinson’s disease. Using a new analysis method, developed by Mezer’s doctoral student, Elior Drori, biological changes in the vena cava tissue of the striatum were clearly revealed.

ALSO READ: Covid infection may increase risk of Parkinson’s disease, mouse study finds

Additionally, they were able to demonstrate that these changes were associated with the early stages of Parkinson’s disease and movement dysfunction in patients. Their findings have been published in the prestigious journal Science Advances.

qMRI achieves its sensitivity by taking multiple MRI images using different excitation energies – much like taking the same photograph in different lighting colors. The HU researchers were able to use their qMRI analysis to reveal changes in tissue structure in distinct regions of the striatum.



The structural sensitivity of these measurements could previously only have been achieved in laboratories examining the brain cells of post-mortem patients. Not an ideal situation for detecting a disease early or monitoring the effectiveness of a drug!

“When you don’t have measurements, you don’t know what’s normal and what’s abnormal brain structure, and what changes as the disease progresses,” Mezer explained. The new information will facilitate early diagnosis of the disease and provide “markers” to monitor the effectiveness of future drug therapies.

“What we discovered,” he continued, “is just the tip of the iceberg.” It’s a technique they will now expand to study microstructural changes in other regions of the brain. Additionally, the team is currently developing qMRI into a tool that can be used in the clinical setting. Mezer predicts it’s about 3-5 years later.



Drori further suggests that this type of analysis will allow the identification of subgroups within the population with Parkinson’s disease – some of whom may respond differently to certain medications than others. Ultimately, he sees this analysis “leading to personalized treatment, enabling future drug discovery with each person receiving the most appropriate drug.”

This story was published from a news feed with no text edits. Only the title has been changed.

The LED lights of an Australian medical marijuana farm turn pink in the night sky

0

Comment

A mysterious pink glow lit up the skies over the Australian town of Mildura on Wednesday evening, leaving residents to wonder if they were witnessing an alien invasion, stray aurora borealis or some kind of solar flare .

Local resident Tammy Szumowski and her family thought the world was coming to an end. “I was just like ‘what the hell is this? It’s very weird, this huge pink light in the sky,” she said. “I’m trying not to freak out because I have my girls in the car.”

Others were looking for an explanation.

“I was driving home and it was dark, and I noticed a very unusual and quite large pink glow,” said Anne Webster, a lawmaker who represents the region in the Australian Parliament. “I thought that was very strange. My first thought was that there must be a logical reason for this.

In fact, the glow emanated from a medical cannabis facility on the outskirts of Mildura which inadvertently revealed its previously undisclosed location while testing LED lights, which reflected off the cloudy night sky to create an eerie, otherworldly scene. that scared and thrilled the city of 56,000.

As the facility’s security guard investigated the source of the bright pink light, he realized it was attracting attention around Mildura, about 340 miles northwest of Melbourne.

“He went out in the evening and noticed a glow and he noticed a few vehicles stopping to see where it was coming from,” Peter Crock, managing director of Cann Group, the cannabis research and production company behind the ‘facility, Told the Australian Broadcasting Corp.

The company normally uses blackout curtains to hide the red spectrum LED lights used to promote plant growth. But on Wednesday the curtains were left open for some time, sending a bat signal visible for miles around the facility, located in the southeastern state of Victoria.

In 2016, Australia legalized the cultivation, research and manufacture of medical marijuana. Today, some 70,000 Australians turn to medical marijuana for relief, generating an estimated revenue of $160 million in 2021, according to Fresh Leaf Analytics, a cannabis market research company. Australians use medical marijuana primarily for pain, anxiety and sleep issues, 2022 study finds study published in the journal Frontiers of Pharmacology.

Prescriptions have increased over the past two years, which the study attributed in part to the “mental health burden” of Australia’s coronavirus lockdown restrictions. The country imposed one of the strictest lockdowns in the world before vaccinating 95% of its adult population.

Scientists are trying to save an Australian ‘tiger’ from extinction

Cann Group was the first company licensed by Australia to conduct cannabis research. He received a $1.4 million grant from the Victorian state government, part of which was used to develop a commercial medical cannabis facility at an undisclosed location until enlightenment incident this week. The Mildura plant, which was built on the site of a former juice factory, harvested its first batch earlier this month.

Mildura is known as a major producer of grapes, supplying wineries in the region. But his adventure in cannabis production is new.

“It provides jobs, and that’s just the tip of the iceberg because it has quite a future for growth,” said Webster, the lawmaker, who toured Cann’s facilities.

“We’ve resumed normal transmission, but it’s definitely got everyone’s attention in the meantime,” Crock, Cann’s chief executive, said of Wednesday’s incident. “All publicity is good publicity.”

Benefits, Sources, Dosage and More

0

When it comes to food sources of lutein and zeaxanthin, you have many options to choose from.

The richest sources are leafy greens — think kale, spinach and collard greens, Grossman says. (Green smoothie, anyone?) Other great food sources include green peas, avocados, and orange peppers.

Lutein and zeaxanthin are also found in some animal products, like egg yolks (in case you need another reason to make a hearty frittata or quiche). Even wheat contains lutein and zeaxanthin, providing another benefit of eating whole-wheat products (given you’re not on a gluten-free diet, of course).

Lutein and zeaxanthin are more bioavailable in animal foods due to the presence of fat because, again, carotenoids are fat soluble, which means they are best absorbed when combined with a fat source.

Now, although it may be difficult, it is possible to get adequate levels of lutein and zeaxanthin through diet. According to Rapoport, the key is to eat plenty of vegetables, especially leafy greens. To increase the bioavailability of lutein and zeaxanthin, try steaming your spinach, kale, or collard greens (rather than eating them raw).

It is worth mentioning that these foods are under-consumed by most people in the United States, as noted in a report by the 2020-2025 Dietary Guidelines for Americans, so it’s essential to eat nutrient-dense meals as much as possible. And when in doubt, a high-quality supplement is a simple and effective way to meet your lutein and zeaxanthin needs.

Boost your immunity with amla this monsoon; know many ways to consume it | Health

0

Amla or Indian gooseberry, considered a powerful and rejuvenating fruit in Ayurveda, is one of the most effective immunity boosters in all seasons. The sweet and sour fruit has high levels of antioxidants, vitamins, flavonoids, fiber, amla is also known for its anti-inflammatory and anti-cancer properties. No wonder, it’s an ancient Ayurvedic remedy used to treat colds, fevers, digestive problems, liver disease, diabetes, and prevent many seasonal infections. According to Ayurveda, amla can cure almost all diseases and balance the tridoshas. (Also read: Monsoon Alert: Nutritionists Suggest Immunity-Boosting, Gut-Friendly Snacks)



During the monsoon, our immunity is low and the digestive system is slow and there are a number of seasonal and digestive issues that pose a health risk. Amla with its cytoprotective properties helps stimulate the production of white blood cells, thus strengthening our immune army. Its regular consumption also helps eliminate toxins from the body.

Amla also works wonders for digestive issues like constipation and acidity. The wonder fruit also helps you fight aging as it can slow cell degeneration and promotes longevity. Regular consumption of amla can also control your blood sugar and even help lower LDL cholesterol. Not to mention its benefits for skin and hair. The abundant vitamins and antioxidants it contains prevent skin infections, skin diseases and reverse the signs of aging.



There are different ways to add amla to your diet. You may have believed it if you can, but if you find it too sour for your taste, there are a variety of ways to consume this powerful fruit. Chyawanprash, amla candy, juice, murabba, pickle, you can try your hand at these countless preparations.

Talking about how amla can be consumed, dietician and nutritionist Dr. Poonam Duneja, founder of Nutrifybypoonam Diet & Wellness Clinic says, “Amla is very rich in vitamin C, even more so than orange. It is good for immunity, skin and hair health and excellent for digestive health. You can consume amla in the following way: add its juice in a salad instead of lemon, fry it with salt and red chili powder; amla pickle also tastes good and amla murabba is equally nutritious and delicious. Nowadays, amla juice is sold in sachets. Include amla in your daily diet for at least two months to see the desired benefits.



So how do you eat amla today?

Follow more stories on Facebook and Twitter

The Benefits of Magnesium for Brain Health

0

Getty Images

There are many nutrients your body needs every day to function optimally. One of them is magnesium, which has specific implications for brain health.

What is Magnesium?

“Magnesium plays a fundamental role in regulating various biological processes that are necessary for proper function,” says Candace Pumper, registered dietitian at Ohio State University Wexner Medical Center in Columbus.

This powerful mineral is used in over 300 enzyme systems in the body that contribute to:

“Magnesium is the fourth most abundant mineral, after calcium, sodium, and potassium, that the body needs on a daily basis,” says Pumper.

The Recommended Dietary Allowance, or RDA, of magnesium for adults is 400 to 420 milligrams per day for men and 310 to 320 milligrams per day for women. Pregnant women need 350 to 360 milligrams of magnesium daily.

Magnesium for brain health

Magnesium’s role in helping the body produce energy is critically important, “because more than 20% of all energy produced in the body is consumed by the brain,” says Dr. Michael del Junco, internal medicine specialist at Providence St. Joseph Hospital in Orange. County, California.

As such, magnesium plays a central role in brain health. “Appropriate levels of magnesium ensure optimal nerve transmission and neuromuscular conduction, and protect against over-excitation of neurons and oxidative stress,” says del Junco. Which, in simple terms, means that if you don’t have the proper levels of magnesium, it can lead to reduced cognitive performance. “Abnormal levels of magnesium have even been linked to conditions such as migraines, depression, chronic pain, strokes, seizures and dementia.

Magnesium is also essential for the normal functioning of neurons and helps regulate neurotransmitters, which are the chemical messengers that help brain cells communicate with each other and with the rest of the body.

Two neurotransmitters in particular – glutamate and gamma-aminobutyric acid, or GABA – depend on proper levels of magnesium.

“Glutamate plays a major role in normal brain function, including shaping learning and memory,” says Pumper. “For the brain to function properly, glutamate levels must be tightly controlled. Any imbalance can disrupt nerve cell communication.

A 2018 review study published in the journal Nutrients found that there is “strong evidence to suggest a role for magnesium in migraine and depression” and there is “emerging evidence” to suggest that magnesium has an effect protective in conditions of chronic pain, anxiety and stroke. “Further research is needed on magnesium as an adjunct treatment for epilepsy and to further clarify its role in Alzheimer’s disease and Parkinson’s disease”

What is currently known, says Pumper, is that “adequate magnesium levels appear to protect against chronic disease and promote brain health, and low magnesium status is increasingly linked to disease risk.” , including neurological and psychiatric disorders and impaired disease management”.

Food sources of magnesium

  • Pumpkin seeds, shelled, roasted: 1 ounce = 156 milligrams of magnesium.
  • Chia seeds: 1 ounce = 111 milligrams.
  • Dry roasted almonds: 1 ounce = 80 milligrams.
  • Cashews, dry roasted: 1 ounce = 74 milligrams.
  • Peanuts, dry roasted: 1 ounce = 49 milligrams.
  • Peanut butter, smooth: 2 tablespoons = 49 milligrams.
  • Whole flax seeds: 1 tablespoon = 40 milligrams.

  • Spinach, cooked: ½ cup = 78 milligrams.
  • Baked potato with skin: 3.5 ounces = 43 milligrams.

  • Black beans, cooked: ½ cup = 60 milligrams.
  • Edamame, cooked: ½ cup = 50 milligrams.
  • Lima beans, cooked: ½ cup = 40 milligrams.

  • Quinoa, cooked: ½ cup = 60 milligrams.
  • Cereals, shredded wheat: 2 large crackers = 61 milligrams.
  • Rice, brown, cooked: ½ cup = 42 to 44 milligrams.
  • Wheat germ: 2 tablespoons = 35 milligrams.
  • Bread, whole wheat: 2 slices = 46 milligrams.

  • Soy milk, plain or vanilla: 8 ounces = 61 milligrams.
  • Yogurt, plain or low fat: 8 ounces = 42 milligrams.
  • Skim milk: 8 ounces = 24-27 milligrams.

  • Dark chocolate, 70-85% cocoa: 1 ounce = 64 milligrams.
  • Dark chocolate, 60-69% cocoa: 1 ounce = 50 milligrams.

The amount of magnesium found in these foods can fluctuate depending on local farming practices, how they’re fertilized, and how they’ve been processed, refined, or cooked, says Pumper.
Some foods, like some breakfast cereals, are fortified with extra magnesium.

Pumper adds that some sources of mineral water and bottled tap water may contain magnesium and may “provide portions of the RDA of this mineral. But the amount varies by source and brand with a range of 1 milligram. per liter to 120 milligrams per liter.

Should I take a magnesium supplement?

Del Junco says if your magnesium levels are normal, you should “avoid supplements.” There is no current evidence to suggest that magnesium supplementation will provide measurable benefit to a patient with normal magnesium levels.

However, some people may not be getting enough magnesium in their diet. Del Junco notes that signs of abnormal magnesium levels are often vague and nonspecific, but can include:

  • Small appetite.
  • Poor concentration.
  • Fatigue.
  • Weakness.
  • Muscle spasms.

Your doctor can test if your magnesium levels are out of whack. Certain populations may be at higher risk for magnesium deficiency, including:

  • Older adults.
  • Patients with uncontrolled diabetes.
  • Patients with chronic diarrhea or other digestive disorders that cause them difficulty in absorbing nutrients from food.
  • People who consume alcohol daily.
  • People taking certain medications, including proton pump inhibitors (such as omeprazole for gastroesophageal reflux) and loop or thiazide diuretics (such as furosemide, hydrochlorothiazide, and chlorthalidone which can be used for congestive heart failure, high blood pressure and other heart conditions).

If you are lacking in this nutrient, del Junco recommends “trying to increase your magnesium intake through your diet. If you’re unable to get enough magnesium from your diet, consider a supplement.
Pumper agrees that food first is best. “Magnesium supplementation can certainly help fill the gaps in a nutrient-deficient diet, but the challenge is discerning which products to choose. For consumers, speak with your doctor before adding a magnesium supplement to your routine. is a good first step.

If you and your healthcare provider determine that supplementation is a good idea, Pumper recommends considering the following when choosing a product:

  • The ideal form and dosage for your needs. “Magnesium supplements come in different forms, each with different absorption capacity, benefits, and effects on the body.” Common forms include magnesium citrate, magnesium oxide, magnesium glycinate, magnesium chloride, and magnesium sulfate. Del Junco says magnesium citrate is the most easily absorbed form of magnesium supplement when taken orally. So what is the best form of magnesium supplement for brain health? “Magnesium citrate is often used to treat low magnesium levels and may also be effective as an acute migraine treatment option,” says Pumper. “This form is gentle on the stomach, has good absorption capacity and is safe”,
  • Product quality. Pumper recommends selecting products bearing “quality certification seals on product labels to ensure product integrity.” Certification bodies include ConsumerLab.com, NSF International, or the US Pharmacopeial Convention.
  • Other medications you are taking. Supplements can sometimes interact negatively with other medications or supplements you are taking, so it is very important to check with your health care provider before adding any herbal product or dietary supplement. Magnesium supplements in particular sometimes interact with and decrease the absorption of certain medications, including antibiotics, diuretics, proton pump inhibitors, bisphosphonates (which are used to treat bone conditions such as osteopenia and osteoporosis) and high doses of zinc (greater than 142 milligrams per day).
  • Medical conditions you have. People with chronic kidney disease should not take magnesium supplements because they can cause large amounts of magnesium to build up in the blood and lead to muscle weakness.

Taking too much magnesium can cause side effects, including abdominal cramps and diarrhea. “If you experience these symptoms, reduce your daily dose,” del Junco says. It is also best to contact your health care provider for further advice.

Vegan turkey burgers are having a moment. Do you want yours 3D printed or from Trader Joe’s?

0

While plant-based beef is everywhere you look, the plant-based turkey category is vastly underexplored. However, new products are coming to market to provide consumers with new choices that are not dependent on the cruel turkey industry.

At grocery chain Trader Joe’s, a new vegan ground turkey product is set to hit stores this month, according to an Instagram post shared by @bigboxvegan. Internal communication with employees shows that the new Turkeyless Ground is made with textured peas and wheat protein and will be stocked in the refrigerated section of the store nationwide.

Priced at $5.49 and sold in 12-ounce packages (may vary by region), the new vegan turkey pomace is intended for use in dishes such as tacos, meatless meatloaf, peppers stuffed, etc. Trader Joe’s suggests seasoning the course with its in-store spices such as Taco Seasoning and Mushroom & Company Umami Seasoning Blend (both vegan) to bring out maximum flavor.

“Plant-based protein is about having options: the ability to make a dish that will satisfy meat eaters and non-meat eaters, the ability to occasionally participate in a Meatless Monday, the ability to enjoy a juicy burger, whatever whatever the preference for protein – we could really go on,” Trader Joe’s product describes. “So we think it’s only fitting that the plant-based protein scope itself is also full of options. In this spirit of plant pluralism, we are proud to present Trader Joe’s Turkeyless Ground, a superbly flavorful protein that evokes the flavor, texture and, at 21 grams per serving, the protein content of ground turkey at a truly delicious degree.

Trader Joe’s Vegan Turkey Burgers

The new, more versatile product will fill the void left by Trader Joe’s pulling its plant-based turkey burgers from the shelves. The grocery chain originally launched its turkey-free protein patties in mid-2020. The formed patties were sold in packs of two 4-ounce patties for $4.99 and had slightly more protein, 23 grams, per serving than the new patterns.

The vegan turkey burger patties closely followed the launch of Trader Joe’s own plant-based beef patties, simply called “Protein Patties”, which Trader Joe’s launched in January 2020. Since then, Trader Joe’s has further expanded its refrigerated section with additional vegan meats, including Impossible Foods’ plant-based ground beef.

3D printed vegan turkey burgers?

And Trader Joe’s New Vegan Grounds aren’t the only new vegan turkey product on the market. Using the power of 3D printing technology, Israeli company SavorEat offers consumers the ability to fully customize their plant-based meats. While SavorEat hit the market with plant-based beef burgers, this week it’s expanding its reach to include plant-based turkey burgers and pork-free breakfast sausages. The company’s technology is based on its Smart Robot Chef, which is powered by machine learning and artificial intelligence. The machine receives preference inputs – such as preferred protein and fat compositions and cooking preferences – from users who interface with an application, and then produces and cooks the desired plant-based meat from these inputs.

VegNews.3DPrintedBurgers.SavourEatSavorEat

This design allows restaurants to reduce waste by using only a specific amount of plant-based meat, while providing the consumer with a product that perfectly matches their nutritional and taste needs. Creating exciting new plant-based beef, turkey and pork options is also a way to reduce waste on the production side, as animal-free meats require fewer environmental inputs and emit fewer greenhouse gases. Greenhouse.

While plant-based beef, and to some extent plant-based pork, is widely available, outside of Trader Joe’s upcoming pitches and a handful of older products, plant-based turkey is a less saturated category that differentiates SavorEat from other companies in the space.

“At SavorEat, we’re passionate about offsetting carbon emissions and reducing waste, which is why we’ve created a product that can do both,” said Racheli Vizman, CEO and co-founder of SavorEat, in a statement. “By expanding into other plant-based meats, we aim to offer greater variety and personalization, to empower the planet to eat differently, with healthier and more sustainable options to reduce ecological impact.”

For the latest vegan news, read:
A startup develops a vegan oyster prototype to save the oceans
Vegan Mushroom Protein Makes Fine Dining Debut at New York’s Bernardin
Why Chipotle Invested in a $150 Million Funding Round for Vegan Steak Startup Meati

Happy Birthday VegNews! To celebrate, we’re having a mega subscription sale, with amazing vegan prizes.

CHECK IT OUT

Protective T cells remain 20 months after COVID-19, study finds – ScienceDaily

0

Patients infected with SARS-CoV-2 develop protective immune responses, mediated by virus-specific T cells and antibodies, soon after infection. However, there are concerns that immunity may not persist over time, which may result in severe COVID-19 upon reinfection.

In the July 12 issue of Proceedings of the National Academy of Sciences (PNAS), Anna Martner and co-authors from the University of Gothenburg report two main findings. First, several virus-specific T cell variants became detectable in the blood shortly after COVID-19, but disappeared strikingly after 10 to 12 weeks.

However, a group of highly specialized T cells designed to facilitate the elimination of infected cells remained active in the blood of all patients previously infected with SARS-CoV-2. These T cells did not disappear or decline even after long follow-up.

The findings may explain the reduced risk of severe disease and mortality in patients who have been reinfected with SARS-CoV-2.

Scientists from the University of Gothenburg and Sahlgrenska University Hospital took 81 blood samples from hospital staff who had contracted mild COVID-19 in the first year of the pandemic and from uninfected controls. The researchers studied the reactivity of T cells to an internal part of SARS-CoV-2 (the viral nucleocapsid), thereby capturing T cell responses that only occur after natural infection.

Blood samples were exposed to more than 100 peptides from the nucleocapsid part of the SARS-CoV-2 virus. The researchers then analyzed which T-cell mediators (cytokines) were produced by blood cells to determine the longevity of T-cell responsiveness after infection.

A subset of specialized T cells (Th1 cells) that promote the destruction of virus-infected cells have been observed to be active for at least 20 months after natural COVID-19. The infected patients also harbored several other types of T cells that reacted with SARS-CoV-2. These last T cells disappeared from the blood about 2 months after the infection was cured.

“While some T cell subsets disappear shortly after infection, highly specialized T cells (T helper cells 1) remain stably present in the blood to suggest that a vital aspect of protective immunity is functional years after COVID-19,” says Anna Martner, Associate Professor of Immunology at the Sahlgrenska Academy. These findings may explain why reinfection with SARS-CoV-2 only rarely results in severe COVID-19.

Source of the story:

Materials provided by University of Gothenburg. Note: Content may be edited for style and length.

Research: Rating Action: Moody’s Raises CEC Entertainment’s CFR to B3

0


No related data.

© 2022 Moody’s Corporation, Moody’s Investors Service, Inc., Moody’s Analytics, Inc. and/or their licensors and affiliates (collectively, “MOODY’S”). All rights reserved.

CREDIT RATINGS ISSUED BY MOODY’S CREDIT RATINGS AFFILIATES CONSTITUTE THEIR CURRENT OPINIONS ON THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, INDEBTEDNESS OR INDEBTEDNESS-RELATED SECURITIES, AND MATERIALS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY’S (COLLECTIVELY, THE “PUBLICATIONS”) MAY INCLUDE SUCH CURRENT OPINIONS. MOODY’S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY FAILURE TO MEET ITS CONTRACTUAL FINANCIAL OBLIGATIONS WHEN DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT OR IMPAIRMENT. SEE THE APPLICABLE PUBLICATION OF MOODY’S RATINGS SYMBOLS AND DEFINITIONS FOR MORE INFORMATION ON THE TYPES OF CONTRACTUAL FINANCIAL OBLIGATIONS COVERED BY MOODY’S CREDIT RATINGS. THE CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK OR PRICE VOLATILITY. CREDIT RATINGS, NON-CREDIT ASSESSMENTS (“RATINGS”) AND OTHER OPINIONS INCLUDED IN MOODY’S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACTS. MOODY’S PUBLICATIONS MAY ALSO INCLUDE MODEL-BASED QUANTITATIVE ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY’S ANALYTICS, INC. AND/OR ITS AFFILIATES. MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE AND DO NOT PROVIDE ANY RECOMMENDATION TO BUY, SELL OR HOLD PARTICULAR SECURITIES. MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS DO NOT COMMENT ON THE SUITABILITY OF ANY INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY’S ISSUES ITS CREDIT RATINGS, ASSESSMENTS AND OTHER OPINIONS AND PUBLISHES ITS PUBLICATIONS WITH THE CARE AND UNDERSTANDING THAT EACH INVESTOR WILL CAREFULLY MAKE HIS OWN RESEARCH AND EVALUATION OF EACH SECURITY THAT IS CONSIDERED FOR PURCHASE, HOLDING OR SALE.

MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE UNINTENDED AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE ANY CREDIT RATINGS, RATINGS, OTHER OPINIONS OR PUBLICATIONS OF MOODY’S WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT, YOU SHOULD CONTACT YOUR FINANCIAL ADVISOR OR OTHER PROFESSIONAL.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY NOT BE COPIED OR OTHERWISE REPRODUCED, RECONDITIONED, TRANSMITTED, TRANSFERRED, DISTRIBUTED , REDISTRIBUTED OR RESOLD, OR STORED FOR FUTURE USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER, OR BY ANY MEANS, BY ANY PERSON WITHOUT THE PRIOR WRITTEN CONSENT OF MOODY’S .

MOODY’S CREDIT RATINGS, RATINGS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY ANYONE AS A REFERENCE AS THIS TERM IS DEFINED FOR REGULATORY PURPOSES AND SHOULD NOT BE USED IN A MANNER THAT COULD CONSIDER AS A REFERENCE.

All information contained herein is obtained by MOODY’S from sources believed to be accurate and reliable. However, due to the possibility of human or mechanical error and other factors, all information contained herein is provided “AS IS” without warranty of any kind. MOODY’S takes all necessary measures to ensure that the information it uses to assign a credit rating is of sufficient quality and comes from sources that MOODY’S considers to be reliable including, where applicable, independent third-party sources. However, MOODY’S is not an auditor and cannot in any case independently verify or validate the information received as part of the rating process or the preparation of its Publications.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim all liability to any person or entity for any indirect, special, consequential or incidental loss or damage whatsoever , arising out of or relating to the information contained herein or the use or inability to use such information, even if MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is informed in advance of the possibility of such loss or damage, including but not limited to: (a) any loss of actual or potential profits or (b) any loss or damage occurring when the financial instrument concerned does not not subject to a particular credit rating assigned by MOODY’S.

To the extent permitted by law, MOODY’S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim all liability for any direct or compensatory loss or damage to any person or entity, including but not limited to limit, any negligence (but excluding fraud, willful misconduct or any other type of liability which, for the avoidance of doubt, cannot be excluded by law) on the part of, or any contingency within the control or beyond the control of MOODY’S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising out of or in connection with the information contained herein or the use or inability to use this information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY CREDIT RATING, RATINGS, OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY’S IN ANY FORM OR MANNER.

Moody’s Investors Service, Inc., a credit rating agency wholly owned by Moody’s Corporation (“MCO”), hereby declares that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred shares rated by Moody’s Investors Service, Inc. have, prior to the assignment of any credit rating, agreed to pay Moody’s Investors Service, Inc. for rating opinions credit and the services it renders fees ranging from $1,000 to approximately $5,000,000. MCO and Moody’s Investors Service also maintain policies and procedures to ensure the independence of credit ratings and Moody’s Investors Service credit rating processes. Information regarding certain affiliations that may exist between MCO directors and rated entities, and between entities that hold Moody’s Investors Service credit ratings and that have also publicly disclosed to the SEC an ownership interest in MCO of more than 5% , are published annually on www .moodys.com under the heading “Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy”.

Additional Terms for Australia Only: Any publication in Australia of this document is in accordance with the Australian Financial Services License of MOODY’S subsidiary, Moody’s Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody’s Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (if applicable). This document is intended for supply only to “wholesale customers” within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from Australia, you represent to MOODY’S that you are, or are accessing to the document as a representative of a “wholesale customer” and that neither you nor the entity you represent will directly or indirectly distribute this document or its contents to “retail customers” within the meaning of section 761G of the Corporations Act 2001. MOODY’S credit rating is an opinion of the creditworthiness of a debt security of the issuer, and not of the equity securities of the issuer or any form of security available to investors in detail.

Additional Terms for Japan Only: Moody’s Japan KK (“MJKK”) is a wholly owned subsidiary credit rating agency of Moody’s Group Japan GK, which is wholly owned by Moody’s Overseas Holdings Inc., a wholly owned subsidiary of MCO. Moody’s SF Japan KK (“MSFJ”) is a wholly owned subsidiary credit rating agency of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization (“NRSRO”). Accordingly, the credit ratings assigned by MSFJ are non-NRSRO credit ratings. Non-NRSRO credit ratings are assigned by an entity that is not an NRSRO and therefore the rated obligation will not qualify for certain types of treatment under US law. MJKK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stocks rated by MJKK or MSFJ (as applicable) have, prior to the assignment of any credit rating, agreed to pay MJKK or MSFJ (as applicable) for credit rating opinions and the services it renders a fee ranging from 100 000 JPY to around 550,000,000 JPY.

MJKK and MSFJ also maintain policies and procedures to meet Japanese regulatory requirements.

As Rajapaksa Loses Immunity, Canadians Call for Sanctions and Prosecutions

0

Yesterday, Canadian lawmaker Gary Anandasangaree called on his government to impose sanctions on former Sri Lankan President Gotabaya Rajapaksa and his brother Mahinda Rajapaksa, days after they lost their immunity from prosecution.

Gotabaya Rajapaksa fled Sri Lanka last week and is currently in Singapore, where he resigned as president. By stepping down, he lost all official immunity, part of the reason commentators say he fled as he feared prosecution.

To press conference in Ottawa on Wednesday, Anandasangaree said “Now more than ever, it is imperative to ensure that leaders who commit atrocities are held accountable.”

“The successive failures of the international community to consistently enforce and respect the rules-based international order have resulted in international impunity and allowed people like the Rajapaksa brothers to move freely,” he said. for follow-up.

“I therefore call on our government to impose sanctions on both Gotabaya Rajapaksa and Mahinda Rajapaksa for their role in the atrocities committed in 2008 and 2009.”

Photograph: A scene of devastation in Mullivaikkal pictured days after the Sri Lankan army invaded the area in May 2009.

The brothers led a military offensive that killed tens of thousands of Tamils at the time, and is increasingly recognized as genocide, including by the Parliament of Canada.

Anandasangaree also revealed that he had written to Singapore’s foreign minister expressing his disappointment at allowing Gotabaya Rajapaksa to enter the country and calling on local authorities to prosecute him under the principles of universal jurisdiction.

“I reiterate the many calls from the Office of the United Nations High Commissioner for Human Rights for Member States to exercise their universal jurisdiction and prosecute those who have committed atrocities in Sri Lanka in their local jurisdiction,” Anandasangaree added. .

His appeal to Singapore comes as local Tamils ​​have also expressed their opposition to the presence of Rajapaksa in the country.

“Under the orders of Gotabaya Rajapaksa and these other military and political leaders, hospitals were repeatedly and intentionally bombed by the Sri Lankan Armed Forces, artillery was used indiscriminately and disproportionately against civilians in the so-called fire-free zones and LTTE fighters. as well as Tamil civilians and children were ordered to be executed in violation of the laws of war,” said Archana Ravichandradeva, Executive Director of People for Equality and Relief in Lanka (PEARL).

Ravichandradeva continued that the appointment of Ranil Wickremesinghe as the last president of Sri Lanka “will continue to lack national accountability for Rajapaksa’s genocidal campaign.”

Responding to a question from the Tamil Guardian, Anandasangaree said that “it is no secret that the Rajapaksa family assisted in the rise to power of Ranil Wickremesinghe”.

“For this reason, it is vital that the international community, including Canada, ensure accountability and justice for Tamils,” Ravichandradeva added.

“Now that he is no longer protected by immunity, he and other alleged perpetrators of mass atrocities in Sri Lanka must face justice and be held accountable. Sanctions are an important tool in the accountability toolbox and we call on the Canadian government to sanction former President Gotabaya Rajapaksa, former President Mahinda Rajapaksa and other key military and political leaders.

“Wherever these perpetrators of the world’s worst crimes end up, countries should exercise universal jurisdiction to hold them to account in their national courts. We also urge Canada to pursue action against Sri Lanka before the International Court of Justice and to call on the International Criminal Court to explore opportunities to investigate and prosecute the mass atrocities committed by Sri Lanka against Tamils.

Venoth Navajeevanantha, President of the Tamil Community Center of Quebec, reiterated her remarks, saying that it was “important that Canada continue to be a safe haven for refugees and provide them with opportunities for healing and prosperity, and send a strong message to the war criminals of Rajapaksa that they will be held accountable.

“It is clear that the current crisis has deep systemic roots and it will be vital for key stakeholders to address the underlying root causes by pushing for reforms and strengthening the rule of law,” said Farida Deif, Canadian Director of Human Rights Watch.

“Ottawa should also urge Sri Lankan authorities to investigate and prosecute official corruption and freeze all assets in Canada if they are suspected of having been obtained from corruption,” Deif continued.

“The Canadian government should make sure the warning signs are heard by taking concrete action now.

See the full press conference below. See our live Twitter coverage here.

Researchers achieve efficient near-infrared luminescence in lanthanide-doped all-inorganic halide double perovskites

0

Fully inorganic lead-free double perovskites (DP) halides have emerged as an important class of environmentally benign phosphors for optoelectronic applications. Studies on them have mostly been limited to the visible spectral region.

Lanthanide (Ln3+) doping is proposed as a valid approach to extend the spectral range of DPs towards the near infrared (NIR) region. Unfortunately, these Ln3+-doped DPs still suffer from low Ln low NIR emission3+ due to the low absorption cross section of Ln3+.

In a study published in Angewandte Chemie International Edition, the research group led by Prof. CHEN Xueyuan of the Fujian Research Institute of Structure of Matter, Chinese Academy of Sciences developed a new class of DPs emitting Ln-based NIR3+-doped Cs2(Na/Ag)BiCl6. Enjoying the Na+– induced rupture of the local symmetry of the site in the Cs2AgBiCl6 DPs, effective NIR emissions from Ln3+(for example Yb3+ and Er3+) are made by Bi3+ sensitization.

The researchers first systematically studied the optical properties of Ln3+-doped Cs2(Na/Ag)BiCl6 phosphors to determine the optimal Na+ content, and then extensively studied the dynamics of the excited state and the process of energy transfer in the optimal Ln3+-doped Cs2AG0.2N / A0.8BiCl6 phosphors using temperature-dependent steady-state and transient photoluminescent spectroscopy.

Raman spectroscopy analysis and first principles Density Functional Theory (DFT) calculations confirmed that the Na/Ag alloy caused the Bi-Cl bond length to change, resulting in the local symmetry breaking of Bi3+ in [BiCl6]3- octahedron.

Compared to that of Cs without Na2AgBiCl6 counterparts, the NIR emission of Yb3+ and Er3+ can be increased by 7.3 times and 362.9 times in Cs2AG0.2N / A0.8BiCl6 DPs, with peak photoluminescence quantum yields (PLQY) of 19.0% and 4.3%, respectively.

Furthermore, the researchers used these Ln3+Cs emitting doped NIRs2AG0.2N / A0.8BiCl6 DP for UV-converted NIR light-emitting diodes (LEDs) at 365 nm, which indicated their potential applications as high-performance optoelectronic devices.

These findings provide new insights into the design of efficient NIR luminescent Ln3+ doped materials based on double perovskite inorganic halides, which could accelerate the development of new NIR optoelectronic devices.

/Public release. This material from the original organization/authors may be ad hoc in nature, edited for clarity, style and length. The views and opinions expressed are those of the author or authors. See in full here.

A new quantitative approach gives scientists and engineers more control over the DNA editing process

0

A team from the University of Minnesota Twin Cities has, for the first time, developed a new tool to predict and tailor the rate of a specific type of DNA editing called “site-specific recombination”. The research is paving the way for more personalized and effective gene and cell therapies for diseases such as diabetes and cancer.

The study is published in Communication Nature.

The process of site-specific recombination involves the use of enzymes that recognize and modify specific DNA sequences in living cells. It has important applications for the treatment of a myriad of diseases using cell therapies.

Immunotherapy, for example, involves extracting immune cells from a patient and genetically modifying them to fight a disease such as cancer. In these applications, it is important to precisely control the timing of gene expression to maximize treatment effects while minimizing adverse effects in the body.

Engineers at the University of Minnesota have developed a method that combines high-throughput experiments with a machine learning model to make the site-specific recombination process more efficient and predictable. The model allows researchers to program the rate at which DNA is edited. This means that they can control the rate at which a therapeutic cell reacts to its environment, thereby controlling how quickly or slowly it produces a therapeutic drug or protein.

“To our knowledge, this is the first example of using a model to predict how altering a DNA sequence can control the rate of site-specific recombination,” said Casim Sarkar, lead author of article and associate professor at the University of Minnesota. Twin Cities Department of Biomedical Engineering. “By applying engineering principles to this problem, we can dial in the rate at which DNA editing occurs and use this form of control to tailor therapeutic cellular responses. Our study also identified novel DNA sequences. DNA that are much more efficiently recombined than those found in nature, which can speed up cellular response times.”

Sarkar and his team first developed an experimental method to calculate the site-specific recombination rate and then used this information to train a machine learning algorithm. Ultimately, this allows researchers to simply enter a DNA sequence, and the model predicts how quickly that DNA sequence will recombine.

They also discovered that they could use modeling to predict and control the simultaneous production of multiple proteins in a cell. This could be used to program stem cells to produce new tissues or organs for regenerative medicine applications or to endow therapeutic cells with the ability to produce multiple drugs in predefined proportions.

“Different patients may require different doses or a faster or slower cellular response – not everyone is the same,” Sarkar explained. “By building genetic circuits inside cells that use multiple DNA sequences with different and defined recombination rates, we can now do things that were hard to do before, like protein production schedule ratios in therapeutic cells. Our rational approach enables personalized treatment for the patient.”

This research was funded by the National Institutes of Health.

In addition to Sarkar, the research team included researchers from the University of Minnesota’s Department of Chemical Engineering and Materials Science, Qiuge Zhang, a recent doctoral student, and Samira Azarin, an associate professor.

Source of the story:

Material provided by University of Minnesota. Note: Content may be edited for style and length.

CULT Food Science Corp Says Recipient Company Pearlita Foods Successfully Develops Cultured Oyster Prototype

0

CULT Food Science Corp (CSE: CULT, OTCQB: CULTF) announced that Pearlita Foods, a company it has invested in, has successfully manufactured the world’s first prototype oyster alternative.

The prototype was farmed to look and taste like a traditional ocean oyster while being produced sustainably.
and ethical, and CULT said it believes the alternative oyster could be key to solving part of the growing global food security crisis.

“We are impressed and proud of Pearlita’s successful production of its first cultured oyster prototype. Pearlita’s commitment to making the world a better place and doing its part to increase global food security is encouraging as we share the same goals,” said Lejjy Gafour. , chief executive of CULT in a statement.

“Pearlita is taking big steps to advance the production of large-scale cultured seafood. We are energized by the positive contributions their team is making to the cellular agriculture industry,” he added.

READ: CULT Food Science says holding company Opalia hits several cultured dairy milestones

Traditional oysters are known to cause foodborne illnesses and have almost completely disappeared due to overfishing. Pearlita’s alternative oyster consists of a proprietary mushroom and seaweed base and the company’s new flavor concoction gives the cultured oyster a pure, delicate and authentic ocean taste and texture, CULT noted.

He said Pearlita also plans to create biodegradable oyster shells that would make shucking its cultured oysters easier for consumers.

Global warming and heatwaves are currently creating a number of challenges for the food industry, and Pearlita’s innovation is key as farmed seafood could serve as a key solution to help reduce food shortages and prices. foodstuffs, CULT added.

In the future, Pearlita also plans to develop squid and scallop prototypes and will work to increase production.

CULT said that by strategically investing in Pearlita, it has increased its involvement in the future of cell-based seafood, which is aligned
with its goals to help commercialize cellular agriculture in the global food supply chain.

CULT Food Science is an innovative investment platform focused exclusively on cellular agriculture that advances the development of new technologies to provide a sustainable, environmental and ethical solution to the global factory farming crisis.

Contact the author at [email protected]

D Cube Analytics has been acquired by Trinity Life Sciences

0

William Blair acted as exclusive financial advisor to D Cube Analytics, a company owned by its founder, in connection with its acquisition by Trinity Life Sciences (Trinity), a portfolio company of Kohlberg & Company (Kohlberg). The transaction closed on July 19, 2022.

About companies

D Cube Analytics supports business leaders, digital transformation leaders, brand managers and other functional leaders on their journey from data to business insights. The company leverages cutting-edge technology, AI/ML and deep industry expertise to deliver the analytics, insights and results needed to develop a deep understanding of patients, physicians and payers and build a superior commercial and clinical value proposition in the marketplace. Their products, applications and services generate unparalleled business opportunities for life sciences companies. D Cube Analytics platforms include DDS Terra™, DDS IRIS™, DDS Unity™, DDS Cosmos™ and the new DDS Commercial Insights Cloud™.

Trinity is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, the company is committed to revolutionizing the business model by providing exceptional levels of service, powerful tools and data-driven insights. Trinity’s portfolio of products and solutions includes industry-leading benchmarking solutions powered by TGaS advisors.

Kohlberg is a leading private equity firm based in Mount Kisco, New York. Since its inception in 1987, the firm has organized nine private equity funds, through which it has raised $12 billion in committed equity. In its 34-year history, Kohlberg has made 88 platform investments and more than 200 follow-on acquisitions, with a total transaction value of nearly $30 billion.

Learn more about our expertise in health informatics.

Latest COVID Conspiracy Claims Multiple Booster Shots Destroy Your Immune System

0

Like a sinister game of Whac-A-Mole, every time one COVID-19 conspiracy theory is debunked, another emerges anew. The latest conspiracy theory making the rounds in anti-vaccine social media circles is the idea that multiple COVID-19 boosters somehow destroy the immune system.

The claim resurfaced last week, likely due to recent news about targeted omicron booster shots possibly coming this fall. As Salon previously reported, the U.S. Food and Drug Administration (FDA) advised manufacturers to reformulate booster shots to specifically protect against the BA.4 and BA.5 omicron variants earlier this month- this. A video doing the rounds, a news anchor said European Union regulators are warning that frequent booster shots of COVID-19 could have a negative effect on the immune system.

So, is there any truth here – or is this just another episode of anti-vaccine misinformation?

While the context in which the video was shared appears as recent news, the allegation dates back to January 2022, when experts from the European Medicines Agency (EMA) argued at a press conference that COVID-19 booster shots should not be administered too close together. The video is an excerpt from when Bloomberg Quicktake Now reported on the conference.


Want more health and science stories in your inbox? Subscribe to Salon The Vulgar Scientist’s weekly newsletter.


“We’re more concerned about a strategy that tangles short-term repeat vaccination; we can’t really continuously give a booster dose every 3 or 4 months,” said Marco Cavaleri, biothreat strategy lead for health and vaccines during the EMA press briefing. in January 2022. “If we have a strategy where we give boosters, say every 4 months or so, we will end up potentially having a problem with the immune response, and the immune response may end up not being as good as we we’d do it like it was.”

As Cavaleri noted during the press conference, there were hypothetical concerns about multiple recalls for several reasons. One concern was that booster makers are likely to play a constant game of catching up with the next variant, which might not make them as effective as they could be. Then there is the risk that the general public will tire of the need for reshoots.

“There is a risk of tiring the population with the continuation of the administration of reminders,” Cavaleri said.

RELATED: More Vaccines in Trial Don’t Cause Autism

Notably, Cavaleri has never advocated giving boosters, nor questioned the safety and effectiveness of COVID-19 vaccines. He rather supported the idea of ​​issuing boosters, but in a more spread out period.

“It would be much better to start thinking about administering more spaced out reminders,” Cavaleri said. “Ideally, if you want to move into an endemicity scenario, then these boosters should be timed with the onset of the cold season in each of the hemispheres, similar to how we do with the flu vaccine.”

“There is no evidence that repeated boosters weaken the immune system,” Dr. Monica Gandhi told Salon. “In fact, this important paper shows that any exposure or recall actually expands and diversifies the T-cell memory repertoire (e.g. expands your immune response).”

Yet Cavaleri’s January remarks have been repeatedly decontextualized to fit an anti-vaccine agenda and scare the public into not getting reminders. Currently, about half of vaccinated Americans have received a single booster. Only a quarter of eligible boosted people over the age of 50 received a second one. This new misinformation, that boosters will “destroy” or “ruin” a person’s immune system, has been perpetuated by anti-vaccine talking heads like Robert Malone and Alex Jones.

Still, experts say the idea that “too many” boosters will ruin people’s immune systems isn’t true. In fact, boosters do the exact opposite.

“There is no evidence that repeated boosters weaken the immune system,” Dr. Monica Gandhi, an infectious disease physician and professor of medicine at the University of California, San Francisco, told Salon via email. “In fact, this important paper shows that any exposure (breakthrough infection) or recall actually expands and diversifies the T-cell memory repertoire (e.g. expands your immune response).”

Gandhi pointed to a second paper published in Nature that suggests exposure to the virus or a booster shot can help a person’s immune system be better prepared to respond to new subvariants.

“Repeated boosters seem to provide enhanced protection, and they actually seem to broaden the immune response,” William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center, told Salon. “And that broadening is important, because you get better coverage against variants.”

Schaffner added that a booster, in general, “does what the name suggests”. In other words, it strengthens the immune system – it does not weaken it.

“It reminds the immune system to become active again, and the immune system creates the protection – the antibodies – and does so in an enhanced way,” Schaffner said. “It does it better than before – that’s what the booster is designed for – so you get more antibodies and you get a broader representation of antibodies.”

In the case of COVID-19 vaccines, recalls were necessary for two reasons, Schaffner said. The first being that the virus has mutated, which may reduce the effectiveness of the initial vaccine. The second reason is that immunity decreases after several months, according to several studies.

“It’s a virus that’s very different from, for example, the measles virus. The measles virus is very stable, it doesn’t mutate, and once you’re safely vaccinated against measles, you’re protected for life,” Schaffner said. . “The whole group of coronaviruses is a different family, and their immune response is not as long-lasting as against measles.”

Finally, Schaffner added that COVID-19 vaccines presented as a two-dose series, plus a booster, were a “misnomer.”

“We first said, ‘oh, the COVID vaccines are a two-dose vaccine,’ and then we’ll get a booster,” Schaffner said. “The vaccines were really a three-dose vaccine, so don’t dwell on the name.”

Read the latest news on COVID-19:

Meelis Münt: Halfway to the decision on the nuclear power plant | Opinion

0

An Estonian company that wants to build a nuclear power plant in Estonia (Fermi Energia – ed.) said last week that the plant could be operational as early as ten years. As the company spokesperson mentioned, this would require a decision to go ahead with the project after the nuclear energy task force delivers its report.

One factor that encourages states and companies to invest in nuclear energy is the decision of the European Parliament on July 6 which classifies investments in nuclear energy as green.

Crucial decision deserving of in-depth analysis

We welcome the company’s initiative and I am happy to say that nuclear know-how is being created in Estonia. But the decision – whether or not to go down the nuclear energy path as a matter of strategic importance – requires careful analysis, reflection and public debate. To this end, Estonia has established a working group on nuclear energy where this work is currently underway.

The energy crisis is serious and important decisions cannot be postponed. That is why the nuclear energy group is working with an optimal schedule and should present its final report to the government and the Riigikogu six months before the scheduled end of 2023.

The adoption of nuclear energy requires a long-standing commitment and the analysis that precedes the decision must be thorough. We need to look at all aspects of the nuclear switchover. How to develop public sector capacities in the field of nuclear energy? Is society ready to accept a nuclear power plant in Estonia? Are there regions whose inhabitants would agree to a nuclear power plant? The working group must answer these questions to the best of its ability.

Potential locations of nuclear power plant and nuclear fuel final disposal sites, nuclear security and emergency preparedness situations are being analyzed. The definition of the legal framework necessary for the launch of the nuclear program, the updating of the nuclear bill and the development of a human resources strategy are then on the agenda. The possibilities for processing nuclear waste and the modalities for shutting down the plant in the future must also be analysed.

The Finns have made the most progress here and plan to launch the Onkalo permanent repository for nuclear waste at a depth of half a kilometer in 2025. Technologies for recycling spent nuclear fuel are also being developed and most of it can be recycled and reused today. Several countries are developing reactors that can use used nuclear fuel which helps reduce the need to mine uranium.

As for nuclear technology that might be suitable for Estonia, we are talking about small modular reactors about the size of the Auvere power plant with a single reactor power not exceeding 300 MW. A single nuclear power plant can have multiple reactors, which any potential location should facilitate. The choice of nuclear technology depends on the solutions available and feasible at the time of planning.

The working group must also determine which international agreements Estonia would have to adhere to and what kind of additional obligations becoming a nuclear state would entail. We need to know everything so that Estonia can make a carefully considered decision on whether to launch a nuclear program.

Last call to the Riigikogu

The task force will soon provide the government with an interim report of its efforts. This will take place in September, after which further decisions will be made. Only after the task force’s final report has been reviewed by the International Atomic Energy Agency (IAEA) and approved by the government will we be able to say whether the adoption of nuclear energy could be a solution to help Estonia achieve 2050 climate goals and ensure energy security.

The final decision whether or not to build a nuclear power plant in Estonia will be taken by the members of the Riigikogu. As the implementation of a nuclear program is a long process, it must transcend the different governments.

Follow ERR News on Facebook and Twitter and never miss an update!

Penn Medicine Awards and Honors: June 2022

0

Penn Medicine Awards and Honors: June 2022

Hematology-Oncology Program Investigator Joshua D. Brandstadter received the Doris Duke Physician-Scientist Fellowship Award. The $220,000 award is given to physician scientists at the subspecialty fellowship level who seek to conduct additional years of research with the goal of assisting in the transition to a research faculty position.

This award will support Dr. Brandstadter’s work on Castleman’s disease, a rare inflammatory disease that causes large lymph nodes and life-threatening inflammation throughout the body.

Timothy Brown, innovation researcher at the Penn Center for Cancer Care Innovation (PC3I) and principal investigator in hematology-oncology, has been named the recipient of the Conquer Cancer 2022 ASCO Annual Meeting Merit Award, given to trainees who are first authors of selected abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Caption: Jennifer EadsJennifer R. Eads, Associate Professor of Clinical Medicine and GI Clinical Research Physician, received the Young Investigator of the Year Award from the ECOG-ACRIN Cancer Research Group.

This award, funded by the ECOG Research and Education Foundation, recognizes extraordinary scientific achievements and contributions to the direction of research made by researchers during the early years of their careers (under 46). ).

Dr. Eads is also Director of the Neuroendocrine Tumor Program.

legend: Alexander HuangAlexander C. Huang, Assistant Professor of Hematology-Oncology, received the 2022 Melanoma Research Foundation Breakthrough Consortium (MRFBC) Young Investigator Research Team Award, a two-year award with a total prize of $300,000, funded by a grant from Bristol Myers Squibb, to advance the field of translational immuno-oncology.

The goal of this award is to help identify and support the next generation of melanoma scientists to focus on either improving clinical outcomes for melanoma patients treated with immuno-oncology agents or advancing the scientific understanding of immuno-oncology and the role of the immune system. system in melanoma.

Legend: Steven KawutSteven Kawut, Professor of Medicine and Epidemiology and Director of the Pulmonary Hypertension (PH)/Pulmonary Vascular Disease Program, received the Pulmonary Hypertension Association (PHA) Outstanding Physician Award at the International Scientific Conference and Sessions PHA 2022. The award recognizes Dr. Kawut as a leader in promoting excellent clinical care, research, education and advocacy for PH patients.

Dr. Kawut has published over 300 papers and is currently funded by the National Institutes of Health to conduct clinical trials and physical activity studies in people with pulmonary hypertension.

legend: Bonnie KyBonnie Ky, associate professor of cardiovascular medicine and epidemiology and director of the Penn Cardio-Oncology Translational Center of Excellence, has been included by Cancer Health magazine in the Cancer Health 25, an annual list that honors people who have made a difference in the lives of people with cancer. Dr. Ky has been a leading force in the development of cardio-oncology, which focuses on the detection, monitoring and treatment of cardiovascular disease before, during and after cancer treatment.

Anne Marie McCarthy, Assistant Professor of Epidemiology, has received $50,000 from the Pennsylvania Breast Cancer Coalition to support her research in cancer epidemiology with a focus on reducing breast cancer disparities by developing breast cancer screening strategies. precision. Dr. McCarthy’s work builds on a growing understanding of breast cancer biology and risk by focusing on a key clinical concern: identifying women who are at high risk for aggressive and potentially go undetected during mammography screening and who could benefit from further screening treatment.

Caption: Sarah SkuliSarah Skuli, a third-year hematology-oncology fellow, has been selected by the American Society of Hematology (ASH) as one of 16 outstanding fellows to receive the 2022 ASH Research Training Award for Fellows (RTAF), a program of year encourage careers in academic hematology by providing protected research time during training. Each RTAF Fellow will receive $70,000 to support a hematology research project for the duration of the program. Dr. Skuli’s area of ​​interest is the highly aggressive and rapidly fatal subtype of acute myeloid leukemia (AML) that harbors inactivating mutations in a key leukemia cell growth suppressor, TP53. Dr. Skuli is working to understand the role that cellular metabolism and cholesterol synthesis play in enabling this subtype of AML to resist current chemotherapies in order to identify new therapies to treat patients suffering from this cancer of the brain. blood.

Caption: Hongjun SongLegend: Brian LittHongjun Song, Professor of Neuroscience, and Brian Litt, Professor of Neurology and Bioengineering and Director of the Penn Epilepsy Center, received the 2022 Landis Award for Outstanding Mentorship from the National Institute of Neurological Disorders and Stroke (NINDS). The award honors Drs. Song and Litt for their dedication to top quality mentorship and training in the field of neuroscience research. They will each receive $100,000 as a supplement to an existing NINDS grant to support their efforts to foster the career advancement of additional trainees.

Scientists reveal a new function of the ADAR1 enzyme linking it to age-related diseases via an independent role in RNA editing during aging

0

Aging and age-related disorders pose a complex challenge to the biomedical research community. Better understanding how senescence is regulated is of great importance to promote healthy aging and treat age-associated disorders. In a research article published today in Cell Biology NatureRugang Zhang, Ph.D., Deputy Director of the Ellen and Ronald Caplan Cancer Center, Christopher M. Davis Endowed Professor and Program Leader of the Immunology, Microenvironment & Metastasis Program, Wistar Institute, and his team revealed a novel ADAR1-SIRT1 axis -p16INK4a in the regulation of cellular senescence and its potential implications in tissue aging.

“Understanding the basic mechanism underlying tissue aging is challenging and cellular senescence offers an angle into the complex biology that drives tissue aging. tissues can in turn be used to promote healthy aging and fight age disorders.” says Zhang.

At the heart of this quest is a protein called p16INK4a because its expression both increases during tissue aging and drives senescence. Previous studies have established that depletion of p16INK4a-expressing cells is sufficient to delay age-associated disorders. Thus, approaches that prevent age-associated increases in p16INK4a expression may have important implications in designing intervention strategies to promote healthy aging.

The research team’s findings relate to a protein called ADAR1. ADAR1 is a specialized enzyme involved in RNA editing and is now revealed in senescence. Postdoctoral researcher in the Zhang lab and first author of the paper Xue Hao, Ph.D., explains that this research was largely inspired by previous independent research conducted on model organisms such as fruit flies and worms showing that the Depletion of the human equivalent of ADAR1 in these organisms reduces lifespan and causes age-related changes such as neurodegeneration.

This story also benefits from a highly collaborative culture of the Wistar Institute. In fact, previous work by Kazuko Nishikura, Ph.D., a professor in the Gene Expression and Regulation Program at the Ellen and Ronald Caplan Cancer Center at Wistar—and a pioneer in ADAR1 biology—showed that stressed cells use ADAR1 as protection against apoptosis, programmed cell death. “As senescent cells are stressed and apoptosis-resistant cells, the first question we asked was whether ADAR1 is related to cellular senescence and second, how does it regulate senescence and what is its involvement? potential in tissue aging.” Ha explains.

The team first examined the expression of ADAR1 in vitro in human fibroblasts and in vivo in several tissues from young and old mice. Next, they experimentally altered ADAR1 expression in multiple cell types in petri dish and mouse tissues to establish ADAR1 as a critical regulator of p16INK4a expression. Curiously, the team found that loss of ADAR1 promotes expression of p16INK4a via SIRT1, another protein known to regulate both tissue senescence and aging. Interestingly, this function of ADAR1 does not depend on its biological role in RNA editing.

They also found that down-regulation of ADAR1 through a process called autophagy (the breakdown and recycling of damaged or unnecessary cellular components) during senescence decreased the stability of SIRT1 mRNA, which in turn down-regulated. up-translation of p16INK4a to induce senescence. Hao elaborates: “Our study revealed a novel ADAR1-SIRT1-p16 INK4a axis that plays an important role in cellular senescence at the translational level, and this newly defined function of ADAR1 is independent of its RNA editing function. “

Zhang says, “Our study begins to reveal the missing link between ADAR1 and tissue aging through the expression of p16INK4a during senescence. Additionally, these findings have provided a scientific rationale to explore whether this newly discovered mechanism can be exploited to therapeutic development regarding age-related disorders.”

“One way to potentially restore ADAR1 expression as a means to suppress p16INK4a and the senescence observed during tissue aging is to inhibit autophagy.” Ah details. She adds about the next steps in research: “Our study raises some interesting questions. For example, what is the relative contribution of this mechanism to p16INK4a expression during aging in different tissues? Additionally, it would be of interest to determine whether intervention of this pathway can attenuate age-associated disorders that are linked to p16INK4a expression in previous published animal models.

Co-authors: Xue Hao, Yusuke Shiromoto, Masayuki Sakurai, Martina Towers, Qiang Zhang, Shuai Wu, Bin Tian, ​​Andrew Kossenkov, Kazuko Nishikura, Pingyu Liu from Wistar Institute; Aaron Havas, Peter D. Adams of Sanford Burnham Prebys Medical Discovery Institute; Lu Wang, Shelley Berger of the University of Pennsylvania.

Work supported by: This work was supported by grants from the US National Institutes of Health (R01CA160331 to RZ, P01AG031862 to PDA, SLB and RZ, R01GM040536 and R01GM130716 to KN, and R50CA211199 to AVK). KN was supported by a grant from Emerson Collective. Support for basic facilities was provided by Cancer Center Support Grant (CCSG) CA010815 to the Wistar Institute.

Eyemart Express Launches Seventh Annual In-Store Cancer Research Fundraiser

0

The optician will donate $5 for each pair of SU2C glasses sold July 18-August. 27

DALLAS, July 18, 2022 /PRNewswire/ — A whopping 1 in 3 people in United States will develop cancer in their lifetime, according to American Cancer Society. To Eyemart Express, local communities can support Stand Up To Cancer (SU2C) research efforts by purchasing new eyewear. The non-profit organization aims to make all cancer patients long-term survivors. For each pair of SU2C glasses purchased from From July 18 to August 27 at the optician, $5 will be donated to an important cause.

Participating in fundraising is easy. Shoppers can visit any Eyemart Express store and have SU2C frames, exclusively made in collaboration with SU2C and Visual Eyes Eyewear, transformed into prescription glasses or sunglasses. The unisex collection accommodates a variety of personal styles, with an assortment of 22 frames ranging from bold, color-block designs to more traditional tortoise and metal frames. Overview of the complete collection, from $69.95, here.

“Cancer touches so many families and communities,” says Katy Hanson, Eyemart Express CMO. “Our fundraiser is an easy way to honor a loved one and contribute to the vital research that Stand Up To Cancer does while keeping your eyes healthy.”

Eyemart Express is committed to $25,000 donation to the organization in honor of its seventh year of organizing in-store fundraising. Over the years, the retailer has raised over $689,000 with this collection dedicated to SU2C in partnership with Visual Eyes Eyewear.

Find a local Eyemart Express to shop the exclusive frame collection and support Stand Up To Cancer at eyemartexpress.com/get-glasses. Get more information about Stand Up To Cancer at standuptocancer.org.

About Eyemart Express
Eyemart Express (EyemartExpress.com) is a national optical retailer known for providing high quality prescription eyewear with an emphasis on affordability and convenience. Eyemart Express ranks among the top optical retailers in the country with its family of brands: Vision 4 Less, Visionmart Express and Eyewear Express. The company is based in Farmers Branch, Texas, and has 236 stores in 42 states. Eyemart Express offers a selection of sturdy frames for the whole family with over 2,000 frames from brands such as Ray-Ban, Coach, Nike and Disney. On-site lens labs and trained lab technicians can deliver high-quality eyewear in as little as 30 minutes.

SOURCE Eyemart Express

Waning Covid-19 immunity, new variants mean ‘tough race’ ahead – immunologist

0

An immunologist warns that ‘we are going to take a beating’ as new variants of Covid-19 and declining immunity make it more likely that people will be infected or re-infected with the virus.

Immunologist and director of the Malaghan Institute, Professor Graham le Gros.
Photo: Provided

The Department of Health said the highly transmissible BA.5 subvariant of Omicron would become the dominant strain of the virus in New Zealand within weeks.

Yesterday the Department of Health reported 6,223 new Covid cases, 254 of which were reinfections of people who had the virus before.

Immunologist and director of the Malaghan Institute, Professor Graham le Gros, said the virus had evolved and people had been infected with previous versions of Covid-19.

“The one that’s circulating now has changed so much that that immunity doesn’t work as well and when you add the factor that the immunity that was generated either by the previous virus infection or by the vaccine, it wears off over a period of six months – it seems to be a very short-lived immunity.”

This meant people were susceptible to infection with new variants, Le Gros said. The first standing.

Health advice now suggests that reinfection can now occur within 29 days of recovering from Covid-19.

People were in a better position than when the virus emerged two years ago, Le Gros said, but immune systems were catching up trying to cope with the new variants.

“With the new variants, you’re just trying to move forward and that’s the nature of the immune system’s evolutionary race against the virus.”

It was a difficult time with the flu virus circulating in the community as well, Le Gros said.

But people had to do what they could to avoid getting viruses and the most important thing to avoid Covid-19 was getting a booster shot, he said.

“The other is to avoid places where a lot of people are talking very enthusiastically and without a mask.”

People with weakened immune systems should be especially careful not to become infected with Covid-19 because it can take much longer than usual to clear the virus, Le Gros said.

Everyone should be aware of that, though, and that’s why mask-wearing was so important, he said.

A growing number of older people were now catching Covid-19 as the country was no longer on lockdown, Le Gros said.

“But I think we have to work with this cause we can’t stay locked up forever.”

Le Gros’ advice for avoiding the virus was to make sure a person had both boosters if they qualified, to make sure they slept and ate well, didn’t drink too much, wore a mask and stayed away from large unmasked crowds.

New Zealand’s per capita Covid-19 death rate is higher than Victoria’s

Australian epidemiologist Tony Blakely said New Zealand had a higher Covid-19 death rate per capita than Victoria – and it was not obvious why.

Blakely co-wrote a paper with New Zealand epidemiologist Professor Michael Baker, saying there is a real risk that current settings will not be enough to prevent health services in both countries from being overwhelmed.

The per capita hospitalization rate for people with Covid-19 in New Zealand and Victoria state was currently about the same, Blakely said. morning report.

But he said that per 100,000, New Zealand’s death rate was 20% higher than Victoria’s.

The reason for this was unclear, although it could be due to a number of factors, he said.

Assigning a cause of death was surprisingly difficult and it could usually take up to a year for authorities to do so, but it had been accelerated due to the pandemic, he said.

Unlike New Zealand, Victoria attempted to split deaths into people who died with Covid-19 and people who died from Covid-19, Blakely said.

“New Zealand may have slightly higher rates due to a larger proportion of the Maori and Pasifika population and also lower socio-economic status, which increases your death rates, people with comorbidities, with high obesity rates, it could be things like that too.”

Another reason could be that Covid-19 infections rose in Australia earlier than in New Zealand, which has been Covid-19-free longer, he said.

This meant that New Zealanders could have less overall immunity to the virus because “if you were naturally infected and vaccinated, you have a bit better immunity than if you were ‘just vaccinated'”.

However, compared to other countries, New Zealand and Australia were doing well and had a low cumulative death rate due to their earlier zero Covid strategies, Blakely said.

“We are now learning to live with the virus which is by definition messy.”

Both Tasman sides were doing well in rolling out vaccinations and rules for the third and fourth boosters and in rolling out antiviral drugs, Blakely said.

“Where there is controversy and debate is over whether masks should be mandatory or encouraged.”

Blakely said a game-changer would be vaccines that prevent people from getting infected, rather than just preventing them from getting seriously ill.

“What we have at the moment is kind of a long battle with this virus to try to keep total morbidity and mortality as low as possible without disrupting society too much.”

People get COVID again and again…and again. Is this the new normal?

0

Increasingly, experts fear, the answer is yes.

Although doctors agree that it is unlikely that people will be infected twice with the same variant, it is likely that in the long term new variants of COVID could infect people again due to evolution at the novel coronavirus lightning speed.

“I wouldn’t be surprised if we saw people getting infected more than once a year,” Dr. Anthony Fauci, President Joe Biden’s chief medical adviser, told NBC News.

Hybrid immunity – the dual protection offered by infection and vaccination – appears to be less protective than it was before against the return of COVID, although vaccines continue to ward off serious illness. But since many people have now had both omicron and a later subvariant such as BA.2, BA.4 or BA.5, studies show that vaccination coupled with prior exposure always prevents reinfection better than a vaccine or infection alone.

“Your previous immunity, including against infection, is worth nothing, it’s just worth less than before,” said Dr. Bob Wachter, chairman of the UCSF Department of Medicine, in a recent episode of the Chronicle’s Fifth podcast. and Mission.

Dr. Monica Gandhi, an infectious disease specialist at UCSF, noted that hybrid immunity is particularly useful in preventing serious consequences.

Although “SARS-CoV-2 is not an eradicable virus by its properties”, she said, increasing global levels of immunity through vaccination, infection or both means that deaths remain weak.

Dr Abraar Karan, an infectious disease physician at Stanford, added that reinfections boost cellular immunity – the way the body remembers deeply how to fight off the virus, which people get either through a vaccine or by their first infection. This means that reinfections should be increasingly mild.

But it also depends on what new “unpredictable” variants bring, he noted, as the virus could evolve to become more severe.

Coronavirus Resources

Covid19 map: Trend data in the Bay Area and throughout California

Recent news: Full coverage of the coronavirus pandemic


With disease containment measures such as improved ventilation and nasal vaccines — which can produce mucosal immunity that’s better at preventing infection than current vaccines — future COVID outbreaks could be more localized, Karan said. . This could limit their ability to spread quickly around the world, which has been one of the biggest problems in recent years in the fight against the pandemic.

“It could be that we slow the spread enough that outbreaks are smaller and occur less frequently,” he said. In other words, “not all epidemics are pandemics”.

He added that slowing the spread of COVID will also help slow the development of new variants, although they will continue to appear.

But COVID remains a relatively new disease, and scientists and experts still don’t know what effect repeated reinfections have on the body, or what that means for the long COVID.

“I think there’s a lot about it that we don’t know, but my focus is that reinfection is not nothing,” Wachter said. “Unfortunately, I think if you get re-infected, we have to assume that has potential consequences.”

Danielle Echeverria is a staff writer for the San Francisco Chronicle. Email: [email protected]: @DanielleEchev

5 Ways to Prevent and Reverse Sarcopenia

0

Omega-3 fatty acids, whey, and exercise are just three effective ways to fight sarcopenia before it strikes.

A form of muscle loss, sarcopenia is a common condition that affects up to 12% of older people. The progressive skeletal muscle loss mass and strength are linked to an increased risk of physical disability, poor quality of life and death.

Despite the lack of international consensus on the diagnosis of sarcopenia, it is characterized by loss of skeletal muscle mass and work in the elderly.

Fortunately, there are significant steps you can take to prevent and reverse sarcopenia. Some of its causes are a natural result of aging, but others can be avoided through healthy diet and lifestyle strategies. Quality food with adequate nutritionfor example, may help preserve skeletal muscle regeneration as you age.

Here are five strategies to help fight this condition naturally.

1. Omega-3

Omega-3 fatty acids are known to stimulate protein anabolism in animals and may benefit sarcopenia. To test this hypothesis, researchers randomly assigned 16 healthy elderly people to receive omega-3 fatty acids or corn oil for eight weeks. The results showed that omega-3s stimulate muscle protein synthesis and may be helpful in preventing and treating sarcopenia.

Omega-3 fatty acids are considered a useful therapeutic agent for the disease due to their anti-inflammatory properties targeting “inflammation”, the chronic age-related low grade. inflammation supposed to contribute to the development of sarcopenia.

A diet rich in pro-inflammatory foods has, in fact, been correlated with a higher risk of sarcopenia, suggesting that an anti-inflammatory diet may be a key to preventing it.

Additionally, omega-3s may also have an anabolic effect on muscles by activating mTOR signaling, which affects dozens of processes including cell growth, proliferation, motility and survival, as well as protein synthesis. Omega-3s can also reduce insulin resistance, which has additional benefits in the face of the diabetes epidemic. Omega-3s may also supplement the effect of exercise or protein supplementation, with the researchers urging further investigation into the exact dosage, frequency, or use of these fats for this purpose.

2. Whey Protein

Protein supplementation is sometimes necessary to maintain skeletal muscle mass, and whey protein is among the best.

In two animal experiments, researchers found that whey protein alleviates induced muscle atrophy by improving net protein content that regulates muscle protein synthesis and breakdown. They called this food a “necessary and likely candidate” for developing functional foods that fight sarcopenia.

Highlighting the combined benefits of therapy and nutritional intervention, separate research has found that, combined with omega-3s, polyphenols and electrical muscle stimulation, whey protein increased muscle strength in older adults with reduced mobility. Combined with Panax Ginseng Berry Extractsoluble whey protein hydrolyzate also improved sarcopenia-related muscle deterioration.

3. Exercise

If there’s anything that can help keep our muscles from wasting away, it’s exercise.

Exercise leads to lasting benefits for sarcopenia in heart failure, helping to reduce skeletal muscle wasting in this population. In older men with sarcopenia, tai chi and whole body vibration have also been shown to be effective in improving muscle strength as well as physical performance.

A 2019 review of 331 articles also found that exercise was beneficial for skeletal muscle regeneration, muscle metabolism, and motor function in mice with sarcopenia. “Exercise intervention methods primarily involved the use of treadmills, voluntary wheel running, force wheel running, swimming, and resistance training,” notes the study, published in Journal of Sport and Health Science in 2019.

4. Miso

Diets marked by a high intake of fish, soy products, potatoes, most vegetables, mushrooms, seaweed and fruits, and a low intake of rice, were linked to lower rates of sarcopenia in older Japanese living in the community.

Miso is a fermented dough which is traditionally added to many Japanese dishes. In a cross-sectional study, habitual miso consumption was associated with a low prevalence of sarcopenia in patients with type 2 diabetes. Insulin resistance is considered a risk factor for the condition, which is typically present in people with diabetes type 2.

5. Vitamin D

Studies on vitamin D supplementationincluding a systematic review of 29 studies, offer compelling evidence of increased muscle strength. Vitamin D deficiency is a common health problem around the world, especially among older people. Vitamin D regulates multiple human functions, including skeletal muscle, so the fat-soluble vitamin may be crucial for maintaining and improving muscle strength and physical performance over time.

In a 2012 study, higher visceral fat and lower muscle mass were associated with lower vitamin D3 levels in older Korean men. The results suggest that screening for deficiency may be appropriate in older adults with visceral obesity or sarcopenia.

Explore research on sarcopenia on the GreenMedInfo.com database to learn more about nutritional and natural interventions for this condition.

Gasoline prices could jump as soon as October

0

Comment

Drivers relieved by the recent drop in gasoline prices could be in shock when the summer ends, with energy analysts warning another price spike could come as early as October.

The prospect of another gas price bump coinciding with the midterm elections worries the White House and many Democrats.

Price concerns relate to the timing of tougher sanctions on Russia, which will further choke off global oil supplies. JP Morgan has warned that in the worst-case scenario – in which Russia retaliates by completely shutting down its supply – the price of oil could climb to $380 a barrel, more than triple what it is today.

“If you asked me where oil prices could go, I would say pick a number,” said Michael Tran, managing director of global energy strategy at RBC Capital, who said that while the outlook is murky, several indicators point to a price. bounce. “This is the tightest oil market we’ve seen in a generation or more.”

The ominous prognosis for consumers, as the country already grapples with historic levels of inflation, has the Biden administration seizing on interventions that could bring relief.

Yet WE political leaders are faced with the reality that even the most aggressive national policy measures often have little impact on prices in a global oil market driven by forces beyond their control.

Economists across the ideological spectrum are warning that the measures the White House is promoting — allowing Russian oil to enter the world market at discounted prices, taxing oil company “windfall” profits, reducing the federal tax on gasoline – could ultimately aggravate the energy crisis in the United States, rather than alleviate it.

“When things like this happen, we tend to focus on short-term fixes,” said Christopher Knittel, a professor of applied economics at MIT’s Sloan School of Management. “But, unfortunately, gas prices aren’t really something you can fix in the short term.”

The White House concerns come at a time when consumers see gas prices as one of the few things in the economy that are headed in the right direction. The cost of a gallon has gone from over $5 a month ago to a national average of $4.60, according to AAA. Oil is trading cheaper than before Russia invaded Ukraine.

Concerns about a potential recession dampening demand played a significant role in lowering prices.

Another key reason why prices have fallen lately is that the initial sanctions against Russia are much less effective than expected. The country’s oil is making its way onto world markets despite restrictions, flowing to places like China and India. This means that global supply is not as tight as expected when the United States and Europe initially joined forces to punish Russia for its invasion.

This could change with the next round of planned sanctions. A total ban on Russian oil cargo shipments to Europe is set to apply on December 5, with the market expected to take notice much sooner.

The sanctions would be accompanied by a ban on insuring vessels carrying Russian oil, preventing them from accessing international waterways. Insurance policies for most oil cargo ships in the world are taken out outside Europe.

As a result, Russia would face huge new hurdles in getting its oil anywhere. The sanctions aim to double the amount of Russian oil withdrawn from the market since the start of the war.

Internal US Treasury analysis predicts the price of oil will climb 50% above its current level. Some market analysts are warning of potentially bigger increases, which could push gasoline prices past $6 a gallon.

The warnings are all accompanied by cautions. In the event of further bad economic news signaling a prolonged recession, for example, prices would likely stabilize. Less gasoline is used when the economy is down.

A new round of coronavirus shutdowns in major Chinese cities would similarly weaken global demand and ease upward pressure on prices.

Yet the imbalance between supply and demand for oil and gasoline is so pronounced at the moment that prices could rise months before new sanctions take effect, central to the medium-term campaign, a said Kevin Book, managing director of ClearView Energy Partners, a research firm. .

“People who buy oil bid early,” Book said. “It takes four to six weeks for it to be delivered. If they think a shortage is coming, they plan for it.

Pump Shock: Why Gas Prices Are So High

The political and economic dilemma highlights the challenges of using energy as a cudgel of foreign policy.

“Energy sanctions have never been the silver bullet people were hoping for,” said Edward Chow, an energy security specialist at the Center for Strategic and International Studies who has worked in the industry for decades. “Politicians tell voters we can do it and people don’t have to sacrifice. It only works if you are willing to make sacrifices and actually reduce demand.

US lawmakers have shown little appetite for the conservation measures the International Energy Agency is urging be implemented as part of the Ukraine aid effort. The 10 point plan the agency unveiled months ago – aimed at reducing oil demand by the equivalent of all cars in China – calls on economically advanced countries to lower speed limits on highways, make car-free cities a day a week and implement vehicle sharing.

The plans are seen as political losers in the United States, echoing the unpopular conservation initiatives that doomed the Carter administration when it faced an energy crisis in the 1970s.

The White House is instead pressuring world leaders to agree to a new price cap that would allow Russia to continue selling its oil after Dec. 5, but at a steeply reduced price. The idea is to avoid a global shortage while reducing the oil profits that Russia uses to finance its war effort.

Although the plan has prominent champions, energy experts are deeply skeptical. They warn that Russia has various levers it could use to throw the market into chaos, including cutting off all overseas shipments, plunging countries like India deeper into crisis.

JP Morgan’s warning that oil prices could more than triple in a worst-case scenario hinges on its conclusion that Russia’s economy can withstand a cut in oil production of millions of barrels a day.

“The problem is that Russia also gets a vote,” Book said. “Just because something hasn’t been done before doesn’t mean it shouldn’t be done. But sometimes there’s a reason it was never done.

Chow called the effort “puzzling.” “I haven’t come across a single person who’s worked in the energy industry who thinks this can work,” he said.

Other measures the Biden administration is pursuing would target oil companies, heavily taxing the “windfall” profits they make from high prices. Leading Democrats argue such actions are overdue.

“In my view, many interventions are appropriate in this market,” said Sen. Sheldon Whitehouse (DR.I.). “You are not as a government interfering in the market. You neutralize the anti-competitive effects of a cartel. Even if you are a believer in the free market, it is right to bring down cartel-driven anti-competitive practices. »

It’s a powerful argument and one that resonates with voters, who blame the oil companies for the high prices. But the United States has a history dating back to the Nixon administration of trying to use regulation to control prices at the pump. Knittel reported in a detailed academic document how these efforts backfired, leading to oil shortages and long lines at gas stations in the 1970s.

Countries currently tinkering with aggressive market interventions face the same dilemma again. Before Russia invaded Ukraine, the Hungarian government imposed price controls capping the cost of gas at $4.80 per gallon. Shortages followed. Drivers are now prohibited from purchasing more than 13 gallons of fuel per day.

“Gas prices are set on the basis of a global oil market, and it’s difficult for a country to have a significant impact on that market in a short period of time,” Knittel said. “The way to stop this is a call for federal legislation that reduces long-term oil demand. So the next time prices go up like this, it won’t hit us as hard.

DOJ says advisers to former presidents may enjoy some immunity from congressional subpoenas, but not in Jan. 6 investigation

0
The DOJ’s stance means that Mark Meadows and other senior Trump White House officials may not be shielded from civil lawsuits to force them to testify on Capitol Hill now that Trump is out and the House Select Committee continues to search for information.
The department disclosed its position in a court filing on Friday in the lawsuit filed by Trump’s White House chief of staff, Mark Meadows, challenging House Select Committee subpoenas.

“The select committee has detailed the information it seeks from the plaintiff (Meadows) and the importance of this evidence to the work of the select committee,” Justice Department attorneys wrote. “The select committee has demonstrated that this information is essential to its investigation.”

During their tenure, Trump and his White House routinely cited “absolute immunity” that would excuse them from appearing when Congress subpoenaed their testimony.

Biden’s Justice Department still supports this protection of advisers to sitting presidents, citing the need to give the presidency some sphere of secrecy when Congress seeks information. But the department says the immunity claim isn’t as compelling once a president leaves office.

The DOJ filing says advisers like Meadows who worked for former presidents could have what’s called “qualified immunity,” meaning the secrecy protections over their work while in office could fall if Congress showed the need.

The question of how much immunity extends around the president has not been settled by the courts, and a trial judge has yet to weigh in the Meadows case.

But the DOJ’s choice is still a blow to Meadows – even after the department chose not to criminally charge him for not testifying in the House investigation.

VF Corp: Potential Business Opportunity in Apparel Manufacturers (NYSE: VFC)

0

quinntheislander/iStock via Getty Images

Drilling from top to bottom

In the process of generating a trade idea, one should refrain from looking at charts until all fundamental data has been analyzed and digested to “explore” specific sectors and complete equity. the universe was derived from such an analysis.

Starting (in our opinion) with the main driver of directional equity investing and trading, the manufacturing PMI, we can arrive at the following view:

There has been a steady decline for over 6 months now, signaling a sharp slowdown in the economic drivers of the stock markets and a subsequent decline in the S&P500. Thus, our authoritarian view of actions is Bearish.

Creating a world view:

US PMI

TradingEconomics.com

Even though the above conclusion is drawn from a sample of a population of indicators, we can align this view and substantiate it with other benchmarks stated in previous reports published in our various media avenues. social; further confirming that our medium-term view for equities is bearish.

Identify industry disruptions:

Now that we have established a bearish view for stocks for a trading period, further analysis is needed to identify industries on which to create a sub-universe of stocks to trade.

Clothes:

Over the past 6 months, the apparel industry has benefited from the high level expansion in the business PMI report with overall positive feedback from the respondents section. However, for the month of June, we see a different story of respondents and commodities.

Quote from the ISM June manufacturing report

ISM manufacturing report for June

This response clearly signals overall expectations of lower sales and orders as well as overstocked inventory across the industry, the first sign of a contraction over the past 6 months highlighting an opportunity to make our point. bearish view on this sector.

Ability to use:

A capacity utilization reading between 78% and 80% is at the higher end and calls for either higher production to increase capacity or a forced slowdown in demand to let the industry catch its breath.

In the case of clothing, we see a reading of 80.2% in June using one of the two simplified solutions provided above. Judging by the slowdown in the consumer sector and all the negative leading indicators for the US economy as well as respondents’ expectations for a slowdown in sales; we conclude that the sector will experience a a slowdown in demand rather than an expansion in capacity.

Raw material pilots:

In the apparel industry, cotton prices are a clear and comprehensive driver of margins and business and consumer demand. Noting a (30%) decline in MoM cotton prices from June to July, we have a new data point to look at to generate a trade idea and then refine our universe of stocks within the sector:

Falling cotton prices can lead to a series of advantages and disadvantages for operators in the industry, we have endeavored to research:

Detriment businesses with slower inventory turns, holding overvalued inventory, and not being fast enough to take advantage of lower prices/higher margins.

Benefit from to higher gross margin companies with faster inventory turnover who can benefit from this decline in raw materials.

US cotton prices

TradingEconomics.com

Universe of clothing stocks:

Have a bearish setting on the Equity asset class and a bearish setting on the apparel industry, along with fundamentals for fast/slow inventory turnover ratios and high/low gross margins to drive the detriment /benefit from the contraction in cotton prices; we are ready to select a comprehensive portfolio of long and short clothing stocks.

Based on fundamental screening, it is intuitive that larger capitalization stocks will benefit from faster inventory turnover and higher margins due to economies of scale, while smaller capitalization stocks will see the antithesis of these advantages.

Additionally, an optimistic/pessimistic P/E multiple can be a clear indication of what participants are willing to pay for the quality of the underlying future earnings as a result of this environment and developing thesis.

By following these parameters and filters, it is complete to focus on the following two activities:

V.F. Corporation (NYSE: VFC) Long bias

A large capitalization of $17 billion can provide guidance on which settings above are desired.

Settings:

PER 14.5x which is above the industry average of 8x. This perceived higher multiple of earnings quality may be a view in support of cotton price dynamics and participants relying on the quality of large caps to benefit from such price changes.

DEER 37% again above the industry average of 6%. This better quality of company fundamentals can provide an additional “base” to attract investors looking to gain exposure to the sector.

Gross margins 54.50% above the industry average of 32.3%. This confirms our metric to take advantage of sustained margins throughout the decline in cotton prices, also increasing the bottom line.

Net margins 10.30% above the industry average of 3.1%. With the above gross margins maintained and improved through lower cotton prices, we can expect this higher net margin to increase EPS at the end of the quarter. Maintaining an industry-leading P/E multiple can be a primary driver and catalyst for taking advantage of the long position.

Stock rotation 3.8-4.2x above the industry average of 2.4x. This again confirms our metric of being able to retain the benefits of lower cotton prices in new inventory and not holding overvalued inventory from previous months, a factor in higher margins and profits.

Delta Apparel Short Bias (DLA)

A small capitalization of $175 million can provide guidance on which settings above are desired.

Settings:

PER 6.3x below the industry average of 8x. This supports a pessimistic view of underlying earnings that can be derived from the above thesis for margins and inventory.

DEER 17.5% above the industry average of 6%. A positive against the industry, but still lower than our long counterpart in $VFC.

Gross margins 23.9% below the industry average of 32.3%. A lower than average gross margin will likely be sustained in lower cotton prices, subsequently diminishing the bottom line.

Net margins 6.11% above an industry average of 3.1%. A positive against the industry, but still lower than our long counterpart in $VFC.

Stock rotation 1.8-2.2x below the industry average of 2.4x. This confirms our parameters of not being able to change inventories quickly enough to take advantage of lower cotton prices and retain overvalued inventories from previous months. This, coupled with lower gross and net margins, will significantly reduce EPS, with the stock already carrying a compressed P/E multiple, this can be a catalyst to profit from a short sale.

Structuring the trade

After defining a universe for long and short stocks within our desired industry, a quantitative structure of the subsequent trade is needed to “synchronize” our entries and exits in the spread trade.

The graph above represents the spread (VFC price minus DLA $ price) for the last 5 years. The median value in Black of $46.50 is our mean reversion price target for this time series. First standard deviations in Green and second standard deviations in Red. A second negative standard deviation opens the question to mean the reversion to “long this deviation” or in other words Long $VFC and Short $DLA.

A P value of 93% provides a high confidence interval for regression to the mean within the deviation. This behavior of cointegration or inversion allows us to hope for a profit by “aspiring” to this gap.

A coverage ratio of 0.27 represents the optimal positioning in order to remain as neutral as possible. This ratio specifically recommends shorting ~$3 DLA for every 1 long in $VFC.

Average reversion and coverage ratio:

Expectations

Assuming a position totaling $2,000 budget, a trader would be allowed to buy $14 VFC and short $52 DLA for a total position of $2,077.

This spread holds a “target profit” at the midpoint of $46.50 of 157% from a theoretical current entry at $17.20. A “Max Profit” is derived from the possibility of exiting at the level of +1 standard deviation of $57.25finally our “Max Risk” is a function of the annualized standard deviation of the series of spreads as well as the internal risk tolerance.

It would make a theoretical profit of $3,266 and a theoretical risk of loss of ($409.88) from this point of view.

Is the position hedged against cotton prices?

Given the delayed equity price reaction to the 30% decline in cotton prices, traders would benefit from understanding the historical behavior of our equity spread position to cotton price action:

The above study demonstrates a negative correlation over 5 years of (60%) between stock spread values ​​and cotton prices. It would therefore make sense that the decline – and continued decline – in cotton prices would statistically represent another driver for profiting from the “desire” for the stock spread and hedging the business risk of such a decline. prices.

Cats injured in wildfires at risk of fatal blood clots

0

A cat treated for care at the UC Davis Veterinary Hospital after the 2018 campfire. Credit: UC Davis School of Veterinary Medicine

According to a new study by researchers at the University of California, Davis, Veterinary Medical Teaching Hospital, cats that suffered burns and smoke inhalation during urban wildfires in California are at risk of forming blood clots. mortals. The study, recently published in the journal Frontiers in Veterinary Sciencefollows a previous discovery which showed that cats injured in urban wildfires had a high incidence of heart problems.

“Prior to these two papers, we did not know that cats affected by urban wildfires were susceptible to clots, which can lead to sudden death,” said co-lead author Ronald Li, associate professor of emergency and intensive care for small animals at UC Davis. “This study will change the standard of care for cats rescued from these wildfires and hopefully save more lives.”

Overactive platelets

Cats treated for their injuries from the 2018 campfire in Paradise, Calif., were among the models in this study. The researchers looked at their platelets, the cells that circulate in the blood and help stop bleeding or form blood clots. They found that wildfire-injured cats had an increase in overactive platelets compared to healthy cats or cats with heart disease, in this case subclinical hypertrophic cardiomyopathy, or HCM. HCM is the most common heart disease in cats and causes thickening of the heart muscle.

“Cats with HCM are hypercoagulable, which means they are more likely to form clots,” explained co-lead author Ava Tan, a veterinary researcher currently working in Li’s lab. used them as a control group to compare with cats in the wildfire group.”

Platelets from wildfire-injured cats also released large amounts of microvesicles, microscopic membranous bubble-like structures filled with proteins, which are associated with cardiovascular disease and a high risk of clotting.

“We found that cats exposed to wildfire smoke and injury were even more prone to shed clots, showing a direct association between wildfire injury, platelet response and clot formation” , said Tan.

In addition to clot formation, platelets have a lot to do with health and cardiovascular disease in general. The study also led to the discovery of a new receptor on cat platelets, Toll-Like-Receptor-4, which may play a role in coagulation and could be the target of treatments developed in the future.

“These findings may have broader implications for the health of our feline patients and underscore the important role platelets play in linking inflammation to the coagulation system,” Li said.

Impact on human health

Forest fires also pose a major risk to humans. ER visits are increasing due to heart attacks and strokes after wildlife exposure. Although the underlying mechanism is not known in humans, this cat study may shed light on the systemic activation of platelets, which plays a crucial role in mediating the likelihood of developing blood clots. from injuries caused by a forest fire.

“This study opens a new door to examining the impact of wildfires on cardiovascular health in humans,” Li said.

The researchers were able to use blood samples taken from cats brought in for campfire treatment, which have been used in these two studies to date. This study also led to a third study, which is ongoing, to uncover new cellular processes that may explain why feline platelets are so sensitive and prone to clotting, especially in cats with heart problems or injuries caused by a forest fire. The data collected is essential for developing early treatment plans, Li said.

Other authors include veterinary cardiologists Joshua Stern, Catherine Gunther-Harrington and Ashley Sharpe; critical care veterinary specialists Yu Ueda, Steven Epstein and Satoshi Haginoya; and research associates Nghi Nguyen and Mehrab Hussain of Li’s Comparative Platelet and Neutrophil Physiology Laboratory.


Are cats the “canary in the coal mine” for the effects of wildfires on human health?


More information:
Avalene W.K. Tan et al, Platelet priming and activation in natural thermal burns and exposure to wildfire smoke are associated with intracardiac thrombosis and spontaneous echocardiographic contrast in feline survivors, Frontiers in Veterinary Science (2022). DOI: 10.3389/fvets.2022.892377

Quote: Cats injured in wildfires at risk of fatal blood clots (July 14, 2022) Retrieved July 14, 2022 from https://phys.org/news/2022-07-cats-wildfires-deadly-blood-clots.html

This document is subject to copyright. Except for fair use for purposes of private study or research, no part may be reproduced without written permission. The content is provided for information only.

Expert Research and Analysis of the Hydrocolloid Gum Market: Key Companies, Growth Drivers, Industry Challenges and Opportunities to 2028 | Cargill Inc, Kerry Group PLC, Archer Daniels Midland Company (ADM)

0

The SMI offers the “Hydrocolloid Gum Market” Report 2022 in its research report store. This is the most comprehensive report available on this market and will help you gain a truly global perspective as it covers geographies. An in-depth study on this topic reports that the Hydrocolloid Gum market size is expected from 2022 to 2028 at a compound annual growth rate (CAGR). The market growth is mainly driven by businesses resuming operations and adapting to the new normal while recovering from the impact of COVID-19. More information The regional and country breakdowns section gives an analysis of the market in each geography and the market size by region and country. It also compares historical and forecast market growth and highlights important trends and strategies that market players may adopt.

Get Sample to understand more details about Gum Hydrocolloids Market Segments:- https://www.stratagemmarketinsights.com/sample/148884

The key players covered in this report:

The research report will help market players to develop future business strategies and learn about the global competition. This report provides an overview of various important research industry data and future trends that help identify products and drive revenue growth and profitability. The reports contain an overview and review of the major companies operating in the industry that are considered to be revenue generators for the market.

Cargill Inc, Kerry Group PLC, Archer Daniels Midland Company (ADM), EI Du Pont De Nemours & Company, Royal DSM, Danisco A/S

Report overview and scope:

SMI provides analysis of key trends in each sub-segment of the Gum Hydrocolloid market, as well as forecasts at the global, regional and country levels from 2022 to 2028. Our report has categorized the market based on type, activity and of the sales channel. The market report defines several important characteristics of the market. It will provide the beginnings of this report, describe the needs of this business and the expected results of the research efforts, identify the constraints in the development of a specific solution and the business processes impacted by the project, and identify external and external entities.

Segmentation by types of products/services:

gellan gum, guar gum, gum arabic, locust bean gum, xanthan gum

Applications of Hydrocolloid Gum Market:

Bakery, confectionery, meat and poultry processing, dairy products, sauces and dressings, cosmetics, pharmaceuticals

Discount until availability on different types of licenses when buying it now (Use corporate email id to get higher priority-https://www.stratagemmarketinsights.com/discount/148884

Main highlights of the report:-

• Overall parent market assessment
• Evolution of significant aspects of the market
• Industry-wide survey of market segments
• Assessment of market value and volume over past, present and forecast years
• Market share assessment
• Tactical approaches from market leaders
• Money-making strategies to help companies strengthen their position in the market

Regional landscape:

The research examines significant changes in the market with particular emphasis. Powerful technologies, significant market trends, development patterns, growth drivers, restraints, challenges, threats, potential opportunities, standardization, value chain, regulatory landscape, future forecast and a critical methodology are all included in its in-depth analysis of the global market.

Geographically, the regions covered in the report:

  • North America (USA and Canada)
  • Europe (UK, Germany, France and Rest of Europe)
  • Asia-Pacific (China, Japan, India and the rest of the Asia-Pacific region)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • The Middle East and Africa (GCC and Rest of Middle East and Africa)

Reason to buy

• Save and reduce time spent on entry-level research by identifying the growth, size, leading players and segments in the global Hydrocolloid Gum market.
• Highlights key business priorities to guide companies in reforming their business strategies and establishing themselves in the vast geography.
• The key findings and recommendations highlight crucial progressive industry trends in the Gum Hydrocolloid Market, thereby allowing players to develop effective long term strategies in order to garner their market revenue.
• Develop/modify business expansion plans using substantial growth offering in both developed and emerging markets.
• Dig deep into the global market trends and outlook associated with the factors that are driving the market, as well as those that are limiting the growth to some extent.

Answers to key questions in the report:

☑ What is the growth potential of the Gum Hydrocolloid market?
☑ Which product segment will take the lion’s share?
☑ Which regional market will impose itself as a pioneer in the years to come?
☑ Which application segment will experience strong growth?
☑ What growth opportunities might present themselves in the Hydrocolloid Gum industry in the coming years?
☑ What are the biggest challenges the market may face in the future?

Immediate delivery of our ready-to-use reports and pre-booking of future studies, thanks to flexible and convenient payment [email protected]https://www.stratagemmarketinsights.com/cart/148884

Contact us:

Mr Shah
Stratagem Market Overview
Tel: US +1 415 871 0703 / JAPAN +81-50-5539-1737
E-mail: [email protected]

VB

Suri’s unilateral decision not granted parliamentary immunity: SC – Newspaper

0

ISLAMABAD: The Supreme Court has issued a detailed judgment explaining the reasons for its decision to overturn a controversial decision by the Speaker of the National Assembly on April 3 which rejected the motion of no confidence against then Prime Minister Imran Khan .

In the verdict written by Chief Justice Umar Ata Bandial, the Chief Justice said that by rejecting the motion of no confidence against Imran Khan, Mr Suri prima facie breached his constitutional duty. Judge Bandial said the April 3 decision was not eligible for protection of parliament’s internal proceedings under Rule 69(1) because it was “not the result of a vote in the ‘National Assembly, but rather a unilateral decision’.

Justice Bandial observed that the Vice President’s controversial action set off a chain of events, the most concerning aspect of which was that it allowed the then Prime Minister to claim the constitutionally repugnant outcome of avoid the motion of censure without a vote of the assembly.

The court’s top priority was the maintenance of constitutional order which could only be achieved if the assembly was restored, Justice Bandial added.

Judge Bandial says text of cipher not shown in court, contents only ‘partially disclosed’

Figure not shown in court

Justice Bandial, while referring to the cipher used by Mr. Suri to dismiss the petition against Imran Khan, explained that the text of the cipher was not shown to the Supreme Court, although its contents were partially disclosed in the detailed reasons given in support of the vice-president’s decision.

The detailed reasons in addition to the April 2 cabinet decision acknowledged the need for an investigation to establish alleged collusion between the opposition and a foreign state.

“Such an inquiry into the facts may, in the first instance, be conducted either by a commission appointed by the Federal Government under the 2017 Act or by a specialized commission appointed by an Act of Parliament or a order”, observed Judge Bandial.

The PTI’s plea that the supreme court should take suo motu the defense of national security and the alleged violation of sovereignty was unprecedented, the decision explained.

Additionally, opposition members who tabled the notice were allowed to bring the motion against the then prime minister on March 28, crystallizing the constitutional right and obligation of a vote under the 95(2) on the motion.

This right/duty can only be overridden or restricted by a vote on the floor of the assembly, the ruling said, adding, “As the Vice President’s ruling unilaterally denied the right to vote afforded by the constitution , no immunity under section 69(1)( ) attaches to it and it may be reviewed by the court.

High treason

Meanwhile, Justice Mazahar Alam Khan Miankhel, who retired on July 13, in his supplementary note observed that the exercise of authority was a sacred trust that was violated by the president and then the prime minister. , the then president, the then vice president and the then law. minister.

“Whether these acts attract Article 6 of the Constitution (high treason) is also left to be determined by parliamentarians to consider whether they leave the doors open to such unconstitutional acts or take appropriate action. to stop such mess in the future,” Justice suggested Miankhel.

The people’s elected representatives were barred from voting on the resolution and for such a flagrant transgression of the Constitution, there must be consequences and the law must take its course, Justice Miankhel added.

“Doctrine of Necessity”

Judge Jamal Khan Mandokhel, in his memorandum, observed that the Vice President’s action was biased, on the grounds that if he were allowed to call new elections, it would amount to giving an authority the right to abuse the extraordinary power of the doctrine of necessity.

This country has already experienced many times misuse of the doctrine of necessity by the hands of unconstitutional forces, which has been legitimized by the supreme court, but it has not achieved the expected results, he added. .

On the contrary, democracy has suffered greatly because of the misuse of the doctrine of necessity, observed Judge Mandokhel. He added that the courts must discourage any action contrary to the constitution and democratic norms.

Posted in Dawn, July 14, 2022

Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

0

– First patient scheduled for enrollment in the fourth quarter of 2022; First CALM-1 results expected in 2H 2024 –

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the treatment of chronic intractable cough and other indications of cough hypersensitivity , today announced a positive End of Phase 2 (“EOP2”) meeting with the U.S. Food and Drug Administration (“FDA”) and details of the Phase 3 CALM program for BLU-5937, a A second-generation highly selective P2X3 antagonist product candidate for the treatment of refractory chronic cough (“RCC”).

“The successful conclusion of our end of phase 2 meeting with the FDA marks an important milestone for BELLUS. We appreciate the support and guidance of the FDA and are pleased to have identified a clear regulatory path to eventual approval of BLU-5937. commented Roberto Bellini, President and CEO of BELLUS Health. “Based on our SOOTHE Phase 2b data, we remain confident in the potential of BLU-5937 to be the best-in-class treatment option for RCC patients, if approved. We are well positioned to execute our CALM Phase 3 program, with sufficient financial resources to bring us the best results with CALM-1, and we look forward to launching this pivotal program in the fourth quarter.”

Based on FDA feedback, the CALM Phase 3 program is comprised of two pivotal trials, CALM-1 and CALM-2, each evaluating the efficacy, safety, and tolerability of BLU-5937 in approximately 675 adults with of RCC. CALM-1 and CALM-2 will be placebo-controlled, randomized 1:1:1 parallel arm trials with expected treatment arms of 25 mg BID, 50 mg BID and placebo. The primary endpoint of 24-hour cough frequency will be measured at 12 weeks for CALM-1 and 24 weeks for CALM-2. The company has aligned with the FDA so that the primary endpoint of the Phase 3 CALM program, similar to the successful Phase 2b trial SOOTHE, can be assessed using the VitaloJAK cough monitoring system in a patient population enriched for a baseline 24-hour cough rate of ≥ 20 coughs/hour (equivalent to awake cough rate ≥ 25 coughs/hour used in the phase 2b SOOTHE trial). Key secondary efficacy endpoints include cough severity using the Visual Analogue Scale (“CS-VAS”), Leicester Cough Questionnaire (“LCQ”), and chronic cough diary ( “CCD”). CALM Phase 3 trials will also enroll participants with baseline 24-hour cough frequency

About the BLU-5937

BLU-5937, a highly selective P2X3 antagonist, is being developed for RCC and other indications of cough hypersensitivity.

The P2X3 receptor, which is involved in cough reflex hypersensitization, is a rational target for the treatment of chronic cough, and it has been evaluated in multiple clinical trials with different P2X3 antagonists. The Company believes that its highly selective antagonist P2X3 has the potential to reduce cough frequency in patients with RCC and improve quality of life while limiting adverse events related to taste disorders.

In addition to RCC, the mechanism of action of BLU-5937 may also have broad therapeutic applicability in other indications of cough hypersensitivity. The Company is evaluating potential opportunities to study BLU-5937 in other cough indications where cough hypersensitivity plays an important role.

About BELLUS Health ( www.bellushealth.com )

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of RCC and other indications of cough hypersensitivity. The Company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS Health is planning a Phase 3 program, with enrollment expected to begin in the fourth quarter of 2022.

Chronic cough is a cough that lasts more than eight weeks. When the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is called RCC. It is estimated that there are approximately 9 million patients in the United States with RCC. CRC is associated with significant negative physical, social and psychological effects on health and quality of life. Currently, there are no specific approved therapies for RCC and treatment options are limited.

The Company is exploring the potential use of BLU-5937 in other patient populations with cough hypersensitivity as well as other P2X3-related hypersensitivity states.

Forward-looking statements

Certain statements contained in this press release, other than statements of fact that are independently verifiable as of the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities laws and regulations, the US Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”. , “projects”, “plans”, and similar expressions. Such statements, based on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond the control of BELLUS. These statements include, but are not limited to, the potential for BLU-5937 to successfully treat RCC and other hypersensitivity-related disorders and to benefit these patients, BELLUS Health’s expectations regarding its studies preclinical and its clinical trials, including timing of initiation and design of its Phase 3 clinical trials of BLU-5937 in RCC, timing and results of interactions with regulatory agencies, potential activity and the profile of tolerability, selectivity, potency, and other characteristics of BLU-5937, including relative to other competing candidates, particularly where direct studies have not been conducted and comparisons between trials may not be directly comparable due to differences in study protocols, conditions and patient populations, the market potential of BLU-5937, including with respect to patient population, pricing and labeling, location BELLUS Health’s financial and sufficiency of cash resources to achieve the best results with CALM-1, and the potential applicability of BLU-5937 and BELLUS Health’s P2X3 platform to treat other disorders. Risk factors that could affect BELLUS Health’s future results include, but are not limited to: the benefits and on-label impact of its fortification strategy, estimates and projections regarding the size and opportunities of the RCC’s addressable market for BLU-5937, the ability to expand and develop its pipeline of projects, the ability to obtain adequate financing, the ability of BELLUS Health to maintain its intellectual property rights and obtain adequate protection future products using this intellectual property, the impact of general economic conditions, general conditions in the pharmaceutical industry, the impact of the ongoing COVID-19 pandemic on BELLUS Health’s operations, plans and outlook , including the initiation and completion of clinical trials in a timely manner or not at all, changes in the regulatory environment in jurisdictions where BELLUS Health operates its operations, supply chain impacts, stock market volatility, cost fluctuations, changes in the competitive environment due to consolidation, achievement of planned burn rate, achievement of planned milestones of preclinical studies and clinical trials, reliance on third parties to conduct preclinical studies and clinical trials for BLU-5937 and that actual results may differ from primary results once finalized and quality-controlled data verification and analysis is complete. Additionally, the duration of the development process for BELLUS Health’s product candidate along with its market size and commercial value depends on a number of factors. In addition, BELLUS Health’s growth and future prospects are primarily dependent on the successful development, patient safety, regulatory approval, commercialization and market acceptance of its product candidate BLU- 5937 and other products. Therefore, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health believes that the expectations represented by the forward-looking statements are reasonable, but there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on the forward-looking statements included in this press release. These forward-looking statements speak only as of the date they are made, and BELLUS Health is under no obligation and disclaims any intention to publicly update or revise these statements as a result of any new information, future events , circumstances or otherwise, unless required by the applicable provisions. laws or regulations. Please see public documents filed by BELLUS Health with Canadian securities regulators, including, but not limited to, its Annual Information Form, and with the United States Securities and Exchange Commission, including, but not limited to limit, its annual report on Form 40-F, for other risk factors that could affect BELLUS Health and its activities.

Ramzi Benamar
Financial director
[email protected]

Media:
Julia Deutsch
Solebury Trout
[email protected]
Source: BELLUS Health Inc.

Investigational drug ABBV-CLS-7262 enters design phase for entry into HEALEY ALS Platform trial

0

BOSTON- The HEALEY ALS Platform Trial conducted by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in conjunction with the Northeast ALS Consortium (NEALS) is a trial in which multiple investigational products are tested and evaluated simultaneously to accelerate development potential new therapies for people with amyotrophic lateral sclerosis (ALS). Drug candidates that enter the platform’s trial are chosen by a panel of expert ALS scientists and members of the Healey & AMG Center’s Scientific Advisory Board. The Healey & AMG Center for ALS at Mass General and Calico Life Sciences LLC recently signed an agreement to work together to test ABBV-CLS-7262 in the HEALEY ALS Platform Trial.

ABBV-CLS-7262 targets eIF2B, a key regulator of the Integrated Stress Response (ISR), a pathway activated in people with ALS. In neurons exposed to cellular stressors, ISR inhibition by ABBV-CLS-7262 restores protein synthesis and dissolves stress granules containing preformed TDP-43. This effect of ABBV-CLS-7262 is of clinical interest because TDP-43-containing stress granules are thought to lead to TDP-43 inclusions, a hallmark of ALS pathology. ABBV-CLS-7262 is currently in a Phase 1b study in ALS patients (NCT04948645).

ABBV-CLS-7262 is an investigational drug developed by Calico in collaboration with AbbVie and not yet approved for use in any country. Calico is a research and development company founded by Alphabet that focuses on understanding the biology that controls human aging. With AbbVie, they collaborate to discover and develop potential new therapies for patients with age-related diseases, including neurodegenerative disorders.

“We look forward to testing ABBV-CLS-7262 as another investigational ALS product in the HEALEY ALS platform trial. It is exciting to be able to test multiple products at once in hopes of ‘accelerating the path to more treatments for ALS,’ says Merit Cudkowicz, MD, MSc, Principal Investigator and Sponsor of the HEALEY ALS Platform Trial, Director of the Sean M. Healey & AMG Center for ALS, Chief of the Department of Neurology at the MGH, and Julieanne Dorn Professor of Neurology at Harvard Medical School.

“We are excited to add ABBV-CLS-7262 to the HEALEY ALS platform trial. The Therapy Review Board assessed ABBV-CLS-7262 for inclusion in the platform trial based on the quality of Calico and AbbVie science and preparation of the platform. -form and we can’t wait to have them on board,” says Sabrina Paganoni, MD, PhD, physician-scientist at the Healey & AMG Center and co-principal investigator.

The platform trial is testing several other products, including: a) zilucoplan, a small macrocyclic peptide inhibitor of complement component 5 [C5]b) verdiperstat, a brain-penetrating myeloperoxidase enzyme inhibitor, c) CNM-Au8, a cellular energy nanocatalyst, d) pridopidine, a highly selective oral Sigma-1 receptor (S1R) agonist, and e) trehalose, a weighty disaccharide that affects autophagy and lysosomal pathways

For trial updates, please join our weekly webinars on the Healey ALS platform.

Watch this video for more information on the mechanism of action behind ABBV-CLS-7262.

Background to ALS
Amyotrophic lateral sclerosis, ALS, is the most common progressive motor neuron disease in adults, affecting about 30,000 people in the United States and about 500,000 people worldwide. ALS causes progressive degeneration of motor neurons, resulting in progressive muscle weakness and atrophy. There are currently few FDA-approved therapies for the treatment of ALS – riluzole, edaravone (IV and oral formulation), and Nuedexta.

About the Sean M. Healey & AMG Center for ALS at Mass General
At the Sean M. Healey & AMG Center for ALS at Mass General, we seek lifesaving therapies for everyone affected by ALS. Launched in November 2018, the Healey Center relies on a global network of scientists, doctors, nurses, caregivers, people with ALS and families working together to accelerate the pace of discovery and development of ALS therapies.

Under the leadership of Merit Cudkowicz, MD and a Scientific Advisory Board of international experts, we are reimagining how to develop and test the most effective therapies to treat disease, identify cures, and ultimately prevent it.

The key to our success lies in our tightly integrated research and clinical efforts, encouraging opportunities to address the challenges our patients face every day in our laboratories, focusing research on finding solutions that will make a meaningful difference to our patients without delay. Our collaborative efforts are helping to design more efficient and effective clinical trials while expanding access to these trials for people with ALS.

Amazon Prime Day comes amid slowing online sales growth

0

Amazon is heading into its annual Prime Day sale event on Tuesday in a very different way to how it entered the pandemic.

The company has long used the two-day event — one of the biggest of the year — to lure people into its Prime subscription, which Amazon recently raised the price to $139 per year from $119 per year. year.

Amazon does not disclose total Prime Day sales, although growth estimates for last year’s event ranged from 7% to 9%. Research firm Insider Intelligence suggests that sales could increase even further this year, in part due to the timing of the event in mid-July, which compared to the June date of last year would allow the company to attract more consumers doing their back-to-school shopping.

Amazon could use the boost amid slowing overall online sales. Once a darling of the pandemic economy, the company posted a rare quarterly loss in April as well as its slowest revenue growth rate in nearly two decades – at 7%. Inflation had added about $2 billion in costs.

Amazon has also acknowledged that it has too many workers and expects its excess capacity from its massive warehouse expansion during the pandemic to total $10 billion in additional costs for the first half of this year.

“It’s causing pain right now, and that pain is significant,” said Neil Saunders, managing director of GlobalData Retail.

It’s quite a reversal from the early days of the pandemic when the e-commerce giant’s profits soared as home shoppers turned to online shopping to avoid contracting the coronavirus. Demand was so high that Amazon nearly doubled its workforce in the past two years to more than 1.6 million people.

It has also increased its storage capacity to cope with the avalanche of orders flooding its site. By the end of 2021, Amazon had leased and owned about 387.1 million square feet of space for its warehouses and data centers, more than double what it reported in 2019.

Then the worst of the pandemic subsided. Americans have felt more comfortable leaving their homes and demand has also slowed across the board. U.S. retail sector online sales growth, which reached 36.4% in 2020, returned to more normal growth in 2021 and 2022, registering 17.8% and 9.4% respectively. %, according to Insider Intelligence.

Retail sales figures for June, due out on Friday, will shed more light on how e-commerce is doing. The most recent figures from May showed online sales fell 1% while overall retail sales fell 0.3% from April in a context of galloping inflation.

“This is a time when consumers are much more frugal thinking about how they spend and buy,” said David Niekerk, Amazon’s former vice president of human resources who oversaw operations. “It’s impacting Amazon.”

Brian Olsavsky, the company’s chief financial officer, said many of Amazon’s warehouse expansion decisions were made two years ago, limiting what the company can do to adjust mid-year. That said, Amazon will spend less on warehouse projects this year compared to last year, and transportation investments will be flat or slightly down.

Saunders said excess capacity would likely be a near-term problem for Amazon, which he said continued to take steps to grow its retail business and attract more sellers to its service. In April, it announced it would extend the benefits of a Prime membership to online stores beyond its own site, a move that will allow merchants to tap into the company’s extensive distribution and delivery networks. .

To address its storage issues, CEO Andy Jassy said in May that the company would let some of its leases expire and postpone construction of others. Amazon also sublets warehouses to reduce costs.

Preliminary data from property market provider Costar Group suggests the company is disproportionately closing its smaller facilities, which tend to have fewer loading and parking docks and are less efficient to operate, said Adrian Ponsen, US director of Costar’s industrial analysis.

Yet the closures are already creating problems. A handful of workers at an Amazon delivery station in Bellmawr, New Jersey, recently walked off the job to protest transfers to other locations after Amazon decided to close the facility.

Paul Blundell, an Amazon worker who led the walkout, said some workers wanted to be moved to nearby facilities after being told to travel to sites 20 miles away. They also wanted a $1 per hour raise to compensate for the disruption. Meanwhile, the company says employees have the option to transfer to other locations with better benefits.

Amazon reported that its other problem – overstaffing – emerged after bringing in new hires to replace sick workers when the omicron variant swept the country last year. But when the sick workers returned, Amazon was overcrowded, costing about $2 billion. That’s a far cry from last year, when the company raised pay to $18 to attract hourly workers in a tight job market.

The problem could be solved naturally by the company’s high attrition rate. Saunders said Amazon is also likely to find use for excess labor as the holidays approach, and may be able to get the problem under control by not hiring new workers in places where they are overstaffed.

Either way, analysts are keeping a close eye on how Jassy will attempt to right the ship. A few weeks ago he called on Doug Herringtona 17-year Amazon veteran, to replace Dave Clark, Amazon’s former head of retail who unexpectedly resigned last month after 23 years with the company.

Amazon shares have fallen this year, falling about 39% year-to-date. And Jassy is under pressure to bring profitability back, Nieker said.

“He’s made a commitment to shareholders and others that he’s really going to focus now on getting the business back to profitability,” Nieker said. “And a big part of that is the consumer sector.”

How long does COVID immunity last? Here’s what doctors are saying amid concerns over the new BA.5 subvariant – NBC Chicago

0

Unlike at the start of the pandemic, COVID-19 reinfections are no longer rare, with more new variants emerging and raising questions about immunity.

The omicron variant has led to a major shift in “natural immunity”, with many previously infected people susceptible to reinfection with the variant, as well as its faster-spreading subvariants, BA.4 and BA.5 .

In May, Chicago Department of Public Health Commissioner Dr. Allison Arwady said data showed most people infected with COVID are protected from the virus for about one to three months afterwards.

Especially when patients are up to date with coronavirus vaccinations, Arwady said there should be no “major concern” about contracting the virus again soon.

“At the beginning we could confidently, you know, sort of in February, we could really say with confidence that 90% of people weren’t reinfected if they already had COVID,” Arwady said. “It has gone down a bit around the world.”

According to the Centers for Disease Control and Prevention, “after recovering from COVID, most individuals will have some protection against repeat infection.”

“However, reinfections do occur after COVID-19,” the CDC says, adding that changes and mutations “may lead to the emergence of variants that may increase the risk of reinfection.”

In addition to being even more contagious than previous variants, scientists are tracking a mutation in the BA.4 and BA.5 subvariants that may help it evade some immunity and cause reinfections.

A genetic trait reminiscent of the pandemic’s past, known as the “delta mutation,” appears to allow the BA.2.12.1 subvariant” to escape pre-existing immunity from vaccination and infection. earlier, especially if you were infected in the omicron wave,” said Dr. Wesley Long, a pathologist at Houston Methodist in Texas. That’s because the original omicron strain that swept the world didn’t have the mutation.

The genetic change is also present in the omicron BA.4 and BA.5 relatives. These have the exact same mutation as delta, while BA.2.12.1 has one that is nearly identical.

This genetic change is bad news for people who caught the original omicron and thought it made them unlikely to get COVID again soon.

Although most people aren’t sure which variant caused their illness, the original omicron caused a giant surge of cases late last year and early this year.

Long lab data suggests that prior infection with the original omicron is not very protective against reinfection with the new mutants, although the true risk of being reinfected, regardless of variant, is unique to each person and each situation.

According to the latest data, those who were already Delta-sick could have additional armor to ward off New Mutants. A study published before being reviewed by other scientists, by researchers at Ohio State University, found that COVID patients in intensive care with delta infections induced antibodies that neutralized new mutants better than patients who had caught the original omicron.

“The omicron infection antibody does not appear to protect well against subvariants compared to delta,” said study author Dr. Shan-Lu Liu, who co-leads the virus and pathogen program. emerging in the state of Ohio.

But Liu said the level of protection provided by a delta infection depends in part on how long a person has been sick. This is because immunity wanes over time.

People who have become delta-ill should not consider themselves invulnerable to the new subvariants, especially if they are not vaccinated, Long said. “I wouldn’t say anyone is safe.”

The Easiest Way to Look Younger, According to Science – Eat This, Not That

0

If age is just a number, there’s no shame in wanting to preserve your youth and delay the signs of aging. With a few healthy habits, slowing down the process is achievable and Eat This, Not That! Health spoke with Dr. Tomi Mitchell, a board-certified family physician with Holistic Wellness Strategies which explains the easiest way to look younger. Read on and to ensure your health and the health of others, don’t miss these Sure signs you’ve already had COVID.

Shutterstock

Dr Mitchell says: “The quest for the fountain of youth is something that has been talked about for centuries. Most people, if asked, would agree that they would like to look younger. In some cases, they want to look better than they are. Whatever the reasons for wanting to reduce the appearance of aging, people have tried different things throughout history in hopes of achieving a more youthful appearance. While some methods, such as the use of cosmetics or surgery, can yield quick results, there is no surefire way to achieve a lasting youthful appearance. Ultimately, aging is a natural process that everyone Everyone has to experiment, and everyone will end up looking older than they seem.

I have worked in the medical field for over a decade and have held many different positions during that time. One of the positions is that of a cosmetic injector. In this role, I’ve seen thousands of clients come to me with a common request: they want to look younger. Whether it’s subtle changes they’re looking for or a complete overhaul, they all want to look younger at the end of the day. There are many ways to help my clients achieve their goal of looking younger. It’s as simple as removing crow’s feet or forehead wrinkles for some. For others, it can be more complicated, like getting fillers to plump up sunken cheeks or getting Botox to smooth out deep wrinkles. Regardless of their individual needs, I strive to give my clients the best possible results.

I love seeing my clients’ transformation when they see their new, youthful faces in the mirror. It is always gratifying to know that I have helped them achieve their goal of looking younger and feeling better about themselves. However, regardless of treatment options, there are steps we can all take to look younger. As we age, it is common for our skin to become dull and dry. We may begin to see wrinkles, dark spots, and other signs of aging. While there’s no way to completely stop the aging process, there are some things we can do to help us look younger. Here are six tips for looking younger:

woman applying face lotion
Shutterstock

Dr. Mitchell explains, “Keeping our skin hydrated is one of the best things we can do to keep it looking young and healthy. When skin is properly hydrated, it appears plumper and firmer, with fewer fine lines and wrinkles. the skin is better able to protect itself from damage caused by sun exposure, pollution and other environmental factors. Additionally, properly hydrating our skin helps it retain its natural moisture levels better, making it less likely to become dry, dull, and prematurely aged. By taking the time to moisturize our skin every day, we can help keep it looking its best for years to come. Hydration helps hydrate the skin and prevent fine lines and wrinkles. It’s not just our face that needs hydration. important not to forget the neck and our feet. Your feet can become flaky, dry, and even cracked. Without adequate hydration, cracked skin is not only painful, but also opens the door to infection. Additionally, dry skin can lead to calluses and corns, further complicating foot care. The best way to prevent these problems is to moisturize your feet daily. This can be done with lotion, cream, or even petroleum jelly. Also, be sure to pay special attention to dryness-prone areas, such as the heels and soles of the feet. By taking these simple steps, you can ensure that your feet stay healthy.”

woman applying lotion on arm after shower
Shutterstock

“As we age, our skin cells start to die off faster than when we were younger,” says Dr. Mitchell. “In addition, our skin produces less sebum, which makes it dry, flaky, and dull-looking. Exfoliation helps slough off dead skin cells and promotes cell turnover, giving skin a refreshed appearance. and more youthful. In addition, exfoliation can help unclog pores and prevent breakouts. When done correctly, exfoliation can make skin feel softer, smoother and more luminous. However, it is essential exercise caution when exfoliating, as excessive exfoliation can damage the barrier function of the skin and lead to irritation.Therefore, it is necessary to consult a skin care professional to determine how often to exfoliate. you have to exfoliate your skin.

woman applying suntan lotion standing outdoors at urban location during sunny weather
Shutterstock

Dr. Mitchell says, “It’s no secret that ultraviolet (UV) rays are harmful to our health. Prolonged exposure can cause skin cancer, premature aging and other serious health problems. That’s why it’s so important to use sunscreen every day, even on cloudy days. . UV rays can penetrate clouds, so don’t let the weather fool you into thinking it’s safe to skip sunscreen. In addition to protecting your health, sunscreen can help you look younger. Sun damage is a major cause of wrinkles and other signs of aging, so daily use of sunscreen can help keep your skin looking young and healthy. So don’t forget to apply sunscreen before going out and enjoy the sun safely!”

woman sleeping peacefully
Shutterstock

Dr. Mitchell shares, “Getting enough sleep is vital for overall health, but did you know it’s also essential for keeping your skin looking its best? This is because when you sleep, your body can repair and regenerate cells, including skin cells. Sufficient rest helps promote collagen production, which keeps skin looking firm and youthful. It also gives your skin a chance to recover from the day’s environmental stressors, such as pollution and UV exposure. Plus, getting enough sleep helps regulate hormone levels, which can impact your skin health. So if you’re looking to keep your complexion looking its best, rest well!”

Shutterstock

Dr. Mitchell reminds us, “A healthy diet helps nourish the body and provide the nutrients needed for cell growth and repair. What you eat affects your overall health. But did you know that a healthy diet is essential to maintain a youthful appearance? It’s true: what you put in your body can help you look your best. A healthy diet helps nourish the body and provide the nutrients needed for cell growth and repair. Additionally, foods like fruits and vegetables that are rich in antioxidants can help protect the skin against free radical damage. Therefore, a healthy diet is good for your health and can also help you look younger and more radiant. So if you want to keep your skin looking its best, include lots of healthy foods in your diet like salmon, avocados, blueberries, turmeric, and spinach.”

Hand crushed cigarette in transparent ashtray on wooden table
Shutterstock

According to Dr. Mitchell, “Smoking damages the skin by reducing blood flow and causing wrinkles. Smoking is one of those habits that I am very passionate about people quitting. There are many health risks associated to smoking, including lung cancer, emphysema, and heart. Not to mention that smoking can age you considerably and make you look older than your actual age. So why does smoking make you look older? The answer has to do with how smoking affects the skin.Smoking decreases blood flow to the skin, decreasing the production of collagen and elastin.These two proteins are essential for keeping the skin young and healthy.In addition, the Smoking also damages the skin cells themselves, leading to wrinkles and sagging skin, so if you’re looking to quit for your health, you might consider quitting for your appearance, too!”

doctor patient close up fatty liver disease
Shutterstock

Dr. Mitchell says, “Whether you’re investing in medical-grade skincare, non-surgical cosmetic procedures, chemical peels, or surgery, it’s imperative to live a healthy lifestyle so you look and feel your best.” you felt better inside. Eating healthy foods, exercising regularly, and getting enough sleep are all essential factors in achieving and maintaining optimal health. Additionally, managing stress levels can also impact your overall well-being. It shows in your appearance when you take care of yourself both physically and emotionally. You’ll have more energy, your skin will glow and you’ll exude confidence. Making healthy lifestyle choices is an investment that will pay off now and in the future.

The new Cambridge institute will house the world’s largest conc

0

image: Heart and Lung Research Institute, Cambridge
see After

Credit: Royal Papworth Hospital

HRH The Duchess of Gloucester will officially open the Heart and Lung Research Institute (HLRI), a major new addition to the Cambridge Biomedical Campus today.

The institute, a joint venture between the University of Cambridge and the Royal Papworth Hospital NHS Foundation Trust, is expected to house the largest concentration of cardiovascular and respiratory scientists and clinicians in Europe.

Through the collaboration, the HLRI will conduct high-impact research to make breakthroughs in the prevention, early diagnosis and treatment of the diseases that represent the greatest health burden in the world. In the UK, one in four deaths is caused by cardiovascular disease and one in five by respiratory disease. Despite growing awareness of risk factors, such as smoking and poor diet, the prevalence of these diseases is increasing.

Professor Nick Morrell from the University of Cambridge, Director of HLRI, said: “This is a hugely exciting day for us, the result of many years of planning and a lot of hard work, and promises to transform the results for patients with cardiovascular and respiratory diseases.

“The HLRI brings together two global powerhouses in discovery, innovation and clinical care. This constellation of clinical and academic excellence, in close proximity to key pharmaceutical industry partners, is unusual – there is nothing like it in the UK.

The HLRI is located next to the Royal Papworth Hospital on the Cambridge Biomedical Campus, a leading life science research center that combines world-class biomedical research, patient care and education on a single site, including AstraZeneca’s new center for global research and development.

Professor Morrell and his colleagues have set an ambitious goal of developing at least 10 new drugs or diagnostic approaches in heart and lung disease within five years. To achieve this, more than 380 researchers and clinicians will be located in the HLRI, which includes:

  • British Heart Foundation (BHF) Cambridge Center for Cardiovascular Research Excellence – state-of-the-art laboratories studying genomics, population science, cellular mechanisms of disease and translational science that will enable scientists to better understand and treat some of the major killers, including coronary artery disease, coronary artery disease, pulmonary hypertension and stroke.
  • The Cystic Fibrosis Trust Innovation Hub, led by Professor Andres Floto, which will look at a number of inflammatory lung diseases including cystic fibrosis, bronchiectasis, asthma and chronic obstructive pulmonary disease (COPD).
  • The Wolfson Lung Injury Unit, led by Professor Charlotte Summers, which aims to understand the mechanisms underlying acute lung injury – including damage resulting from pneumonia and COVID-19, among other causes – in order to develop new therapies.
  • A clinical research facility, due to open later this year and led by Dr. Mark Toshner. This new facility will allow up to 10 patients at a time to participate in studies. Dr. Toshner aims to transform the way these studies are done, working with patients to co-design research.
  • Collaborative space for universities, healthcare, charities and industry to work together, and educational facilities including seminar rooms and an amphitheater.

Funding for HLRI is provided by the UK Research Partnership Investment Fund, which contributed £30 million, the University of Cambridge and the Wolfson Foundation. The British Heart Foundation donated £10million to the project, while the Royal Papworth Hospital Charity contributed £5million. Additional support was provided by the Cystic Fibrosis Trust for a Cystic Fibrosis Trust Innovation Center within the institute.

Professor John Wallwork, President of the Royal Papworth Hospital, added: “This will be a huge step forward and will demonstrate the best of the Cambridge Biomedical Campus – cross-site collaboration with the world’s best researchers to help save lives.

“HLRI means that new treatments will be created, tested and delivered in one place to fight the leading causes of premature death around the world. It will also allow us to provide additional education and training to clinicians tackling heart and lung disease around the world.

“Bringing together the world’s best researchers, scientists and clinicians will help save lives and enable us to move even faster to bring tomorrow’s treatments to today’s patients.

Professor Sir Nilesh Samani, Medical Director of the British Heart Foundation, said: “The HLRI will provide incredible opportunities for the world’s leading experts to work together more closely than ever to boost heart and circulatory disease research. We are proud to support the institute as it achieves its ambitious goals and becomes a new leader in the fight against the world’s biggest killers.

According to the World Health Organization, cardiovascular diseases cause almost 18 million deaths a year, mostly from heart attacks and strokes, with respiratory diseases coming close behind. The combined global cost of this is over £840billion each year.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Calendar of events, rewards and opportunities

0

Every week, we update this list with new meetings, awards, scholarships, and events to help you advance your career. If you would like us to feature something you offer to the bioscience community, send us an email with the subject line “For the calendar”. Offers from ASBMB members are given priority and we do not promote products/services. Learn how to advertise in ASBMB today.


July 12: Virtual Registration Deadline for Mass Spec Meeting

This five-day conference will be held August 14-18 in person in Cambridge, Massachusetts, and online. It will be an international forum for discussing the remarkable advances in cell biology and human proteins revealed by ever more innovative and powerful mass spectrometry technologies. The conference will juxtapose sessions on methodological advances with sessions on the roles these advances play in solving problems and seizing opportunities to understand the composition, dynamics, and function of cellular machinery in many biological contexts. In addition to celebrating these successes, the organizers also intend to articulate urgent and unmet needs and unresolved issues that will guide the field into the future. The registration deadline was July 1, but you have until July 12 to register to participate virtually. Learn more.


July 14: oral abstracts expected for transcriptional regulation meeting

This in-person meeting will be held September 29 through October 2 in Snowbird, Utah. Sessions will cover recent advances and new technologies in the regulation of RNA polymerase II, including contributions of non-coding RNAs, enhancers and promoters, chromatin structure and post-translational modifications, molecular condensates and other factors that regulate gene expression. Patrick Cramer from the Max Planck Institute will present the keynote address on the structure and function of transcriptional regulatory complexes. The deadline for abstracts of oral presentations is July 14. The deadline for abstracts for poster presentations is August 18. Learn more.

July 15: Deadline to apply for the Colorado PRIDE – AGOLD program

Head to beautiful Denver, Colorado for a summertime experience as PRIDE (Programs to increase diversity among those engaged in health-related research) scholar. PRIDE is an initiative of the National Heart, Lung, and Blood Institute that trains junior faculty from underrepresented and/or disabled backgrounds to advance their scientific careers and make them more competitive for external research funding . The University of Colorado PRIDE (led by Sonia C. Flores, who also chairs the ASBMB’s Minority Affairs Committee) is one of nine national PRIDE sites. It focuses on “the impact of ancestry and gender on the omics of pulmonary and cardiovascular disease” (which is why it’s called PRIDE-AGOLD). The program consists of two back-to-back summer institutes (two and one week, respectively) that provide comprehensive formal instruction in multi-omics, data science, and bioinformatics, with an emphasis on data-based interpretations. ancestry and/or sex; career development and grant application tools; pairing with expert mentors; and pilot funds to develop a small research project. Learn more.

July 28: Virtual presentations on COVID-19 and women

The National Institutes of Health’s Office of Women’s Health Research offers a free quarterly lecture series called “Diverse Voices: Intersectionality and the Health of Women.” The July 28 event will include presentations by Heather Shattuck-Heidorn of the University of Southern Maine and Stephaun Wallace of the Fred Hutchinson Cancer Research Center. Register.


August 2: Abstracts expected for Epigenetics and Genome Stability meeting

Most epigenetics and chromatin meetings focus on transcription, while most genome integrity meetings pay little attention to epigenetics and chromatin. This conference in Seattle will fill this gap to connect researchers interested in epigenetic and chromatin regulations with those interested in genome integrity. The deadline for oral and poster abstracts and the early bird registration deadline is August 2. The regular registration deadline is August 29. Learn more.


August 15: Workshop and interest group proposals due for #DiscoverBMB

For Discover BMBthe ASBMB annual meeting in March in Seattle, we are looking for two types of proposals:

September 28: Deadline for the new HHMI Freeman Hrabowski Fellowship Program

In May, the Howard Hughes Medical Institute launched an approximately $1.5 billion program to “help build a scientific workforce that more fully reflects our increasingly diverse country.” The Freeman Hrabowski Fellowship Program will fund 30 fellows every two years, and each appointment can last for up to 10 years. This represents up to $8.6 million in total support per fellow. HHMI welcomes applications from scholars “who are strongly committed to advancing diversity, equity, and inclusion in science.” Learn more.


November 2: ASBMB Virtual Career Fair

Save the date for the ASBMB careers exhibition. This virtual event aims to highlight the diversity of career choices available to modern biomedical researchers. Regardless of your career stage, this exhibition will provide you with a plethora of career options to explore while simultaneously connecting you with professionals skilled in those careers. Each 60-minute session will focus on a different career path and will include breakout rooms with professionals from those paths. Participants can choose to meet in a small group with a single professional for the entire session or move freely between breakout rooms to benefit from the advice of several professionals. The sessions will feature the following five sectors: industry, government, science communication, science policy and others. The exhibition will take place from 11 a.m. to 5 p.m. Eastern Time on November 2. Stay tuned for a link to register!


Call for proposals for virtual scientific events

The ASBMB provides members with a virtual platform to share research and scientific achievements and to discuss emerging topics and technologies with the BMB community.

The ASBMB will manage the technical aspects, market the event to tens of thousands of contacts and present the digital event live to a remote audience. Additional tools such as polls, Q&As, breakout rooms, and post-event Twitter chats can be used to facilitate maximum engagement.

Seminars usually last one to two hours. A workshop or a conference can be longer and even last several days.

Potential organizers can submit proposals at any time. Decisions are usually made within four to six weeks.

Propose an event.


Take over JLR’s Twitter account

If you are a graduate student, postdoc or early career researcher interested in hosting a #LipidTakeover, complete this request. You can spend a day tweeting from the Journal of Lipid Research account (@JLipidRes) about your favorite lipids and your work.

IUBMB Relocation Assistance for Displaced Interns

The International Union of Biochemistry and Molecular Biology is offering $500 to graduate and postdoctoral students displaced from their laboratories due to natural disaster, war, or “other events beyond their control that interrupt their training.” . The money is for travel and installation. Learn more and spread the word to those who might need help.

Against a burgeoning immune evasionist Omicron, boosters and masks are Australia’s best weapons | Catherine Bennett

0

Living with Covid has taken on a whole new meaning in 2022.

We had been prepared for the virus to stay in our communities, but Omicron took that to a different level. This is what “vaccine escape” looks like.

As we watched the Delta outbreaks in NSW and Victoria slowly come under control in 2021 with more people completing our primary vaccination cycle, we had every reason to be optimistic about some relief. during the summer, even with the international and open state borders.

But that was wiped out with the arrival of Omicron even before the end of the year.

Omicron took off in South Africa, where it was first reported, then gradually circled the globe, culminating in Australia on January 14 this year. It was oddly able to quickly establish vast waves wherever it landed, and not just because it was inherently better at spreading. It is more effective due to its ability to evade our immunity.

Neither previous infection nor vaccination offers much protection against infection with this variant. It’s immune evasion, which comes from the fact that it’s physically different enough from other variants that our immune system doesn’t immediately recognize it to mount an attack, and Omicron represents a bigger change than the one we we saw in the previous immune leak with Delta – so much so that some argue that Omicron should not be lumped together with the other Sars-CoV-2 variants seen in this pandemic at all.

Immune evasion undermines the immune system’s ability to ward off infection, but luckily we still have enough cross-immunity against vaccination, infection, or both to reduce our risk of serious illness. During the peak last January, we had more than 50 times the infections reported in the Delta wave, but only a third more people in intensive care.

What’s even weirder about this variant of Omicron, and all of its derived sub-variants, is that an infection with Omicron boosts our immunity against coronavirus infection, but not against Omicron. You are less likely to contract Delta after infection with Omicron, but re-infection with Omicron is still relevant, especially with the succession of new subvariants that followed BA.1.

This means that Omicron can continue to take center stage in the pandemic, not only by being more transmissible, but by actively eliminating other variants.

On the other hand, it could also eliminate other potentially nasty mutant variants that never get a foothold. But it’s the ability to cause reinfections, even in those who have had a recent infection, that keeps Omicron’s infection rates high, creating the long epidemic we’ve seen persist since the day it landed on our shores.

With the arrival of Omicron, the booster dose of the vaccine suddenly became important for all of us.

Not only does it protect against waning immunity, but the booster also elicits a different type of immune response than the first paired doses. Remarkably, it not only boosts protection against severe disease to the levels seen with Delta, it also restores, at least for a short time, some protection against infection, reducing infection rates by approximately 40 % during the first two months.

Not as good as Delta’s epidemic control impact, but not bad now, we’re in the shadow of the imminent next peak of the BA.5 subvariant.

This different world of infection that we now find ourselves in is the same challenge facing the whole world. We were ahead for some time in current infection rates as the northern hemisphere entered summer, and we are currently behind France, New Zealand and Singapore. We drop to 16th in the world when we look at the latest data on new per capita death reports, behind still-summer European countries.

We also only have half the daily death rate of New Zealand.

Australia’s death rate has climbed with successive waves of Omicron, and we are yet to return to the peak rate of three deaths per million that we saw then. Other countries, in their last winter when the first wave of Omicron hit, recorded death rates of between 4 and 18 per million.

We are doing relatively well, even if it is our turn to face Omicron in winter.

We are also far from the total number of deaths per capita seen in the world, grouped with Singapore, Taiwan and New Zealand among the few countries with less than 400 deaths per million inhabitants.

Canada has more than 1,000, France and the United Kingdom more than 2,000, and the United States has recorded a total of more than 3,000 deaths among every million Americans.

It doesn’t help the news that we have now had over 10,000 Covid-19 deaths in Australia, but apply the statistics from these other countries to our population size and it reaffirms the lives we have also saved.

If we matched the death rates from Canada or Denmark, we would have already had almost 30,000 Covid-19 deaths in Australia, 45,000 with German rates or 70,000 with the UK.

Sweden’s death rate translates to almost 50,000 total deaths in a population the size of Australia, but many still see this as something of a model of success.

So what comes next?

Well, if everyone eligible for a booster came out and got it tomorrow, we could keep a lid on the BA.5 wave. If those most at risk of severe illness all got their winter dose, we would also see fewer people end up in hospital as infection rates rise.

There is no guarantee that you can prevent infection, and we are now exposed to most places we go, especially in major cities. But reducing the risk could mean the difference between having an exposure and having an infection. Or between having one infection or several.

There are currently between 600 and 900 reported active cases per 100,000 people in Victoria, and you can double or triple that figure to get an idea of ​​actual infection rates. This represents between 1 and 2% of the population.

Some will self-isolate, some won’t, and many won’t even know they’re infected.

In New South Wales, new cases reported in the past four weeks exceed 100 per thousand in metropolitan Sydney and 50 in many regional areas. It is between 5 and 10% of these populations who have reported recent infection, which probably translates to up to a quarter of the population.

Masks, reminders and general precautions will not stop Omicron, but will reduce our risk of re-infection and help us get through the winter.

Antivirals are also an important secondary prevention step for those infected and at risk of serious illness. If we can limit infections and reduce the risk of disease escalation in vulnerable people, we can undermine Omicron’s main weapon, reinfection.

The Fintech office / WIT Design & Research

0

The Fintech office / WIT Design & Research

The Fintech Office / WIT Design & Research - Image 2 of 32The Fintech Office / WIT Design & Research - Interior photography, kitchen, lighting, windows, chair, handrailThe Fintech Office / WIT Design & Research - Interior Photography, BeamThe Fintech Office / WIT Design & Research - Interior Photography, Painting+ 32

Birth of a brand of office spaces focused on design. End of 2020. A Fintech investor called Luo, founding partner of WIT: “I decided to invest in Fintech Ⅲ. Let’s collaborate again, before the end of the year. For WIT, the invitation not only marked a progress from underground space design to standard above-ground office space design, but also provided an opportunity to explore how to make the unconventional conventional office space and increase Fintech brand awareness.

The Fintech Office / WIT Design & Research - Interior photography, kitchen, lighting, windows, chair, handrail
© Visual Mille Degrés

May 2020. Fintech Ⅱ started designing. The Fintech was launched with a cost per square meter almost 20% higher, which meant that WIT was “free to install terrazzo tiles for the floor”. However, at that time, the pandemic was hovering over the office market and the government was calling for remote work. In October 2020, during the first week of completion, a database company rented the triangle-shaped space from Fintech Ⅱ, which before the renovation was in a miserable state. However, another AI company was not so lucky. Failing to secure the rental of the space, she asked the developer to arrange for WIT to design another office space of the same quality in the building. According to the son of the company’s investor who had returned from the United States, the office is “even more comfortable than home”.

The Fintech Office / WIT Design & Research - Image 8 of 32
© Visual Mille Degrés

February 2020. The Fintech OfficeⅠand Dragon Restaurant, located in and developed by the Ronghui International Building, were put into operation simultaneously. An office building dedicated to serving the fintech industry, the Ronghui International Building had received great support from the Beijing government, but like many other businesses in Beijing, including those in the CBD, it felt the bite of the pandemic. It was in these difficult times that the Fintech Office got its start. A few days later, a former Google artificial intelligence scientist, who had decided to start his own company and had received funding from Google and Volkswagen, rented the entire space of the Fintech OfficeⅠ, which was originally intended to be a co-working space. He made up his mind as soon as he walked into the lobby, despite the rent being almost as high as a CBD apartment building. Considering that the -1F’s limited height had once hampered the building’s rental business, the deal was a win for both the developer and WIT, who had undertaken the design of the -1F and -2F.

The Fintech Office / WIT Design & Research - Interior Photography, Beam
© Visual Mille Degrés

After the Fintech Ⅲ was reserved for the use of the investor himself for a year, more and more potential tenants came to visit the space and tried to negotiate the rental of the space. The competitive price ultimately prompted the developer to lease the space. Meanwhile, the Fintech Office began to receive invitations to cooperate, including from the operator of an existing building of more than one hundred thousand square meters wishing to use its branding, design and management service. Over the past two years, the Fintech Office has thrived amid the pandemic. The Dragon office space and restaurant, funded by the building’s developer and designed by WIT Design & Research, provided “an ideal dining experience and ‘one-minute life circle’ for stressed professionals in the Fintech industry who are in pursuit of peace of mind, and they serve as an example of an office community breaking the spell of the business crisis in the rental industry.This is how the Fintech Office brand was born , with Dragon Restaurant, which offers the best dining environment of any other restaurant in the chain across China.WIT suggested that the design of the sunken atrium be included in the contract, and the landscape of indoor/outdoor also extends the physical/psychological office space available to staff and allows them to embrace city life.

The Fintech Office / WIT Design & Research - Interior Photography
The concrete “waterfall” and “swimming ducks” become perfect alternatives for outdoor water games during Beijing’s long cold winter. Image © One Thousand Degree Visual
The Fintech Office / WIT Design & Research - Image 27 of 32
Shape programming, material testing and construction
The Fintech Office / WIT Design & Research - Image 2 of 32
Floodlights are placed above the atrium recreation area to simulate moonlight, creating a holiday vibe. Image © One Thousand Degree Visual

Technology follows hospitality. The staircase was designed using parametric software rather than being drawn by hand to accentuate the characteristics of the fintech industry. Despite its extremely low cost, “design” solves problems, creates value and, above all, looks glamorous.

The Fintech Office / WIT Design & Research - Image 28 of 32
Shape programming, material testing and construction
The Fintech Office / WIT Design & Research - Interior Photography, Wood
© Visual Mille Degrés
The Fintech Office / WIT Design & Research - Interior Photography, Painting
© Visual Mille Degrés

Priority given to efficiency over capacity. Challenged by limited space, WIT believes that “it’s okay to have an imperfect space, and that’s where designers can maneuver to make the most of it.” It is the responsibility of the developer and the designers to ensure a satisfactory number of sales per unit area, but the extent to which the functionality and usability of the space can be provided by the design will ultimately be felt by the people who are the users of it. space, and this is WIT’s priority. During the design process, we kept asking ourselves: what is the nature of efficiency when we talk about office space?

The Fintech Office / WIT Design & Research - Image 11 of 32
In order to maximize the net ceiling height, the space is well thought out down to the centimeter. Image © One Thousand Degree Visual
The Fintech Office / WIT Design & Research - Image 10 of 32
Design for sharing. Image © One Thousand Degree Visual
The Fintech Office / WIT Design & Research - Image 12 of 32
With an average workspace of 6.6㎡ per person, the desk is small but ideal in every detail. Image © One Thousand Degree Visual

When it comes to working in the modern era, working from home remains a controversial topic. Technology is helpful, but not a panacea: it cannot facilitate sincere conversations and build trust the way face-to-face communication does. This is especially the case when employees in the high-tech industry work under enormous pressure and require great coordination – they will need a physical space to work together for the foreseeable future.

The Fintech Office / WIT Design & Research - Image 24 of 32
To relieve worker fatigue after long hours, the space offers open desks and “first class” seating. Hand drawn by Dan. B
The Fintech Office / WIT Design & Research - Image 13 of 32
To relieve worker fatigue after long hours, the space offers open desks and “first class” seating. Image © One Thousand Degree Visual
The Fintech Office / WIT Design & Research - Image 15 of 32
To relieve worker fatigue after long hours, the space offers open desks and “first class” seating. Image © One Thousand Degree Visual

The discussion around work efficiency continues between the investor and Luo, who together built the Fintech Office brand, inspired by the birth of the efficiency-focused design of semicircular office clusters at Bloomberg London.

The Fintech Office / WIT Design & Research - Interior photography, Living room, Chair
© Visual Mille Degrés

Netherlands-based researchers develop budding smart window

0

The Netherlands-based research center TNO has developed a smart window using thermochromic smart glass. They partnered with Sunnovate on the Interreg project to realize this latest innovation. The window is designed to switch between absorbing heat or letting it pass.

What is Smart Window Technology?

The smart window has a thermochromic active material. It can automatically change its optical properties at a certain temperature, around 20⁰C. As the temperature rises, the glass changes its infrared transmission when the sun hits it. When this happens, its transparency changes and the window becomes less transparent to solar heat.

This effect occurs in the infrared part of the solar spectrum, making the window transparent to human eyes. The transition to the infrared transparent state usually occurs at night and at cooler temperatures as the glass surface cools. The switch occurs automatically and is integrated into the laminated glass. This allows the smart window to be installed without special installation requirements.

Simply put, the window blocks heat from the sun when outdoor temperatures are high and absorbs heat when outdoor temperatures are lower.

Speaking to reporters, researcher Paskal Buskens explained, “VO2 changes its crystal structure at a certain temperature. With this change in the crystal structure, the electrical and optical properties also change, which means that the material absorbs more infrared light in the high temperature crystal phase and the absorbed solar energy is not transmitted into the building.

Vanadium dioxide (VO2) is a functional material in pigmented polymer film coating. It changes its crystal structure and optical properties at high temperatures, making it suitable for technology. A standard low-emission coated glass was used in the thermochromic coating.

Buskens said, ‘Thermochromics can change their infrared modulation properties from transmissive to blocking depending on the temperature of the glazing. Integrating VO2 into a film or coating for application in smart thermochromic windows can lead to a significant reduction in energy consumption for heating and cooling buildings in an intermediate climate.

In January, the Netherlands Organization for Applied Scientific Research (TNO) and its partners launched Driving test on the smart window to examine the properties and performance in a real environment. They implemented two 1m2 smart window demonstrators at the SolarBEAT test facilities in Eindhoven, making it the first time to test the adaptive thermochromic effect under real conditions. The results were positive and the demonstration will continue until the end of the year to obtain information on the four seasons.

The optimum switching temperature is around 20⁰C but can be adjusted by metal ion doping for optimum energy savings. The researchers claim that the smart window can guarantee energy savings of up to 8% compared to state-of-the-art HR++ windows in independent buildings, duplexes and townhouses.

Although pricing is unconfirmed, Busken said final costs depend on which glass companies sell the product. ‘But due to the low costs of the material itself and the great potential for savings, an attractive business case is ensured, while keeping the return on investment for end users at an acceptable level of around seven years.

Startup stories: Chinese company ZXBio develops and manufactures antibody-based medical products

When did you get the idea for this startup?

In 2014, I learned that a friend with non-Hodgkin’s lymphoma had chosen traditional treatment because of the high cost of Rituximab, a biological antibody with excellent therapeutic efficacy. At that time, these advanced therapeutic drugs were almost non-existent in China. I realized that China lacked domestic enterprises capable of manufacturing biological diagnostic tools and pharmaceutical drugs. After studying at Yale SOM, I identified in vitro diagnostic crude antibodies and flow cytometry antibody reagents as a good entry market in China, and launched ZXBio in China in 2017.

What is the problem you are trying to solve or the gap you are trying to fill?

For in vitro diagnostics (IVD) and pharmaceutical industry, most antibody raw materials, diagnostic reagents and biological drugs are imported from foreign companies. China lacks R&D and manufacturing capabilities for these biological materials. I want to provide local people with low-cost, high-quality diagnostic and pharmaceutical products, filling a critical gap in the upstream value chain of the Chinese pharmaceutical and IVD industry.

What has been the most important resource that Yale SOM has brought to your startup?

Yale helped me develop an approach to thinking about my personal and professional development. I learned to strive for excellence while developing skills that will generate value in the market. At Yale SOM, I was exposed to the worlds of finance, consulting, and business. I started to appreciate the whole landscape of the healthcare industry, which helped me make decisions about my own career path. I also worked at Yale-New Haven Hospital as a clinical trial coordinator. The experience helped me understand how laboratory science, drug development and clinical application work together.

What is the biggest milestone your startup has taken since graduating?

Since our establishment, ZXBio has developed and launched hundreds of diagnostic reagents for cancer, infectious diseases and immunological diseases. We have built a 10,700 square foot antibody development platform and a 10,500 square foot GMP facility for the production of antibody diagnostic reagents. We also operate a 20,000 square foot third-party diagnostic center, and in 2022 we launched a mall in Shanghai. Also in 2022, we closed a pre-A financing with a Chinese A-share listed DIV company, Zhejiang Orient Gene Biotech Co., Ltd, which is one of the companies with the highest market value in China’s IVD market

The strength and extent of antibody responses elicited by hybrid immunity to vaccination or COVID-19 infection alone

0

In a recent study published on medRxiv* preprint server, researchers assessed neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after receiving a dose of vaccine.

Study: Strong neutralizing antibody responses to SARS-CoV-2 variants after a single vaccine dose in subjects previously infected with SARS-CoV-2. Image Credit: CI Photos/Shutterstock

Background

Evidence shows that a history of SARS-CoV-2 infection stimulates the immune system, causing hybrid immunity in individuals recovered from coronavirus disease 2019 (COVID-19) after subsequent vaccination. However, further research is essential to understand the extent and efficacy of hybrid immunity stimulated by severe or mild COVID-19 infection.

About the study

In the current study, researchers compared the strength and robustness of antibody responses obtained in vaccinated individuals with a history of COVID-19 infection and in uninfected individuals.

The team obtained blood samples from individuals recovered after administering a dose of the COVID-19 vaccine. COVID-19 severity was defined as mild or severe, with mild infection including laboratory-confirmed SARS-CoV-2 infection without reported hospitalization, and severe infection including cases of SARS-CoV-2 infection. Laboratory-confirmed CoV-2 requiring hospital treatment. Data related to patient demographics, COVID-19 vaccination history, and clinical characteristics were collected from the National Immunization Registry and the National Infectious Disease Registry.

The team detected 2,586 subjects aged 18 and over who tested positive for the polymerase chain reaction (PCR) for COVID-19 between February and April 2020. Blood samples were taken from 1,074 patients to determine the concentration of SARS-CoV-2 specific serum antibodies at eight and 13 months after diagnosis of COVID-19. The study included patients who received one dose of BNT162b2 or ChAdOx1 COVID-19 vaccines seven to 90 days or two doses of BNT162b2 seven to 120 days prior to the 13-month sampling.

The team randomly selected matched serological samples from 30 of 55 study participants with a history of COVID-19 infection with subsequent vaccination with BNT162b2 22–90 days prior to sample collection for titer determination. of neutralizing antibodies (NAb) against SARS-CoV-2 strain wild type (WT) and variants Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron ( B.1.1.529/BA.1) . Samples were collected from 15 participants 59 to 90 days after vaccination. Of the 15 people, eight had a history of severe COVID-19. Another 15 participants were selected to collect blood samples 21-30 days after COVID-19 vaccination by matching the severity of disease, sex and age of the participant to the first group.

Serum samples were collected from 640 participants aged 18 years and older nearly 13 months after PCR-confirmed diagnosis of SARS-CoV-2 WT infection without any history of COVID-19 vaccination. The team also obtained serum samples from a total of 38 participants with previous SARS-CoV-2 WT infection but no history of COVID-19 vaccination at an average of 51 days and 118 days post-treatment. infection.

Results

Study results showed that 97% and 89% of participants tested positive for the presence of SARS-CoV-2 spike (S) immunoglobulin G (IgG) and NAbs against SARS-CoV-2 strain. CoV-2 WT before receiving the COVID-19 vaccination eight months after diagnosis of COVID-19. The team also noted that a single dose of the COVID-19 vaccine caused nearly 20 times higher IgG levels in people with a history of COVID-19 infection compared to uninfected people. Additionally, hybrid immunity stimulated following mild infection resulted in significantly higher mean S-IgG levels compared to concentrations seen in individuals experiencing only mild infection.

The team also noted a twice higher concentration of S-IgG following a diagnosis of infection after vaccination with a dose of BNT162b2 compared to a double vaccination with BNT162b2 alone. Nearly 98% of patients with hybrid immunity and 100% of doubly vaccinated patients showed NAbs against SARS-CoV-2 WT. A comparison of the neutralization capacity of Abs that target the viral spike protein showed that an almost three-fold higher neutralization capacity of Abs was achieved through hybrid immunity as opposed to that after double vaccination. Additionally, while mean antibody levels declined 90 days after hybrid immunity was achieved, 97% of individuals had detectable levels of NAbs.

A vaccine dose of BNT162b2 elicited substantially elevated IgG and NAb titers in subjects with a history of COVID-19 infection compared to induction observed prior to vaccination. The team also found the highest average NAbs titers against the WT strain, but reduced titer levels against the Alpha, Beta, Delta, and Omicron BA.1 variants. Variations in mean NAb titer levels ranged from 30 to 46 and eight to 27 depending on the infecting strain for the severe and mild disease cohorts, respectively. This indicated that hybrid immunity was more pronounced after severe infection than after mild infection.

Conclusion

Overall, study results showed that one dose of COVID-19 vaccine given nine to 12 months after diagnosis of COVID-19 significantly increased anti-nab antibody and IgG levels. specific to spikes in people with a history of SARS-CoV-2 WT infection.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be considered conclusive, guide clinical practice/health-related behaviors, or treated as established information.